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1 INTRODUCTION AND OBJECTIVES 
1.1 Introduction 
Inhalation products are routinely used in the therapy of the local treatment of respiratory dis-
eases [1]. The focus of attention is on diseases such as bronchial asthma, chronic obstructive 
pulmonary disease (COPD), cystic fibrosis or lung cancer [2]. Thereby, different drug appli-
cation devices such as nebulizers, pressurized metered-dose inhalers (pMDIs) and dry powder 
inhalers (DPIs) are used for an efficient delivery of the active pharmaceutical ingredients 
(APIs) to the lung [3]. Anticholinergic bronchodilators, β2-adrenoceptor agonists and inhala-
ble corticosteroids are usually prescribed for the benefit of the patients [4].  
DPIs are especially well established on the market and thereby arouse a great interest. For this 
type of device formulation strategies revolve around carrier or carrier-free systems [5]. On the 
one hand the micronized API (particle size about 5 µm) is formulated with coarse carrier par-
ticles (> 100 µm) in a binary mixture. On the other hand spheroids (soft aggregates) are man-
ufactured by controlled agglomeration (spheronisation) of micronized particles [6]. In both 
cases the dispersion of these agglomerates (drug-to-drug/drug-to-carrier) is generated by in-
duced air turbulences through grids/rotators, shearing forces and particle collisions to achieve 
a significant amount of drug depositing in the lungs. 
In general, an extended understanding of the particle structure and de-agglomeration behavior 
of the micronized API is needed to optimize these formulations. Several physico-chemical 
parameters have to be determined which have an influence on the detachment of the drug 
from the carrier (powder flow, particle size, shape, surface morphology, contact area, hygro-
scopicity) [7–9]. A specific parameter for inhalable products is the aerodynamic diameter 
(dae) of the API. It takes the particle shape/particle density into account and it should be in the 
range of 0.5 µm and 5.0 µm for an efficient pulmonary drug delivery [10]. APIs which con-
tain particles larger than 5.0 µm might impact in the upper airways and thus boost side effects. 
Formulation strategies such as “particle engineering” focus on a high fine particle fraction 
(FPF: % of delivered dose < 5µm) which is characterized by a narrow particle size distribu-
tion (PSD), good flow and dispersion properties of the excipient and the API [11]. 
Furthermore, it is well-documented in the literature that standard pharmaceutical operations 
such as intensive blending, milling and also sieving can induce structural changes [12] and 
cause disruption in the crystal structure (amorphous content) to the surface of both, excipients 
and active pharmaceutical ingredients. These mentioned disorders in the surface structure 
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have a high affinity to water vapor [13] and might induce a lowering in the glass transition 
temperature [14] which can lead to a re-crystallization process of the thermodynamic unstable 
amorphous amounts. These conditions can affect processing, performance and the product 
stability [15]. In any case, the kinetics of process induced disorders are only partly under-
stood. In addition, finding a reliable method to accurately determine the amorphous content in 
pharmaceutical powders down to a level < 1% is still a challenge. The need of quantifying, 
monitoring and controlling amorphous parts is therefore absolutely essential.  
First studies demonstrated that the performance of inhalation powder blends is significantly 
affected when amorphous lactose is added to the carrier lactose for the simulation of the be-
fore mentioned disorders [16,17]. It is assumed that the micronization of the APIs lead to 
post-operational relaxation in the inhalable mixtures inducing particle size changes and re-
crystallization effects.  
Nevertheless, the exact imitation of process-induced disorders is hardly to achieve as the qual-
ity of the structural changes may differ. It is well known that there are different states of 
amorphicity depending on the conducted process. So far fully amorphous samples were pre-
pared by spray-drying [18], freeze-drying [19] or quench cooling [20]. Subsequently these 
purely amorphous materials were mixed with crystalline material to produce calibration 
curves. 
However, various analytical techniques can be used when addressing the issue of the determi-
nation of amorphous content in a powder. Over the years different papers have been published 
using traditional analytical techniques such as Powder X-ray Diffraction (XRPD) and Differ-
ential Scanning Calorimetry (DSC) (limit of detection: 5-10%) [21]. Furthermore, near infra-
red spectroscopy was used to differentiate between amorphous and crystalline states by evalu-
ating the peak intensity and shifts in the known fingerprint regions of the spectra (limit of 
detection: 1%) [22]. In conclusion all these bulk analytical techniques measure the properties 
of the sample as a whole and thus the amorphous content becomes a small part of the total 
signal [23]. Furthermore, studies using isothermal microcalorimetry (IMC) were published 
(limit of detection: 1%) [24]. One disadvantage of this technique is that a potential re-
crystallization of the amorphous solid may not be detected due to the time required to equili-
brate the sample [25]. This equilibration process in the isothermal microcalorimetry takes 
place unmonitored for nearly 1 hour. Furthermore, no data can be recorded confirming that 
amorphous amounts remain stable in this period of time. 
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Amorphous parts which might act as “reactive spots” on the surface can be determined espe-
cially in hydrophilic samples by water moisture sorption isotherms [26]. In their review 
Sheokand et al. divided the DVS-methods into three main groups for the quantification of 
amorphous amounts [15]. Equilibrium moisture uptake (based on absorption), water uptake 
method (based on re-crystallization) and residual weight (based on solvated solvent) method 
are in focus. For hydrophobic material, which is chemically more stable against water vapor 
and the change in crystallinity is self-limiting, only a few approaches (DVS) are available 
which focus on organic solvents. For example Mackin at al. used acetone as a solvent (for 
benzyl ether derivative) and Samra et al. used mixtures of ethanol/water and etha-
nol/n-propanol in their investigations with hydrophobic terfenadine [25,27]. 
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1.2 Objectives 
This thesis focuses on the production and evaluation of amorphous amounts, the development 
of a detection method (< 1%) especially for more hydrophobic APIs based on absorption 
techniques (Dynamic vapor sorption) and on the influence of amorphous amounts on the de-
agglomeration behavior over a defined storage time (six months). Furthermore, the applicabil-
ity of a dissolution testing system (Andersen Cascade Impactor and USP paddle apparatus 2) 
for inhalable blends is investigated determining the influence of different amorphous amounts 
on dissolution behavior. 
Firstly, the work schedule consists of the preparation of semi-crystalline and fully amorphous 
samples by using different technologies and the investigation of the process conditions. The 
focus is set on methods such as ball-milling, spray-drying, freeze-drying and quench cooling 
for the establishment of purely amorphous material. On the contrary, the generation of small 
proportions of amorphous forms mainly localized on the surface of the particles is performed 
by jet-milling and intensive blending (simulation with glass beads). Furthermore, the influ-
ence of these process-induced disorders on the stability and shelf-life is investigated. 
In the second part the establishment and the qualification of DVS sorption methods that ena-
ble the quantification of amorphous parts down to a level of < 1% are performed. Firstly, hy-
drophilic and hygroscopic APIs such as Ipratropium bromide, Formoterol fumarate and Sal-
butamol sulphate are investigated and moisture sorption isotherms are determined, respective-
ly. Afterward, hydrophobic APIs such as Ciclesonide, Budesonide and Glibenclamide are 
evaluated. Thereby, a change from polar (water) to nonpolar organic solvents is necessary to 
increase the affinity of the drug to the solvent (organic solvent screening). Finally, the method 
is meant to be simplified as much as possible because the development of a one-step meas-
urement is desired. The determination of the optimal vapor (p/p0) value and the adjustment of 
the temperature are required. In addition, the influence of amorphous quality, particle size and 
surface on the absorption behavior is investigated. To complete the described method a vali-
dation of the one-step DVS method based on the ICH Guideline Q2 (R1) is performed.  Here-
by, the linearity, precision and the limit of quantification (LOQ) are investigated. The ap-
plicability of all six model APIs is tested and a general guidance for the adaptation of the 
method to other drugs is established. Finally, the calculation of the amorphous amounts in the 
unknown samples and the energy-dependent introduction of an amorphous phase onto solid 
surfaces are desired to be feasible. In addition, the extent of amorphous parts depending on 
the material properties (melting point, hydrophobicity) is evaluated. 
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The thematic field of inhalation addresses the impact of amorphous content in API/lactose 
blends on the physical stability (six months). The focus is set on process conditions that intro-
duce amorphous amounts to the API and on the investigation of the re-crystallization process 
for these inhalable blends. Of great interest is the diversified behavior of hydrophilic and hy-
drophobic samples. Furthermore, inert glass beads replace the hydrophilic lactose as a model 
carrier. 
The completion of the work schedule involves the dissolution testing. The applicability of a 
dissolution test system (Andersen Cascade Impactor and USP paddle apparatus 2) is investi-
gated for hydrophilic and hydrophobic active pharmaceutical ingredients. The objective is to 
evaluate the influence of different amorphous amounts in inhalation powders on the dissolu-
tion rate. 
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2 THEORETICAL BACKGROUND 
2.1 Human respiratory tract 
The respiratory system is essential for supplying the organism with oxygen and removing 
carbon dioxide. It is mainly responsible for pulmonary ventilation and the movement of air 
into and out of the lungs [28]. Depth of respiration and breathing frequency is regulated by a 
complex and specific regulatory system [29].  
Basically, the airways are divided into two major regions, the upper and lower respiratory 
tracts. The first part includes the nasal passages, throat, pharynx and the larynx. The lower 
tract is divided into the trachea, bronchi, bronchioles and the alveoli (attractive respiratory 
region [30]). These subdivisions facilitate gaseous exchange to blood vessels which is enabled 
by the very large surface area (80-90 m²) and thin absorption membranes (0.1-0.2 µm) of the 
lung [31]. Furthermore, high lung perfusion (5-6 l/min) allows a rapid distribution of mole-
cules [29]. 
Figure 4 shows the division of the respiratory system and the relationship between particle 
size and lung deposition. In chapter 2.2.4 the general deposition principles (impaction, sedi-
mentation and diffusion) are illustrated. 
2.2 Achievements and challenges of pulmonary drug delivery 
The efficient delivery of active pharmaceutical ingredients (APIs) to the lung by inhalation 
products depends on several parameters which include the formulation (flowability, particle 
size, shape, surface), the inhaler device (nebulizers, pressurized metered-dose inhalers 
(pMDIs) and dry powder inhalers (DPIs)), the metering system (capsule, multi-unit dose or 
reservoir dose) and the patient’s inhalation technique (e.g. flow rate) [32]. A specific parame-
ter for inhalation products is the aerodynamic diameter (dae) of the API. It takes account of the 
particle shape/particle density and it should be in the range of 0.5 µm and 5.0 µm for efficient 
pulmonary drug delivery [33]. This value is defined by the equation 2.1, where dgeo is the ge-
ometric diameter, ρp and ρ0 = 1 g/cm³ are the particle and unit densities, respectively and XS is 
the dynamic shape factor. Large porous particles might have the same aerodynamic behavior 
as smaller particles with higher density. 
𝒅𝒂𝒆 =  𝒅𝒈𝒆𝒐 ∙  √
𝝆𝒑
𝝆𝟎 ∙ 𝑿𝑺
  2.1 
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For very small particles (0.1-0.3 µm) the Cunningham correction factor (CC) needs to be in-
troduced [34]. APIs which exhibit larger particle size might impact in upper airways and thus 
boost side effects. Consequently, the efficiency of the treatment of respiratory diseases such 
as bronchial asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis or lung 
cancer can be lowered. Formulation strategies such as “particle engineering” focus on a high 
fine particle fraction (FPF: % of delivered dose < 5 µm) by supplying a narrow particle size 
distribution (PSD), good flow and dispersion properties of the excipient and the API [35]. An 
interest in the systemic drug delivery has emerged recently [36] and promotes the potential for 
the entry of peptides, proteins, antibiotics or vaccines over the lung. Affrezza
®
, for example, 
is an inhalable insulin which improves the blood sugar control in adult patients with diabetes 
(MannKind Corporation) [37]. Recently, Adasuve
®
 (Ioxapine), an inhalation powder has been 
approved for the acute treatment of agitation associated with schizophrenia or bipolar disor-
ders in adults (Alexza Pharmaceuticals). 
2.2.1 Drug application devices 
In general, drug application devices can be distinguished into four main groups. 
2.2.1.1 Nebulizers 
Nebulizers are used for solution- and suspension-based medications. The aerosolization is 
performed by a vibrating mesh (Mesh nebulizers), ultrasonic transducer (Ultrasonic nebuliz-
ers) or by compressed air (Jet nebulizers) [38]. These types are effective in aerosol delivery in 
children (mouthpiece or facemask) [39]. One main disadvantage is the high price and fur-
thermore the need for maintenance of the equipment and consequent supervision during drug 
application [40]. Also the droplet size might be affected by changes in temperature, as well as 
the concentration of the nebulizing solution in the reservoir during the inhalation process [41]. 
2.2.1.2 Pressurized metered-dose inhalers (pMDIs) 
pMDIs are formulated as solutions or suspensions. Aerosol delivery from pMDI is a complex 
process involving the discharge and the atomization of a pressurized propellant-based formu-
lation following a rapid evaporation of volatile components [42]. Mainly the propellant 
(e.g. HFA), semi-volatile cosolvents (e.g. ethanol), non-volatile excipients (e.g. surfactant 
lipids) and the API are formulated [43]. In the past, environmentally damaging chlorofluoro-
carbon propellants (CFCs) were used [44], however, today these are replaced by more harm-
less propellants of hydrofluoroalkane-type (HFAs). Typically pMDIs are robust to chemical 
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degradation but suffer from various physical instability, including flocculation, sedimentation 
or creaming and wall losses [45]. pMDIs may be used in combination with a spacer device for 
inhalation of steroids and for asthma treatment in children. 
2.2.1.3 Dry powder inhalers (DPIs) 
DPIs offer various designs for mouthpieces, air inlet channels and aerosolization chambers 
leading to differences in aerodynamic characteristics [46]. On the market, different concepts 
are present, such as capsule- or blister-based formulations that can either be inserted manually 
into the device by the patient or are irreversibly inserted during manufacturing. Commonly, 
the API is formulated with coarse carrier particles (e.g. mannitol or lactose) to improve flow-
ability and dispersibility [32]. The dispersion energy is generated by the inhalation pattern 
(flow rate, volume and breath-holding time) [47]. The disadvantages of this treatment are the 
moisture sensitivity [48] and electrostatic charging [49]. In general, DPIs are physically stable 
and more harmless to the environment [50]. These properties are interesting and lucrative for 
further DPI-developments in the future. In this study the focus is set on DPIs. This type of 
inhaler is used in various investigations to determine the influence on particle deposition and 
dissolution behavior of amorphous parts in micronized powders. 
2.2.1.4 Soft mist inhalers (SMIs) 
The Respimat
®
, a so-called SMI, produces a slow aerosol cloud (< 10 m/s) which results in 
higher lung deposition due to facilitation of slow-breathing maneuver [51]. This SMI gener-
ates small particles over a longer duration (1.5 s) which, in particular, is an advantage for pa-
tients with lower flow rate and volume. The aerosol is generated by pressing a metered 
amount of liquid through a nozzle system (250 bar) forming two jets disintegrating into fine 
droplets (Soft Mist™) by collision [52]. One disadvantage is the high prize of the SMIs com-
pared to other devices. 
2.2.2 Formulation strategies in dry powder inhalers (DPIs) 
In general, the API (about 5 µm) is formulated with carrier particles (about 250 µm) to a bina-
ry mixture [53]. Thereby, interactions between API-API and/or API-carrier are present of 
different kind and degree (Chapter 2.2.3). A further approach to increase the drug de-
agglomeration is the addition of micronized carrier particles (fines). This ternary mixture fa-
cilitates the saturation of high-energy binding sites on the carrier by the fine particles (active 
site hypothesis), protect the drug particles against high press-on forces (buffer hypothesis) and 
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trigger the formation of API-carrier agglomerates (agglomeration hypothesis) [54–58]. These 
phenomena might enable a better dispersibility of the API. Another formulation strategy con-
cerns with carrier-free systems. Hereby, for example spheroids (soft aggregates) are manufac-
tured by controlled agglomeration (spheronisation) of micronized particles [32]. 
2.2.3 Interparticulate interactions in DPIs - Agglomeration behavior of solid particles 
Interparticulate interactions (cohesion of drug-drug and adhesion of drug-carrier) occur most-
ly on DPIs and are dominated by physical forces and interactions [59]. Physical forces can be 
divided into binding mechanisms with or without material bridges which were described by 
Schubert et al. [60,61]. The solid bridges include behaviors such as sintering induced by tem-
perature (Figure 1, a) and particles which are melted together due to re-crystallization pro-
cesses of amorphous regions (b). Liquid bridges that are mostly generated by water vapor are 
based on an adsorption layer between particles (capillary forces, e).  
 
Figure 1: Simplified schematic interactions between carrier particle and micronized API modified from 
Pilcer et al., 2012 
These capillary forces (FCF) arise when the formation of liquid concave-shaped menisci (me-
niscus force) around the contact area of two neighboring particles (radius of sphere R1 and R2) 
come into existence [62]. In this calculation the surface tension γ and the contact angle ϴ are 
taken into account (Equation 2.2) [63]. 
𝑭𝑪𝑭 =  − 
𝟒 ∙  𝝅 ∙  𝑹𝟏 ∙  𝑹𝟐 ∙  𝜸 ∙  𝒄𝒐𝒔 𝜽
𝑹𝟏 +  𝑹𝟐
  2.2 
 
Van der Waals forces (f), electrostatic charges (d), and mechanical interlocking (c) are domi-
nated by physical forces without material bridges. Van der Waals forces (FvdW) occur once 
dipole interactions are induced, the separation distance between particles is sufficiently small 
(< 100 nm) and the size of the particle is small (< 10 µm). Equation 2.3 shows the calculation 
by Hamaker (sphere and sphere), where AH represents the material-specific Hamaker constant, 
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R is the radius of a sphere (R = 2 R1 ∙ R2/(R1 + R2)) and x is the distance of both particles 
[60,64]. 
𝑭𝒗𝒅𝑾 =  
𝑨𝑯  ∙  𝑹
𝟏𝟔 ∙  𝝅 ∙  𝒙𝟐
  2.3 
 
Electrostatic charge arises by direct surface contact and charge transfer between donor and 
acceptor particles. Triboelectrification describes the electrostatic charging by a short collision 
or by intense friction [65]. Contact charging is classified into three main parts (metal-metal, 
metal-insulators or insulator-insulators) [66]. In summary, the extent of Van der Waals forces 
(FvdW), electrostatic charges and capillary forces (FCF) are dependent on the materials [67]. 
Other interactions are based on chemical forces such as acid-base interaction forces (g) or 
hydrogen bonding. Hydrogen bonding is based on the Coulomb interaction between negative 
charge of a free electron pair and the partially exposed positive charge of a proton [68].  
Furthermore, particle size, shape [69], surface properties (adhering particles, roughness) [70], 
press-on forces during the mixing process [71] and the relative humidity (RH) [72] show an 
enormous effect on agglomeration behavior. Nevertheless, in optimal powder formulations 
adhesive forces and de-agglomeration forces have to be balanced. These interactions have to 
be strong enough to guarantee homogenous, stable powder blends and on the other hand weak 
enough to enable the separation forces during inhalation to detach a substantial fraction of 
drug dose from carrier particles [71]. In general, several of these described effects are rein-
forced and mechanisms may overlap. 
2.2.4 Aerodynamic behavior of particles in the laminar/turbulence air flow  
Mostly, the dispersion of these agglomerates (drug-to-drug/drug-to-carrier) is generated by 
induced air turbulences through grids/rotators, shearing forces and particle collisions. In this 
case the physical stress has to dominate the adhesive forces [73]. These complex mechanisms 
can be enhanced by optimized formulation, well-designed devices and a good inhalation prac-
tice. Figure 2 shows an example for an agglomerated powder (spray-dried Ciclesonide parti-
cles) which might de-agglomerate into single particles for an effective therapy.  
Flow forces and the mechanism of stress to de-agglomerate particles are divided into four 
categories (Rumpf and Raasch, 1962) and can be described individually. Figure 3a demon-
strates the effect of a linear flow. The maximal stress (resistance force FR) is present if a sta-
tionary particle/agglomerate is accelerated in the air stream. 
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Figure 2: Agglomerate of spray-dried Ciclesonide particles 
This flow condition is generally associated with turbulence and shear flows. The resistance 
force (FR) is calculated on the relative velocity (vrel), air density (ρa), the diameter of the ag-
glomerate (xAggl) and air viscosity (η) (Equation 2.4,  2.5). 
𝑭𝑹 =  
𝝅
𝟖
 ∙  𝝆𝒂  ∙  𝒗
𝟐
𝒓𝒆𝒍  ∙  𝒙
𝟐
𝑨𝒈𝒈𝒍  ∙  𝑹𝒆  2.4 
 
𝑹𝒆 =  
𝒗𝒓𝒆𝒍  ∙  𝒙𝑨𝒈𝒈𝒍 ∙   𝝆𝒂 
𝜼
   2.5 
 
 
Figure 3: Mechanisms of stress to de-agglomerate particles by air flow modified from Weiler et al., 2008 
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Part b (Figure 3) describes the rotation of the agglomerate in the shear flow. In addition, to the 
direct effect of stress, the shear flow causes an additional rotation of the particles by its center. 
This leads to the reinforcement of centrifugal forces and tensile stresses which facilitates the 
de-agglomeration. Mechanism c (Figure 3) is based on turbulences which are caused by shear 
stress and velocity fluctuations. These turbulence transport processes influence the rate of the 
mixing processes, lead to changes in the particle size and reinforce the acceleration of particle 
agglomerates [73]. The effect of impact processes is explained in part d (Figure 3). Hereby, 
particle-particle agglomerates or particle-wall collisions are caused by high particle concen-
trations and turbulences. This exchange of impulses may lead to dispersion or deformation of 
the agglomerates.  
2.2.5 Deposition behavior of inhalable particles within the respiratory tract 
Once the API is de-agglomerated from the surface of the carrier, the focus is brought to the 
particle deposition in the lung. The intensity of each lung deposition mechanism in the air-
ways varies with the particle parameters (diameter and density), morphometric parameters 
(airway radius, branching angle and gravity angle) and breathing parameters (residence time 
or particle velocity) [74]. Figure 4 shows the three main overlapping deposition principles in 
the lung (impaction/sedimentation/diffusion).  
 
Figure 4: Division of the respiratory system linked to the overlapping deposition principles in the lung 
modified from Meier et al., 1981 
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Larger particles (> 10 µm) are impacted in the upper airways of the lung due to inertial sepa-
ration and centrifugal force (Figure 4 A) and, thus, may not follow the air stream [75]. Once 
impacted to the mucus of the lung, the particles are removed by ciliary clearance [76]. The 
dimensionless Stokes’ number (Stk) describes the probability of particle deposition in the air-
ways via impaction (Equation 2.6). The higher the Stokes’ number the more particles will be 
impacted. Thereby, the particle density (ρp), the particle diameter (d), air velocity (V), air vis-
cosity (η) and the airway radius (R) are involved.  
𝑺𝒕𝒌 =  
𝝆𝒑 ∙   𝒅
𝟐 ∙   𝑽
𝟏𝟖 ∙   𝜼 ∙  𝑹
  2.6 
 
Sedimentation (Figure 4 B) is a time-dependent physical process in which particles settle 
down depending on their gravitational forces [77]. In this case, lung deposition can be in-
creased by breathing maneuvers (e.g. breath-holding) [78]. Stokes’ law can be used to calcu-
late the setting velocity (VS), where ρa is the density of air and g is the gravitational accelera-
tion (Equation 2.7). For very small particles a correction factor (Cunningham CC) is applied to 
Stokes’ law. 
𝑽𝑺 =  
(𝝆𝒑 −  𝝆𝒂) ∙  𝒅
𝟐  ∙  𝒈
𝟏𝟖 ∙   𝜼
  2.7 
 
Diffusion (Figure 4 C) occurs when small particles (≤ 0.5 µm) undergo a random motion in 
the air stream due to the collision with gas molecules [77]. This mechanism is also known as 
the Brownian motion and is correlated to the particle size and can be described by the Stokes-
Einstein equation 2.8, where Diff is the diffusion coefficient, k is the Boltzmann’s constant 
and T is the temperature. The Brownian motion increases with decreasing particle size and 
becomes an important mechanism for particle deposition in the deep lung [78].  
𝑫𝒊𝒇𝒇 =  
𝒌 ∙  𝑻
𝟑 ∙  𝝅 ∙  𝜼 ∙  𝒅
  2.8 
 
2.3 Crystallinity and physical stability of amorphous systems 
2.3.1 Thermodynamic state 
Pharmaceutical solids can be present in crystalline or amorphous forms. Regarding the crys-
talline state, the constituent atoms or molecules are arranged repetitiously in a specific three-
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dimensional array. Whereas in the case of amorphous materials, the atoms or molecules are 
randomly placed, comparable to a liquid [78]. 
Figure 5 shows the comparison of the crystalline form (lattice structure with a high degree of 
order and with a defined melting point Tm) and the amorphous form (without near-order and 
with glass transition Tg). Amorphous amounts can be prepared by rapid precipitation, cooling 
or lyophilization. Furthermore, amorphous regions are especially created on the surface of 
particles during high-energetic processes (such as milling, blending and even sieving) [79]. 
These regions have a huge potential to change during handling and storage and should be con-
trolled and limited to a minimal level. The metastable state tends to change over time, initiat-
ed by changes in relative humidity and/or temperature [80].  
 
Figure 5: Differences between the crystalline and the amorphous state 
In 1910 W. Ostwald introduced the concept of metastable state and the increase in the poten-
tial free energy [81]. Later, Kauzmann investigated the temperature-dependent decrease in 
configurational entropy of the liquid and the crystalline state [82]. The diagram (Figure 6) 
shows that a crystalline material turns into the liquid phase at its melting point (Tm) when the 
temperature increases. As soon as the liquid is rapidly ‘supercooled’ the metastable, amor-
phous form is built at the glass transition Tg (‘glassy state’) [83]. This time-dependent inter-
mediate state has a higher potential free energy that may promote the transformation from an 
unstable to a more stable product. The ‘glassy state’ tries to re-establish an energetic equilib-
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rium and reach the crystalline state again. This can be achieved by water uptake due to storage 
at higher relative humidities.  
 
Figure 6: Temperature-dependence of liquid and crystalline state 
As a result of the higher content of water the molecular mobility increases (plasticizer effect) 
and the glass transition temperature is reduced. This facilitates the spontaneous re-
crystallization [84]. By extrapolation to lower temperatures the liquid state has a lower en-
thalpy than the crystal state. The Kauzmann temperature is located (TK) at this intersection 
point at which the difference in entropies becomes zero. 
2.3.2 Glass transition (Tg mix) of amorphous mixtures  
The binary mixture of amorphous materials (API/API or API/solvent) is also defined by a 
common glass transition (Tg mix) [85]. The intended application is capable of determining glass 
transitions of a mixture (two components) or to determine the interaction between a sample 
and humidity upon vapor absorption. This behavior can be described by the Gordon-Taylor-
equation (2.9, 2.10), where w1 or w2 is the weight fraction of the single component, Tg1 or Tg2 
is the glass transition of the single component (powder or water), K is the constant and ρ1 or 
ρ2 is the true density of the pure component. 
𝑻𝒈 𝒎𝒊𝒙 =  
(𝒘𝟏  ∙  𝑻𝒈𝟏) + (𝑲 ∙  𝒘𝟐 ∙  𝑻𝒈𝟐)
𝒘𝟏 + (𝑲 ∙  𝒘𝟐)
  2.9 
 
𝑲 =  
𝝆𝟏  ∙  𝑻𝒈𝟏
𝝆𝟐  ∙  𝑻𝒈𝟐
  2.10 
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The glass transition temperature (Tg mix) of the sample is decreased if more water is adsorbed 
due to the low Tg of water. This behavior might initialize an earlier re-crystallization of the 
amorphous amounts. In summary, the determination of the glass transition behavior is a pow-
erful tool for the understanding of the quantification of water mobility in products and for 
controlling the shelf-life of products [86].  
The published value of the Tg of water is 136 K [87]. For the other solvents (methanol, etha-
nol, isopropanol and ethyl acetate) the Tg was estimated by calculating Tg with equation 2.11 
under consideration of the melting temperature (Tm) of the pure substance [88]. Table 1 shows 
an overview of the glass transitions (Tg) of the used solvents. 
𝑻𝒈 =  
𝟐
 𝟑 
 ∙  𝑻𝒎  2.11 
 
Table 1: Glass transition temperature of the used solvents 
SOLVENT Tg [K] 
Water 136 
Methanol 116 
Ethanol 104 
Isopropanol 122 
Ethyl acetate 126 
Methylene chloride 118 
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3 MATERIALS AND METHODS 
3.1 Materials 
For this investigation, six different active pharmaceutical ingredients (APIs) were chosen as 
model drugs due to their varying physico-chemical properties (e.g. lipophilicity, solubility and 
hygroscopicity). These are thought to allow a substantial view on different research issues. 
Mostly, these APIs are for inhalation application. 
One issue is the production of fully amorphous and semi-crystalline APIs. The main objective 
is to develop tailored methods for the quantification of the amorphous content in these differ-
ent hydrophilic and hydrophobic APIs by applying an individually dynamic vapor sorption 
technique. Finally, the influence of amorphous amounts is determined by storage stability 
tests (6 months) and the dissolution behavior analyzed. 
3.1.1 Selection of the model active pharmaceutical ingredients (APIs) 
3.1.1.1 Ipratropium bromide (ITB) 
Ipratropium bromide (ITB, Ph. Eur. 8), an anticholinergic bronchodilator [89], is routinely 
used in the treatment of respiratory diseases such as bronchial asthma and chronic obstructive 
pulmonary disease (COPD) [90]. The competitive antagonism prevents constriction of the 
bronchioles. ITB is part of the short-acting muscarinergic antagonists (SAMAs) substance 
class [91]. This API (e.g. marketed product Atrovent N
®
 [92]) is available as a well-
established pMDI formulation. The dosage is about 20 µg per inhalation. Furthermore, ITB is 
characterized by a very good solubility and high affinity to water vapor (Chapter 4.1.2). Fig-
ure 7 shows the chemical structure of this model drug (molecular weight: 430.4 g/mol, one 
stereogenic center). 
 
Figure 7: Chemical structure of Ipratropium bromide 
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3.1.1.2 Formoterol fumarate (FF) 
Formoterol fumarate (FF, Ph. Eur. 8) belongs to the group of the long-acting β2-adrenoceptor 
agonists (LABAs) and is mainly used for the regular treatment of COPD [93]. It leads to the 
relaxation of the smooth muscle of the bronchioles and therefore to an extension of certain 
airways. In the literature, it is described to be 10-20 times more potent than SBS [94]. FF can 
be found as a mono or combined preparation (e.g. combined with Budesonide) on the market. 
This potent API is applied with low doses (12 µg) in a capsule based DPI formulation (Fo-
radil
®
, Novartis). Figure 8 shows the structural formula (molecular weight: 478.5 g/mol, two 
stereogenic centers). 
 
Figure 8: Chemical structure of Formoterol 
3.1.1.3 Salbutamol sulphate (SBS) 
Salbutamol sulphate (SBS, Ph. Eur. 8) belongs to the substance class of short-acting β2-
adrenoceptor agonists (SABAs) and is routinely used in the treatment of respiratory diseases 
such as bronchial asthma [95,96]. On the market it is available as a pMDI (dose: 100 µg), DPI 
(dose: 200-400 µg) as well as solutions for nebulization (dose: 0.5-5.0 mg/ml). Figure 9 
shows the chemical structure of SBS (molecular weight: 576.7 g/mol).  
 
Figure 9: Chemical structure of Salbutamol 
Mostly, racemic mixture (1:1 ratio) are marketed, in which the R-enantiomer (levalbuterol) 
shows more beneficial effects [97]. The S-enantiomer can increase airway hyperactivity and 
boost the airways smooth muscle contractility in response to allergens [98]. In addition, com-
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binations with ITB (Combivent
®
) are available (SAMAs/SABAs) [99]. This API was chosen 
as the most important representatives of the hydrophilic category. Further investigations were 
performed to study the influence of amorphous amounts on the aerodynamic deposition and 
dissolution behavior. 
Table 2 shows an overview of typical characteristics of the three used hydrophilic model 
drugs. 
Table 2: Typical characteristics of the hydrophilic model drugs 
API ITB FF SBS 
Molecular weight [g/mol] 430.4 478.5 576.7 
Solubility Soluble in H2O Slightly soluble in H2O Soluble in H2O 
Melting point [°C]
*
 237.9 ± 0.4 143.7 ± 1.1 
210.7 ± 0.4 
282.8 ± 0.5 
Water content [%]
*
 3.65 2.28 0.47 
Lipophilicity [LogP] 
(Source: DrugBank) 
-1.80 1.06 0.34 
Drug class SAMA LABA SABA 
Market product Atrovent N
®
 Foradil
®
 Ventolin
®
 
Dose [µg] 20 12 100 
*
 measured 
3.1.1.4 Ciclesonide (CS) 
A major focus has been put on Ciclesonide (CS, Ph. Eur. 8), a hydrophobic API, in this study 
(amorphous amounts, aerodynamic, deposition and dissolution behavior). It has a molecular 
weight of 540.7 g/mol, belongs to the inhaled corticosteroids (ICSs) and improves lung func-
tion in patients with mild-to-moderate persistent asthma [100]. CS is a pro-drug and is con-
verted to its pharmacologically active metabolite (desisobutyryl-ciclesonide) in the lungs by 
the endogenous esterase [101]. This on-site activation (Figure 10) results in a 100-fold greater 
relative glucocorticoid receptor binding affinity [102]. A commercial product on the market is 
the MDI Alvesco
®
 (typical dose: 80-160 µg). Unfortunately, these ICS are generally un-
derused due to lack of compliance (no instant effect) and steroid fear but this third generation 
type shows an improved therapeutic index and pharmacologic profile [103]. It can be shown 
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that CS has a low water affinity due to its hydrophobic characteristic and therefore has an 
enormous stability for the amorphous amounts (Chapter 4.1.2). 
 
Figure 10: Chemical structure of Ciclesonide (pro-drug) and ester hydrolyzes 
3.1.1.5 Budesonide (BS) 
Budesonide (BS, Ph. Eur. 8) is an inhalable corticosteroid (ICS) which is recommended as the 
first-line treatment for patients with persistent asthma [104]. This effective medication is 
characterized by reducing airway inflammation and mucus production [105]. Figure 11 shows 
the chemical structure of BS (molecular weight: 430.5 g/mol). This API is available as a sin-
gle preparation (Pulmicort
®
 Turbohaler
®
, AstraZeneca) or in combinations with Formoterol 
(ICS/LABA) because of synergistic effects [106]. Typically, it is marketed with doses of 
200-400 µg. Nevertheless, it was demonstrated that it has a higher affinity to water and amor-
phous amounts are less stable compared to hydrophobic CS. 
 
Figure 11: Chemical structure of Budesonide 
3.1.1.6 Glibenclamide (GC) 
Glibenclamide (GC, Ph. Eur. 8) was chosen as the final hydrophobic model API which is not 
applied in the inhalation field but primarily processed as tablets (Euglucon N
®
, typical dose: 
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3500 µg) and used in peroral therapy. This hypoglycemic drug is applied to treat type 2 diabe-
tes [107]. The activity is based on the depolarization of pancreatic beta cells and the release of 
insulin to control diabetes [108]. The structural formula is shown in figure 12 (molecular 
weight: 494.0 g/mol). As a result of its good biomembrane permeability and its very poor 
water solubility, it is rated as a class II drug of the Biopharmaceutics Classification System 
[109]. 
  
Figure 12: Chemical structure of Glibenclamide 
Table 3 shows a summary of physico-chemical characteristics of the used hydrophobic APIs, 
respectively. 
Table 3: Typical characteristics of the hydrophobic model drugs 
API CS BS GC 
Molecular weight [g/mol] 540.7 430.5 494.0 
Solubility Insoluble in H2O Insoluble in H2O Insoluble in H2O 
Melting point [°C]
*
 210.4 ± 0.2 260.4 ± 2.1 173.1 ± 1.5 
Water content [%]
*
 0.46 0.38 0.29 
Lipophilicity [LogP] 
(Source: DrugBank) 
5.32 2.73 3.78 
Drug class ICS ICS Antidiabetic 
Market product Alvesco
®
 Pulmicort
®
 Euglucon N
®
 
Dose [µg] 80-160 200-400 3500 
*
 measured 
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3.1.2 Selection of the excipient 
3.1.2.1 α-Lactose-monohydrate 
α-Lactose-monohydrate (Respitose® SV003, x50 = 57.9 ± 0.2 µm, Ph. Eur. 8) was kindly pro-
vided by DFE pharma (Goch, Germany) and was used as carrier in the studies to investigate 
aerodynamic deposition and dissolution behavior with SBS and CS. Commonly, α-lactose-
monohydrate is used in marketed DPI products [110] because these carrier particles have a 
safe toxicological profile and are physically/chemically stable. A further advantage is the 
availability on the market and the inexpensive purchase [59].  
In general, the carrier particle size for lactose is between 40 µm and up to 200 µm. It is char-
acterized by a tomahawk-like particle shape [111]. Figure 13 shows this typical structure 
(blends with SBS as model drug) which may facilitate the detachment of the drug during in-
halation. The magnification (B) demonstrates the agglomeration of API crystal needles on the 
surface. After preparing a stable homogeneous powder blend with the API (typically in a ratio 
of 1:67.5 (w/w) [112]), the drug particles should be de-agglomerated and re-dispersed during 
the inhalation process [113].  
 
Figure 13: Tomahawk-like particle shape of lactose and agglomerated needle-like SBS crystals 
Figure 14 shows the two monomers (D-galactose and D-glucose) of lactose which are linked 
β-1-4-glycosidic. The production is carried out using milk or whey as starting material in in-
dustrial scale. Lipids, proteins and minerals are removed by pasteurization, microfiltration, 
ion exchange and ultimately lactose is crystallized [114]. 
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Figure 14: Disaccharide lactose (condensation of D-galactose and D-glucose) 
3.1.3 Selection of inhalation devices 
3.1.3.1  DPI - Easyhaler® 
In this thesis, the Easyhaler
®
 (Hexal) was used for aerodynamic investigations, storage stabil-
ity tests of amorphous blends (Next Generation Impactor) and for the preparation of certain 
powder fractions for dissolution testing (membranes with fine particles, Andersen Cascade 
Impactor). Figure 15 shows a cross-sectional view of the reservoir based inhaler and the de-
agglomeration principle during the inhalation. A defined amount of the powder blend is me-
tered (volumetric) by the rotary gate feeder. The drug release and the de-agglomeration from 
the carrier lactose are induced by the patient’s air flow (dispersion energy) during inhalation. 
 
Figure 15: Cross-sectional view of the reservoir based Easyhaler
®
 and de-agglomeration principle 
3.1.3.2 DPI - HandiHaler® 
The HandiHaler
®
 (Boehringer Ingelheim, figure 16) was used for the aerodynamic investiga-
tions and storage stability tests with the API mixed with glass beads (Next Generation Im-
pactor). In this case the better dosage of the glass beads was significant compared to the res-
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ervoir based Easyhaler
®
. The API de-agglomeration of the glass beads is facilitated mainly 
when the powder leaves the capsules by generated turbulences after piercing the capsule 
(30 ± 2 mg) and starting the inhalation process [92]. 
 
Figure 16: HandiHaler
®
 as capsule based model inhalation device 
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3.2 Methods 
3.2.1 Preparation of fully amorphous and semi-crystalline samples 
Four methods to produce fully amorphous powders and two procedures for low amorphous 
samples were evaluated. In this case study, all six model APIs with different physico-
chemical characteristics were tested. 
3.2.1.1 Ball-milling (BM) 
The principle of this ball-mill is based on the opposing rotation of the grinding vessel and the 
counterweight/sun wheel (Figure 17). The crystal structure is transformed and the grinding 
process leads to amorphization due to friction and impact forces of the grinding balls 
[115,116]. 
Crystalline APIs were ball-milled in zirconium oxide grinding jars (500 ml) containing a de-
fined number of zirconium oxide grinding balls (30 mm) using a Retsch PM 100 mill (Haan, 
Germany). The grinding time, the rotation speed and the filling level was adjusted for each 
API, respectively. During the process the temperature (cold storage room: 1-3 °C) was moni-
tored. To avoid re-crystallization after milling the fully amorphous samples were stored over 
phosphorous pentoxide (P₂O₅).  
 
Figure 17: Movement of grinding chamber in ball-mill process 
3.2.1.2 Spray-drying (SD) 
Initially, the atomization (dual nozzle) of the solution with defined solid concentration takes 
place in the spray-drying process. By supplying a heat flow on the formed droplets the solvent 
is quickly removed mostly resulting in amorphous solid particles at the end of the drying pro-
cess. 
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Amorphous SBS was produced by spray-drying a 5% (w/w) aqueous solution with a Büchi 
Mini Spray Dryer B-290 (Flawil, Switzerland). An inlet air temperature of 150-151 °C, an 
outlet temperature of 80-82 °C, feed flow of 4.5 ml/min and an aspiration of 100% was used. 
Amorphous CS and BS were prepared by spray drying a 5% (w/w) methylene chloride solu-
tion at an inlet air temperature of 50-51 °C, an outlet temperature of 34-35 °C, feed flow of 
3.75 ml/min and an aspiration of 100%. To avoid re-crystallization the amorphous samples 
were stored over P₂O₅. 
3.2.1.3 Freeze-drying (FD) 
In the freeze-drying process ice crystals (water) sublimate directly into the gaseous state 
without intermediate appearance of a liquid phase. Amorphous powders are formed by drying 
of the frozen solution under vacuum. Amorphous ITB and SBS were prepared by freeze dry-
ing of a 2% (w/w) aqueous solution with a Christ alpha 1-4 freeze dryer (Osterode, Germany). 
First the fluid was applied by means of a burette into liquid nitrogen (Dewar vessel, 50 ml); 
the frozen balls were sieved and frozen at -30 °C in the freeze dryer for 15 minutes. After-
ward, vacuum was applied (2.56 mbar) and the primary drying process was started at -10 °C 
and continued for 40 hours. Then the secondary drying at 0.0001 mbar was started at +10 °C 
and lasted for 20 hours. The time depending change of temperature and pressure is shown in 
figure 18. To avoid re-crystallization the amorphous samples were stored over P₂O₅.  
 
Figure 18: Freeze-drying profile: time depending change of temperature and pressure 
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3.2.1.4 Quench-cooling (QC) 
In general, the melting of the crystal lattice of the respective sample and the sudden conver-
sion of the melt into liquid nitrogen (-196 °C) leads to the formation of amorphous substances 
[117]. 
1 g of GC was weighed into an aluminium cup (Figure 19) and melted on a Kofler-heat bench 
(Wagner Munz, Munich, Germany) at 220 °C or 230 °C. The melt was carefully transferred 
into liquid nitrogen. The amorphous powder was sieved (425 µm) and stored over P₂O₅ to 
avoid re-crystallization.  
 
Figure 19: Transformation of crystalline to amorphous material by quench-cooling 
3.2.1.5 Jet-milling (JM) 
In a mill, the material is mechanically cracked, whereby small amorphous regions are formed 
at the point of rupture carried out by high speed particle-particle or particle-wall collisions 
[118]. Once a certain degree of comminution is achieved the material leaves the grinding 
chamber because of the decreasing centrifugal forces. The powder sample can be collected by 
a filter or a cyclone. Figure 20 shows the schematic structure of the jet-mill used in this study. 
 
Figure 20: Schematic structure of the jet-mill (JM) 
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5 g of each crystalline API was jet-milled (JM1) using the Jet-O-Mizer Modell 00 (Fluid En-
ergy Aljet, Plumsteadville, USA). The grinding pressure was adjusted to 8.0 bar (pure nitro-
gen of quality 2.8) and up to three grinding cycles (Gc 1-3) were performed by repeating this 
procedure. In further experiments the grinding pressure was changed to lower pressures 
(JM2 = 2 bar, JM3 = 3 bar and JM4 = 4 bar). To avoid re-crystallization the partly amorphous 
samples were stored over P₂O₅. 
3.2.1.6 Mixing tests with glass beads (Turbula blender) 
The powder and the admixed glass beads are mechanically strained by the rotation of the 
mixer. The powders and its crystal lattices are physically stressed by the induced impact forc-
es of the glass beads. 
The powder blends with crystalline API (1 g) and glass beads (24 g, 0.25 mm or 4.0 mm, 
Roth, Karlsruhe, Germany) were accurately weighed into a stainless steel container by using 
the double sandwich method (8 g beads/0.5 g API/8 g beads/0.5 g API/8 g beads). All blends 
were prepared with a Turbula blender (W.A. Bachofen AG, Basel, Switzerland). The mixing 
speed (42 rpm) and the mixing time (45 min) were fixed. Figure 21 shows the rotation of the 
Turbula mixer. After the blending process the glass beads were separated by an air jet sieve 
(time: 3 minutes; pressure: 3.000 Pa; mesh size: 150 µm) and a cyclone (Hosokawa Alpine, 
Augsburg, Germany). 
  
Figure 21: Rotation of the Turbula mixer 
3.2.2 Other manufacturing processes 
3.2.2.1 Blending of samples with different amorphous amounts (for calibration curves and 
validation) 
Firstly, powder blends (5 g, filling level of the mixing vessel: 30%) with fully amorphous 
(e.g. ball-milled or freeze-dried) API (0.1%, 0.15%, 0.2%, 0.25%, 0.5%, 2.0%, 5.0%, 8.0% 
and 15.0%) and crystalline API were sieved (mesh size: 500 µm) and then accurately weighed 
Materials and Methods    29 
 
 
into a stainless steel container by using the double sandwich method. All blends were pre-
pared with a Turbula mixer (W.A. Bachofen AG, Basel, Switzerland). The mixing speed 
(42 rpm) and the mixing time (3 × 15 min and after every 15 min sieved with the 500 µm 
sieve) did retain unchanged. For micronized, crystalline starting materials (e.g. FF or BS) an 
electrostatics discharge stick (Haug GmbH, Leinfelden, Germany) had to be used in order to 
guarantee a homogeneous mixture by removing electrostatic charge from the powder.  
3.2.2.2 Conditioning 
In general, the amorphous samples (e.g. micronized powders or blends) were stored over P2O5 
in a desiccator (volume 2.4 l, room temperature) to avoid re-crystallization.  
Different amorphous amounts in powder samples (aerodynamic investigations/dissolution 
testing) were produced on the basis of different storage conditions (solvent and vapor). To 
avoid re-crystallization after the milling process (JM1 Gc1 and JM1 Gc3) the amorphous 
samples were stored over P2O5 in a desiccator, respectively (are named: SBS 1/SBS 2 or 
CS 1/CS 2). The hydrophobic CS sample (JM1 Gc3) was stored over 10 ml isopropanol for 
2 hours (CS 3) and the other half of the hydrophilic SBS sample (JM1 Gc3) was stored over 
saturated KCl solution at 85% RH for 16 hours (SBS 3) in order to re-crystallize the main 
amorphous parts (volume 2.4 l, room temperature). 
To determine the influence of storage stability all produced powder blends (lactose or glass 
beads with SBS 2/SBS 3 and CS 2/CS 3) were stored open in a petri dish at room temperature 
and at 45% RH in a desiccator (volume: 2.4 l). After defined time points (1 day, 1 week, 
2 weeks, 1 month, 3 months and 6 months) the aerodynamic particle size distribution of each 
blend was investigated. 
In order to investigate the surface of the hydrophobic samples and the interaction with organic 
solvent, these samples were stored over 10 ml methanol or isopropanol (BS), isopropanol 
(CS) and isopropanol or methylene chloride (GC). The samples were compared by SEM anal-
ysis after 2 hours of storage in a desiccator (volume: 2.4 l, room temperature). 
3.2.2.3 Blending powder for inhalation/Dissolution testing (Turbula blender) 
Powder blends (NGI, Study 1, chapter 4.4.1) with micronized amorphous or crystalline API 
(SBS 2/SBS 3 or CS 2/CS 3, 0.25 g) and α-lactose-monohydrate (24.75 g) were firstly sieved 
(mesh size: 500 µm) and then accurately weighed into a stainless steel container by using the 
double sandwich method (8.25 g/0.125 g/8.25 g/0.125 g/8.25 g). All blends were prepared 
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with a Turbula mixer (W.A. Bachofen AG, Basel, Switzerland). The mixing speed (42 rpm) 
and the mixing time (3 × 15 min and after every 15 min sieved with the 500 µm sieve) did 
retain unchanged. Finally, two blends for every API with low and high amorphous amounts 
were produced, respectively (Table 4).  
Powder blends (NGI, Study 2, chapter 4.4.2) with micronized amorphous or crystalline API 
(SBS 2/SBS 3 or CS 2/CS 3, 0.15 g) and glass beads (24.85 g, 0.25 mm, Roth, Karlsruhe, 
Germany) were prepared using the same conditions. Finally, two blends for every API with 
low and high amorphous amounts were produced, respectively (Table 4).  
Powder blends (ACI, Dissolution testing, chapter 4.5) with micronized amorphous or crystal-
line API (SBS 1/SBS 2/SBS 3 or CS 1/CS 2/CS 3, 0.25 g) and α-lactose-monohydrate 
(24.75 g) were prepared using the same conditions. Finally, three blends for every API with 
low, middle and high amorphous amounts were produced, respectively (Table 4). 
Table 4: Overview of the produced and tested mixtures 
Conditioning process Amorphous content Carrier type Area of application 
SBS 1 middle Lactose Dissolution testing 
SBS 2 high Lactose NGI, Study 1 
SBS 2 high Lactose Dissolution testing 
SBS 2 high Glass bead NGI, Study 2 
SBS 3 low Lactose NGI, Study 1 
SBS 3 low Lactose Dissolution testing 
SBS 3 low Glass bead NGI, Study 2 
CS 1 middle Lactose Dissolution testing 
CS 2 high Lactose NGI, Study 1 
CS 2 high Lactose Dissolution testing 
CS 2 high Glass bead NGI, Study 2 
CS 3 low Lactose NGI, Study 1 
CS 3 low Lactose Dissolution testing 
CS 3 low Glass bead NGI, Study 2 
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3.2.3 Methods for characterization and analysis of amorphous content 
3.2.3.1 Dynamic vapor sorption (DVS) 
Amorphous powders adsorb water molecules not only on the surface also by absorption into 
the material. The mass of adsorbed and absorbed solvent depends on the solvent used and the 
adjusted relative humidity (p/p0). Screening vapor sorption measurements were conducted 
with a DVS-1, Surface Measurement Systems Ltd., London, UK using a gravimetric method 
to determine the humidity-dependent increase in mass (1 sample). For all screening measure-
ments water was used as a solvent to determine moisture sorption isotherms of crystalline 
starting materials and fully amorphous samples. Furthermore, the contrasting increase of mass 
between hydrophilic and hydrophobic APIs was investigated. For all measurements the p/p0 
value was increased from 0.0 p/p0 to 0.9 p/p0 (steps 0.1 p/p0), then again decreased to 0.0 p/p0 
(steps 0.1 p/p0) and finally the cycle was repeated a second time. The equilibrium criteria for 
each step was reached after no further mass change was detected within four single mass data 
points. 
All other dynamic vapor sorption measurement was conducted with a DVS-HT, Surface 
Measurement Systems Ltd., London, UK using a gravimetric method to determine the humid-
ity-dependent increase of mass (up to 10 samples) in order to classify the amorphous content 
after a calibration with known amorphous amounts (Figure 22). 
 
Figure 22: Set-up of the DVS-HT: Giving the option for testing 10 samples and application of organic 
solvents 
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For each hydrophilic and hydrophobic API individual parameters were used. Different sol-
vents (polar and nonpolar) and different p/p0 values (0.05 p/p0 up to 0.5 p/p0) were adjusted 
for screening measurements, respectively. Hydrophilic APIs were measured with ddH₂O and 
hydrophobic APIs were screened with ddH₂O, methanol, ethanol, isopropanol, ethyl acetate, 
methylene chloride, acetone and hexane (mean ± sd). 
3.2.3.2 X-ray powder diffraction (XRPD) 
X-rays are generated in an evacuated X-ray tube. A high voltage is applied at the cathode 
(Wolfram), whereby electrons are released and accelerated in the direction of the metal anode 
(Figure 23). This kinetic energy is mainly converted into thermal energy while only a small 
fraction is emitted as X-rays. 
 
Figure 23: Structure of the evacuated X-ray tube 
XRPD is used for identifying the structure of a crystal lattice by measuring the angles and 
intensities of the diffracted beams (Ph. Eur. 8, 2.9.33). All powders were examined by X-ray 
powder diffraction (XRPD, Stoe&Cie GmbH, Darmstadt, Germany) to investigate the state of 
crystallinity of the samples. The X-ray Cu anode was operated at a voltage of 40 kV and 
strength of 30 mA. The samples were measured in the range of 8-35° at a step rate of 
2 ϴ = 0.05° with 2 seconds measuring time per step. 
3.2.3.3 Differential scanning calorimetry (DSC) 
In order to determine the re-crystallization temperature and the melting temperature the sam-
ples were analyzed by differential scanning calorimetry (Perkin Elmer PYRIS Diamond DSC, 
Massachusetts, USA). The differential heat flow between the sample and the reference cell is 
determined during a temperature-time-program of the measurement. For the measurement 
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2-3 mg of powder was accurately weighed into pierced aluminum DSC pans. The samples 
were investigated at a heating rate of 10 °C min
 -1
 under a nitrogen flow of 20 ml min
-1
 be-
tween 0 °C and 300 °C. The calculation of melting temperature (Tm), onset temperature (To), 
re-crystallization temperature (Tc), the corresponding event area [mJ] and enthalpy (∆H) was 
carried out by PYRIS software 3.8 (Perkin Elmer) (mean ± sd). 
3.2.3.4 Temperature-modulated differential scanning calorimetry (TMDSC) 
A modulated temperature DSC (Perkin Elmer PYRIS Diamond DSC, Massachusetts, USA) 
was used to determine in triplicate the change in heat capacity (delta Cp) and to measure the 
glass transition temperature (Tg) of the samples (Figure 24) (mean ± sd). 5-6 mg of powder 
was filled into pierced aluminum DSC pans. All samples were measured at a heating rate of 
5 °C min
-1
, amplitude of 3 °C and an isothermal length of 1 minute under a nitrogen flow of 
20 ml min
-1
 between 0 °C and 150 °C. 
 
Figure 24: Principle of temperature-modulated heating rate 
3.2.3.5 Hyper-differential scanning calorimetry (Hyper-DSC) 
In order to determine the re-crystallization temperature (Tc) and the melting point (Tm) Hyper-
DSC (Perkin Elmer PYRIS Diamond DSC, Massachusetts, USA) was used. 2-3 mg of powder 
was accurately weight into pierced aluminum DSC pans. The samples were run at a heating 
rate of 300 °C min
 -1
 under a nitrogen flow of 20 ml min
-1
 between -80 °C and 280 °C. 
3.2.3.6 Dynamic mechanical analysis (DMA) 
Dynamic mechanical analysis (DMA) is mainly used to determine structure, morphology and 
viscoelastic behavior of polymers but also for the analysis of crystalline and amorphous mate-
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rials [119]. 15 mg of powder was accurately weighed into aluminum pockets. These powder 
pockets show a time-dependent deformation (strain ɛ) under sinusoidal mechanical stress σ 
(Figure 25). The measurement was carried out using a temperature gradient (heating rate of 
5 °C min
 -1
 and temperature range of 40 °C to 230 °C) and a Frequency of 1 Hz. The strain is 
correlated to the viscosity of the sample [120]. Herewith, the elastic modulus (G
*
) and tan δ 
can be calculated (Figure 26). They are composed of the storage modulus (G
’
, mechanical 
energy which is stored in shear and elongation experiment) and the loss modulus (G
’’
, con-
verted mechanical energy into heat energy). The behavior of the sample during mechanical 
stress can be divided into 3 main parts.  
Case 1: Elastic behavior: sample (crystalline) reacts without delay to the force (∆δ = 0) 
Case 2: Viscous behavior: sample reacts with the most delay to the force (∆δ = 90°) 
Case 3: Viscoelastic behavior: sample (amorphous) reacts in between case 1 and case 2      
 (0° < ∆δ < 90°) 
 
Figure 25: Viscoelastic behavior of amorphous samples 
Equation 3.1 shows the calculation of the phase angle δ considering the temporal phase 
shift (∆t) and the angular frequency (ω, equation 3.2). Here, the frequency (f) and the peri-
od (Tp) are included in the calculation.  
𝜹 =  ∆𝒕 ∙   𝝎  3.1 
 
𝝎 = 𝟐𝝅 ∙  𝒇 =  
𝟐𝝅
𝑻𝒑
  3.2 
 
The storage modulus (G
’
, equation 3.3) and the loss modulus (G
’’
, equation 3.4) are calculated 
from the maximum values of the stress σ and strain ɛ taking account of the phase angle δ. 
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𝑮′ =  
𝝈𝒎𝒂𝒙
ɛ𝒎𝒂𝒙
 ∙  𝒄𝒐𝒔 𝜹  3.3 
 
𝑮′′ =  
𝝈𝒎𝒂𝒙
ɛ𝒎𝒂𝒙
 ∙  𝒔𝒊𝒏 𝜹  3.4 
 
 
Figure 26: Relationship between elastic modulus, storage modulus and loss modulus 
3.2.4 Methods for powder and particle characterization 
3.2.4.1 Particle size distribution (PSD) determined by laser diffraction analysis 
A parallel laser beam is diffracted by particles located in the measuring zone resulting in a 
unique diffraction pattern from which a PSD is calculated (Ph. Eur. 8, 2.9.31). The diffracted 
light is recorded on a multi-element photodetector after it has been focused by a Fourier lens. 
The diffraction angle is proportional to the particle size and can be described mathematically 
by the Mie- or Frauenhofer-theory [121].  
The particle size distribution (PSD) of the samples was determined by the Sympatec Helium-
Neon Laser Optical System (HELOS
®
, Sympatec GmbH, Clausthal-Zellerfeld, Germany) 
with the dry dispersion module RODOS
®
. The powders were dispersed into the measuring 
zone by compressed air (3 bar). A R2 lens (focal length: 50 mm and measuring range: 
0.25 µm up to 87.50 µm) or a R5 lens (focal length: 500 mm and measuring range: 0.50 µm 
up to 875.00 µm) were used depending on the expected particle size. The calculation of the 
volumetric particle diameter was done with Windox 5 software based on FREE (Fraunhofer 
Enhanced Evaluation). The cumulative volume-based distribution (Q3), the values of x10, x50, 
x90 and the specific surface area (Sv) are determined in triplicate and specified as the charac-
teristic parameters (Figure 27). On basis of the equation 3.5 the Span is calculated which rep-
resents the width of the particle size distribution (mean ± sd). 
𝑺𝒑𝒂𝒏 =  
𝒙𝟗𝟎 − 𝒙𝟏𝟎 
𝒙𝟓𝟎
  3.5 
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Figure 27: Cumulative volume-based particle size distribution 
3.2.4.2 Density measurement 
The density of the powder samples is determined by gas pycnometry. The principle is based 
on the displacement of a gas as a result of the volume of the sample. The solid density can be 
determined due to the pressure rise and the known mass of the powder sample (Ph. Eur. 8, 
2.9.23). Because of the smallest atoms among the noble gases and the ability to cover the 
smallest open pores (true density) helium (inert test gas) is specified. 
The true density was measured with a Helium-pycnometer (Pycnomatic ATC, Porotec, Hof-
heim, Germany). A suitable amount of powder was accurately weight into the vessel, fol-
lowed by a ten-fold determination. Every powder was analyzed three times (mean ± sd).  
3.2.4.3 Scanning electron microscopy (SEM) 
An electron beam is thermionically emitted from a cathode (Wolfram), accelerated and fo-
cused in the direction of the sample. Thereby, signals due to the interaction of the sample and 
electron beam are detected. The recording of the samples up to a magnification of 100,000 is 
possible due to the shorter wavelength of the electron beam. 
By using a scanning electron microscope (SEM) the particle and surface morphology powders 
were investigated. The samples (non-conductive) were prepared by fixing the powder on a 
carbon sticker and coating the sample with gold using a BAL-TEC SCP 050 Sputter Coater 
(Leica Instruments, Wetzlar, Germany). The samples were visualized with a Zeiss Ultra 55 
plus (Carl Zeiss NTS GmbH, Oberkochen, Deutschland) using the SE-2 detector and a work-
ing voltage of 2 kV.  
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3.2.4.4 Inverse gas chromatography (iGC) 
Alkanes are separately injected into a standard column packed with the solid sample and the 
retention time of the vapor is measured by a flame ionization detector, respectively. The re-
tention times changes due to interactions with the powder as a function of surface and bulk 
properties. 
The dispersive surface energy was determined by means of inverse gas chromatography (Sur-
face Measurement Systems Ltd., SMS, London, UK). At least 100 mg powder was packed 
into a pre-silanized glass column, with an inner diameter of 3 mm and length of 30 cm, with 
silanized glass wool. The columns were compacted using the iGC column packer (SMS, Lon-
don, UK) at a medium intensity (corresponds to level 6) for 10 min and conditioned for 
2 hours at 0% RH and 303 K to remove impurities and physisorbed water. Different alkanes 
(decane, nonane, octane, heptane and hexane) were injected three times. The flame ionization 
detector (FID) was used to measure the highest surface energy of the samples. The dispersive 
part of the surface energy was calculated (3-fold) with help of the iGC software (SMS, Lon-
don, UK) for all starting materials of each API (mean ± sd). A detailed illustration of the cal-
culations is described by Ylä-Mäihäniemi et al. [122]. Figure 28 shows the schematic set-up 
of the inverse gas chromatography. 
 
Figure 28: Schematic of inverse gas chromatography (iGC) 
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3.2.4.5 Surface area determined by Brunauer, Emmett and Teller (BET) method 
The determination of the specific surface is performed by a gas adsorption method 
(Ph. Eur. 8, 2.9.26). The principle is based on the physical adsorption of inert gas molecules 
(nitrogen) onto solid surfaces [123]. The amount in which the surface is coated by a monolay-
er of adsorbed nitrogen is determined. The mass-specific surface (Sm) is calculated based on 
the surface area of nitrogen molecules and the sample mass.  
The specific surface area (SSA) was measured under vacuum using the nitrogen adsorption 
BET method with a Gemini 2360 system (Micromeritics Instrument Corporation, Norcross, 
USA). All samples (weight > 300 mg) were evacuated in a VacPrep 061 (Micromeritics In-
strument Corporation, Norcross, USA) for at least 24 hours at 40 °C to remove adherent sub-
stances from the surface. Glass beads were weighed in the reference cell to reduce the volume 
difference between the sample and the reference cell. Therefore the true density was measured 
with the Pycnomatic ATC (Porotec, Hofheim, Germany) to obtain an adequate volume of 
glass beads. Eleven relative pressures between 0.05 p/p0 and 0.3 p/p0 were used in the meas-
urement (liquid nitrogen, T = 77 K) and the molar amount of adsorbed gas (nads) is deter-
mined. Every sample was analyzed in triplicate (mean ± sd). Thereafter, the monolayer can be 
calculated using the BET equation (Brunauer, Emmett and Teller, equation 3.6). 
𝒑
𝒑𝟎⁄
𝒏𝒂𝒅𝒔 ∙  (𝟏 −
𝒑
𝒑𝟎⁄ )
=  
𝟏
𝒏𝒎 ∙  𝑲
 + 
𝑲 − 𝟏
𝒏𝒎 ∙  𝑲
∙  
𝒑
𝒑𝟎⁄   3.6 
 
The monolayer nm (Equation 3.7) and the constant K (Equation 3.8) are calculated from the 
intercept (a = 1 / nm ∙ K) and the slope (b = (K - 1) / (nm ∙ K)) by plotting the determined 
y-values to p/p0. 
𝒏𝒎 =  
𝟏
𝒂 + 𝒃
  3.7 
 
𝑲 =  
𝒃
𝒂
+ 𝟏  3.8 
 
The mass-specific surface Sm is calculated (Equation 3.9) from the surface of the nitrogen 
molecule A, the Avogadro constant NA and the determined monolayer capacity nm. 
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𝑺𝒎 =  𝒏𝒎 ∙  𝑨 ∙ 𝑵𝑨  3.9 
 
3.2.4.6 Residual moisture determined by infrared scale (IR) 
The moisture analyzer (Sartorius MA 45, Sartorius Weighing Technology GmbH, Göttingen, 
Germany) was used to determine the residual moisture of hydrophilic and hydrophobic APIs. 
At least 1.8 g (mwet) were weighed onto the measuring pan and dried to a constant mass at 
105 °C. Thereafter, the residual moisture was calculated based on the initial mass 
(Equation 3.10). 
𝑹𝒆𝒔𝒊𝒅𝒖𝒂𝒍 𝒎𝒐𝒊𝒔𝒕𝒖𝒓𝒆 [%] =  
𝒎𝒘𝒆𝒕 −  𝒎𝒅𝒓𝒚
𝒎𝒅𝒓𝒚
∙ 𝟏𝟎𝟎%  3.10 
 
3.2.5 Methods for blend characterization and in-vitro deposition behavior 
3.2.5.1 Determination of blend homogeneity 
Ten randomly taken powder samples (10 mg for each sample) of every blend (powders for 
inhalation/dissolution testing, Easyhaler
®
) were accurately weighed and solved with 10 ml 
9:1 methanol/double distilled water for CS or with ddH₂O for SBS (mean ± sd). 30 mg were 
weighed for the investigations with the glass beads (HandiHaler
®
/capsule). In each study the 
sample size corresponded with the size of a single dose [124]. Afterward, the content of API 
was determined by a validated HPLC analysis. The coefficient of variation (CV) was ≤ 5% 
for a content uniformity. 
3.2.5.2 High performance liquid chromatography (HPLC) 
The API content was analyzed by HPLC (Waters™, Eschborn, Germany) using a LiChro-
CART
®
 125-4 LiChrospher
®
 100 RP-18 (5 µm) column with a precolumn (Merck KGaA, 
Darmstadt, Germany) and a calibration between 1-80 µg (Ph. Eur. 8, 2.2.29). For SBS a 
wavelength of 220 nm was applied and a mobile phase containing 78% buffering system 
(heptanesulfonate and potassium dihydrogen phosphate) with a pH adjusted to 3.65 (by ortho-
phosphoric acid 85%) and 22% acetonitrile was utilized. The flow rate was set to 0.8 ml/min 
and the injection volume was 100 µl. The limit of quantification (LOQ) was 0.1 µg/ml. CS 
was analyzed at a wavelength of 243 nm. The mobile phase contains 15% ddH₂O and 
85% methanol. The flow rate was set to 1.2 ml/min and the injection volume was 100 µl. The 
LOQ was 0.05 µg/ml. 
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Both methods for CS and SBS had to be validated in order to demonstrate that the specified 
requirements are compliant. Especially the storage stability of the samples (up to 5 days) had 
to be checked due to the transport of samples from Ingelheim to Kiel. The linearity, limit of 
quantification (LOQ), accuracy, precision and robustness was validated based on the 
ICH guideline Q2 (R1). 
 Linearity: The ability to obtain test results which are directly proportional to the con-
centration. 7 different concentrations were prepared (1-80 µg) and were measured six 
times by HPLC (R² > 0.99). 
 Limit of quantification (LOQ): The lowest amount of analyte which can be quantita-
tively determined with suitable precision and accuracy. Different dilutions 
(0.05 µg/ml, 0.08 µg/ml, 0.1 µg/ml, 0.2 µg/ml, 0.5 µg/ml and 1.0 µg/ml) were pre-
pared and measured (Signal to noise ratio > 10:1). 
 Accuracy: Expresses the closeness of agreement between the value which is accepted 
either as a conventional true value or an accepted reference value. The same concen-
tration was prepared six times and then measured (recovery: 98-102%). 
 Precision: Expresses the closeness of agreement between a series of measurements ob-
tained from multiple sampling of the same homogenous sample. One concentration 
was injected six times and then measured (coefficient of variation < 2.0%). 
 Robustness: Its capacity to remain unaffected by small, but deliberate variations in 
method parameters. It provides an indication of its reliability during normal usage. 
The stability of one concentration (room temperature and daylight) was measured at 
day 1, day 3 and day 5 (six times injected). 
For all samples the average (mean), the standard deviation (sd) and coefficient of varia-
tion (CV) was calculated (Appendix 8.3.1). 
3.2.5.3 Cascade impactor - Next Generation Impactor (NGI) 
The aerodynamic particle size distribution (APSD) of an inhalation powder is determined by 
impaction analyzes. Thereby, the aerosol is segregated due to differing gravitational forces 
depending on the particle mass and, thus, can be further classified in aerodynamic particle 
size fractions. This behavior is comparable to the separation mechanisms of the lungs.  In this 
study, the Next Generation Impactor (NGI) is used for storage stability tests of crystalline and 
amorphous powder blends regarding its impact on aerodynamic behavior (Ph. Eur. 8, 2.9.18 – 
Gerät E). This in-vitro characterization system is using a specific device design (nozzle size 
Materials and Methods    41 
 
 
and nozzle spacing) to classify particles into aerodynamic size ranges (Figure 29). Larger par-
ticles impact on initial stages (e.g. size, density and inertial forces) whereas smaller particles 
can further follow the airflow and impact on final stages [34,125]. 
 
Figure 29: Set-up of an open NGI with collection cups 
The aerodynamic particle size distributions (APSD) were determined using the Next Genera-
tion Impactor (NGI, Copley Scientific, Nottingham, UK). The throat, the preseparator and the 
8 stages were coated with a mixture of Brij
®
 35 (15%), ethanol (51%) and glycerol (34%). 
Each powder blend (triplicate determination) was filled into the model device Easyhaler
®
 and 
aerodynamically assessed at a flow rate of 50.5 L/min (corresponding to a pressure drop of 
4 kPa, 4 l volume). The glass bead blends (30 ± 2 mg) were filled into capsules and tested 
with the HandiHaler
®
 as model device (flow rate of 50.5 L/min, triplicate determination). SBS 
samples were solved with ddH₂O; CS samples were solved with 9:1 methanol/ddH₂O mixture 
and analyzed by HPLC analysis. The FPF (% of delivered dose < 5 µm), FPD (µg of deliv-
ered dose < 5 µm), MMAD (Mass Median Aerodynamic Diameter, it is defined as the diame-
ter at which 50% of the particles are larger in mass and 50% are smaller) and GSD (Geomet-
ric Standard Deviation, it is a measure of the spread of an aerodynamic particle size distribu-
tion) were calculated with C.I.T.D.A.S. 3.0 software (Copley Scientific, Nottingham, UK). 
The FPF is calculated from the delivered dose (DD) and the measured FPD (Equation 3.11). 
𝑭𝑷𝑭 [%] =  
𝑭𝑷𝑫 [𝒎𝒈]
𝑫𝑫 [𝒎𝒈]
 ∙  𝟏𝟎𝟎  3.11 
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3.2.5.4 Cascade impactor - Andersen Cascade Impactor (ACI) 
A modified Andersen Cascade Impactor (ACI) was used to cover a cellulose membrane (pore 
size 0.45 µm, Whatmann, Dassel, Germany) with fine particles (Figure 30) for dissolution 
testing (Ph. Eur. 8, 2.9.18 – Gerät D).  
 
Figure 30: Modified Andersen Cascade Impactor with filter stage for dose collection  
Powder blends were filled into the Easyhaler
®
 and aerosolized at standard USP airflow condi-
tions (4 kPA pressure drop, 4 l volume). In order to obtain a homogenous particle distribution 
on the membrane a cylindrical shaped stage extension was inserted between stage 1 and the 
filter stage (F). After the vacuum pump stopped, the ideal waiting time for the sedimentation 
was set to 5 minutes [126,127]. Prior of the analysis the preseparator and impact plates 
(stage 0 and stage 1) were again coated with a mixture of Brij
®
 35 (15%), ethanol (51%) and 
glycerol (34%). 
3.2.6 Methods for dissolution behavior 
3.2.6.1 Paddle apparatus with membrane holder (Dissolution testing) 
A paddle apparatus (Sotax, Lörrach, Germany) with a membrane holder was used for the dis-
solution testing (Ph. Eur. 8, 2.9.3 – Apparatus 2). The membrane holder (Copley, Scientific, 
Nottingham, UK) consists of a watch glass and a plastic mesh. The tests were performed with 
a stirring speed of 100 rpm at 37 °C in phosphate buffered saline (PBS) buffer at pH 7.4 
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[126,127]. The samples were taken and filled into vials automatically following a defined 
time schedule with a simultaneous replacement of the dissolution medium with fresh buffer 
(Figure 31). The residual amounts of drug on the membrane and the watch glass were deter-
mined after the single measurements. The total amount of drug was measured using the max-
imum of the cumulatively released amounts. All dissolution experiments were performed in a 
3-fold determination (average ± sd). 
 
Figure 31: Paddle apparatus with membrane holder 
3.2.6.2 Optimization of drug deposition on the filter membrane (ACI) 
The drug deposition on the membrane was optimized to reach a higher drug concentration. 
Different inhaler devices (Easyhaler
®
/HandiHaler
®
), different filter stages and different loads 
(1-10 actuations, 1-10 capsules) were tested in a single determination. Ultimately, equal 
amounts of CS and SBS were to be present on the filters. 
3.2.6.3 Solubility measurements - Saturation solubility 
The dissolution medium (PBS buffer, 100 ml) had to be optimized due to the poor solubility 
of CS. Saturated solutions (50 mg of CS 1/CS 2/CS 3 blends) were prepared without and with 
surfactant. Sodium dodecyl sulfate (SDS, 0.05%, 0.1% and 0.5%), Tween
®
 20 (0.5%), 
Plasdone
®
 (0.5%) and a mixture of 9:1 methanol/ddH₂O were used in the solubility test. The 
solutions were stirred for 48 hours at room temperature and afterward filtered (Minisart 
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RC 15, Sartorius). All solubility measurements were performed in 3-fold determination and 
the concentrations were determined with HPLC after dilution (average ± sd). 
3.2.7 Design of Experiments (DoE) 
The aim of a statistical experimental design is the efficient consideration of complex process-
es. Finally, an empirical model is developed in which the tested factors fit well the obtained 
results [128]. The preparation and the evaluation of the statistical experimental designs were 
done with Design-Expert
®
 8 (Stat-Ease, Inc., Minneapolis, USA). In this study different im-
portant parameters (temperature, solvent vapor, amorphous content and absorption behavior) 
of dynamic vapor sorption (DVS) measurements were investigated. Table 5 shows important 
parameter of the implemented analysis of variance (ANOVA). 
Table 5: Important parameter of the analysis of variance (ANOVA) 
Evaluation F value 
p-value 
Prob > F 
Pred                
R-squared 
Adj          
R-squared 
Adeq  
Precision 
Definition 
Random variable 
which has a 
F distribution 
(degrees of free-
dom) 
Tests a statistical 
hypothesis 
Proportion of 
variance in the 
design space 
explained by the 
model 
Explanatory 
variables 
are added to 
the model 
Ratio 
signal/noise 
Target 
value 
> 1.0 is desirable 
< 0.05 indicate 
model terms are 
significant 
± 0.2 is in rea-
sonable agree-
ment with Adj R² 
0.7–0.9 is 
desirable 
A ratio > 4 
is desirable 
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4 RESULTS AND DISCUSSION 
4.1 Amorphous content and estimation of stability behavior 
In the last years the interest in amorphous regions of inhalation dry powder formulations grew 
more and more. In general, the production techniques, the detection methods, solubility tests 
and stabilization trials of the amorphous state are in the focus and require greater attention 
[129–132]. The common active pharmaceutical ingredients (APIs) are synthesized as crystal-
line solids and subsequently processed by standard pharmaceutical operations such as milling 
[133], blending [134] and even sieving. These processing steps may lead to structural chang-
es, crystal defects and amorphous regions which may have a huge potential to change during 
handling and storage and should be limited to a minimum. The conditions and kinetics of such 
process-induced disorders and changes during storage may affect product stability. In terms of 
the determination and control of the amorphous content, there is still lack in a reliable method 
to accurately assess the amorphous content in pharmaceutical powders down to a minimal 
level (< 1%). 
4.1.1 Fully amorphous samples 
First of all, suitable and reproducible methods for the production of fully amorphous samples 
were investigated. The applicability of four different techniques (BM, SD, FD and QC) was 
evaluated with regard to the varying physico-chemical properties of the APIs (e.g. lipophilici-
ty, solubility and hygroscopicity). The absence of crystalline material in the postulated fully 
amorphous samples (ITB, FF, SBS, CS, BS and GC) was determined by DSC, TMDSC and 
XRPD techniques. Hereafter, these amorphous samples were blended with fully crystalline 
material to produce calibration curves with known amorphous amounts for DVS analytics. 
The ball-milling process is targeted as the most qualified method for the production of amor-
phous content because of the high similarity in particle properties (shape/roughness) com-
pared to the investigated micronized powders. 
4.1.1.1 Ball-milling process 
This complex process incorporates four main variables and therefore is very time-consuming 
for an optimized production of fully amorphous samples. The interplay between the variables, 
filling level, grinding time, rotation speed and number of grinding balls is demanding. The 
main aim is to produce a fully amorphous state and a non-degraded API despite a high ther-
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mal stress. Figure 32 visualizes solid bridges between particles of a sintered ball-milled API 
due to the influence of friction heat and an increase in temperature.  
 
Figure 32: Solid bridges of a sintered ball-milled API 
The produced samples are investigated by DSC measurement, whereby the area of the re-
crystallization event (Tc) is determined. The final powders are supposed to show the largest 
possible area [mJ] and should be comparable to other fully amorphous powders (such as 
spray-dried powders). As an additional measurement a XRPD analysis is performed where a 
broad background signal (“Halo”) is expected. Table 6 gives a generic overview of the opti-
mization process for the determination of the ideal milling parameters to produce fully amor-
phous BS. 
Table 6: Optimized ball-mill parameters for BS 
No. 
Variable 1 
Filling 
level [g] 
Variable 2 
Grinding time 
[h] 
Variable 3 
Rotation speed 
[U/min] 
Variable 4 
Number of 
grinding balls 
Area [mJ] 
Tc 
XRPD 
sharp 
peaks? 
1 25.0 2 and 6 360 4 -12/-15 Yes 
2 25.0 2 and 6 400 4 -15/-16 Yes 
3 25.0 6 and 24 420 4 -16/-28 Yes 
4 6.8 12 400 6 -31 Yes 
5 4.6 28 430 4 -40 Yes 
6 3.0 3.5 380 3 -53 Yes 
7 2.0 15 345 2 -91 Hardly 
8 2.0 20 345 2 -188 No 
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Hereby, the ratio of the filling level (g) to the weight of grinding ball(s) (one grinding ball = 
85 g) plays an important role on the amorphization extent. Over a series of experiments the 
ratio of the API weight to grinding ball weight was increased from 1:13.6 up to 1:85.0. For 
BS the Tc was determined at 107.0 ± 3.9 °C associated with a maximal area up to -188 mJ. In 
general, the ball-milling method was successfully applied to 5 of 6 APIs for the preparation of 
fully amorphous content (FF, SBS, CS, BS and GC). Table 7 presents the final parameters for 
each API, respectively.  
Table 7: Parameters for all APIs in the ball-milling process for the production of fully amorphous samples 
API 
Filling 
level [g] 
Grinding time 
[h] 
Rotation speed 
[U/min] 
Number of 
grinding balls 
XRPD 
sharp 
peaks? 
FF 2.5 16 340 4 No 
SBS 25.0 24 450 6 No 
CS 25.0 2 350 4 No 
BS 2.0 20 345 2 No 
GC 2.0 24 240 3 No 
 
The fully amorphous state was further determined with XRPD analysis and compared to the 
fully crystalline starting material (Appendix 8.3.2). Regarding this analysis all crystalline API 
starting materials showed sharp peaks in contrast to the amorphous samples, which produce a 
broad background signal (Figure 33). These results confirmed the absence of crystalline mate-
rial in the fully amorphous samples and supported the findings from the DSC analytics. 
 
Figure 33: Comparison of fully amorphous and fully crystalline APIs 
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Regarding the hygroscopic drug ITB the ball-milling process was not suitable. Even after the 
grinding chamber was fumigated with argon and the starting material was dehydrated (3.7% 
to 0.4% water content, 2 hours at 150 °C) it was not possible to receive fully amorphous ITB. 
Therefore other production methods were required such as freeze-drying (freeze-dried ITB
*
, 
figure 33). 
Furthermore, the influence of an extended grinding time up to 3 days and the thermal re-
sistance was analyzed during ball-milling for CS (Table 8). The particle size is reduced over a 
longer milling period [135] and this investigation additionally shows a decrease in the melting 
point (Tm) and the glass transition (Tg). The milled and stressed powders showed a slight yel-
low coloring (beginning of decomposition) and a trend of a decreasing delta Cp was deter-
mined (related to the extent of amorphous content). As a consequence it is recommended to 
choose the grinding time very carefully. 
Table 8: Influence of longer grinding times on CS samples 
API Tm [°C] Onset Tg [°C] Tg [°C] Delta Cp [J/g ∙ °C] 
CS starting material 209.4 / / / 
CS SD 208.7 88.5 97.7 0.318 
CS BM 2 h 208.5 88.2 96.4 0.326 
CS BM 6 h 207.5 86.9 96.1 0.337 
CS BM 24 h 204.3 84.8 94.1 0.311 
CS BM 48 h 198.6 80.1 91.1 0.288 
CS BM 72 h 192.7 76.9 87.4 0.308 
 
4.1.1.2 Spray-drying process 
Firstly, a suitable solvent with a good solubility for the specific API was determined (fits well 
the requirements of spray-drying apparatus). The spray-drying process was successfully per-
formed for SBS with water, for CS and BS with methylene chloride as the suitable solvent. 
Table 9 shows the relationship between a low particle size (x50) and an increase in the specific 
surface (Sv) of the powder samples. All spray-dried APIs are in the range of 0.5 µm and 
5.0 µm and might be used in adhesive mixtures for efficient pulmonary drug delivery.  
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Table 9: Characterization of successful produced fully amorphous spray-dried powders 
API x10 x50 x90 Span Sv [m²/cm³] Tg [°C] 
SBS 0.62 ± 0.03 2.20 ± 0.12 5.13 ± 0.16 2.05 ± 0.05 4.26 ± 0.20 116.50 ± 1.35 
CS 0.62 ± 0.02 1.26 ± 0.02 2.36 ± 0.05 1.37 ± 0.02 5.53 ± 0.11 96.10 ± 1.04 
BS 0.67 ± 0.02 1.77 ± 0.03 4.63 ± 0.07 2.24 ± 0.09 4.44 ± 0.09 77.17 ± 1.11 
 
In general, the inlet temperature and the concentration of the solution have both a fundamental 
influence on the surface morphology (roughness or smoothness, figure 34) and the particle 
size of the spheres. A significant influence on the extent of amorphous content was not deter-
mined for the various test experiments. ITB with water as a solvent showed a fast re-
crystallization during spray-drying which led to a crystalline powder [99]. For certain parame-
ters a clear melt was found in the cyclone of the spray-dryer which may be linked to the hy-
groscopic behavior of the API.  
 
Figure 34: Difference in surface morphology: Comparison of rough and smooth spheres 
For GC a low solubility was determined for common organic solvents such as methanol, iso-
propanol and methylene chloride. Spray-drying from a suspension led to crystalline powders 
without a glass transition. In summary, for both APIs (ITB and GC) other methods were se-
lected for the production of fully amorphous samples. 
4.1.1.3 Freeze-drying process 
In this investigation the freeze drying process was performed only with the hydrophilic, wa-
ter-soluble substances, and proved to be the means of choice especially for ITB and SBS. 
Figure 35 shows the porous amorphous structure of a freeze dried SBS sample. One disad-
vantage is the wide particle size distribution for future preparations of homogeneous mixtures. 
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This method was not applied on organic soluble substances due to the incompatibility of the 
freeze-dryer. 
 
Figure 35: Freeze-dried, porous SBS sample 
4.1.1.4 Quench-cooling method 
As an alternative method compared to the spray- and freeze-drying process the quench cool-
ing was also used for the preparation of fully amorphous samples. The DSC analytics were 
used to determine the melting point of the APIs, respectively. ITB and FF showed decomposi-
tions near the melting point because of less precise baseline above their Tm (Figure 36). This 
degeneration of API is impractical for this approach. Table 10 summarizes the specific DSC 
events. It should be mentioned that the release of hydrate water is not listed (for ITB and FF). 
The individual measurements are listed in the appendix (8.3.3). 
 
Figure 36: DSC measurement of the hydrophilic APIs 
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In addition, a degeneration was not determined for GC [117] (Figure 37). The identified tem-
peratures were used as setting parameters for the melting of larger quantities (> 0.5 g) of API 
on the Kofler heat bench. The melt was successfully transferred into liquid nitrogen. After the 
amorphization process the particles were sieved to receive a narrow particle size distribution. 
Table 10: Overview of the investigated APIs by DSC measurement 
API To [°C] Tm [°C] Area [mJ] ∆H [J/g] 
ITB 235.68 ± 0.52 237.91 ± 0.36 233.64 ± 15.04 103.21 ± 12.58 
FF 138.29 ± 2.54 143.74 ± 1.11 374.26 ± 14.29 84.65 ± 10.11 
SBS 192.89 ± 1.32 210.72 ± 0.41 421.06 ± 52.43 161.63 ± 2.91 
CS 208.19 ± 0.02 210.38 ± 0.19 414.01 ± 66.46 74.59 ± 11.16 
BS 258.09 ± 1.93 260.40 ± 2.09 188.96 ± 33.40 71.10 ± 1.64 
GC 169.94 ± 1.20 173.10 ± 1.50 444.19 ± 37.58 83.06 ± 2.43 
 
 
Figure 37: DSC measurement of the hydrophobic APIs 
4.1.2 Stability assessment of the amorphous APIs and shelf-life 
TMDSC (detection of glass transition), Dynamic vapor sorption (determination of moisture 
sorption isotherms) and XRPD analytics (determination of pattern) are examined to estimate 
the stability of the amorphous drugs, respectively. 
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With the increase of the Tg a slower re-crystallization behavior is expected. It was possible to 
correlate the glass transition of each fully amorphous API to its molecular weight (Figure 38). 
The individual Tg measurements are listed in the appendix (8.3.4). 
 
Figure 38: Glass transition of amorphous APIs dependent on molecular weight 
As expected, an increase of the glass transition temperature can be linked to an increasing 
molecular weight. Higher molecular weight leads to lower mobility [136]. In this case the 
spray-dried Budesonide shows the exception. Significant differences between hydrophilic and 
hydrophobic samples could not be detected. In general, a higher glass transition is advanta-
geous and contributes to a longer shelf life. It is assumed that ITB, FF and BS show a lower 
stability of amorphous amounts compared to GC, CS and SBS.  
Furthermore, the behavior of these APIs was evaluated in a humidity atmosphere (2 cycles, 
0-90% RH, water). Typically, amorphous samples show a significantly higher solvent absorp-
tion compared to crystalline materials and the different types of API also differ in their physi-
co-chemical behavior. As expected, the screening vapor sorption measurements (DVS-1) 
showed different results for the investigated crystalline hydrophilic and hydrophobic APIs 
(Figure 39).  
Moisture sorption isotherms of crystalline ITB showed the highest mass adsorption (increase 
of 1.1%) at 0.9 p/p0 for all six investigated APIs. This mass increase of ITB was followed by 
the crystalline FF (increase of 0.6%) and SBS (increase of 0.4%). These hydrophilic, crystal-
line materials adsorb water on the surface [137] and show a high affinity to the polar solvent. 
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In this case the bromide (salt) has the greatest affinity to water vapor compared to fumarate 
and sulphate [138].  
 
Figure 39: Adsorption behavior of fully crystalline APIs 
The hydrophobic APIs showed the lowest adsorption behavior for water vapor (increase of 
< 0.3%). These APIs were much more inert against the polar component (water vapor). The 
reason is that the polar solvent only has limited access to the hydrophobic surface and pores 
[27].  
However, it is assumed that the hygroscopic APIs (e.g. ITB) are difficult to examine using 
DVS-method development because the amorphous amounts might be very unstable due to 
high water uptake (even at low humidity). 
A significantly higher absorption can be detected for the fully amorphous samples applying 
even the same measurement parameters (2 cycles, 0-90% RH, water). Due to the change in 
the crystal lattice during the re-crystallization the second cycle shows a different curve pro-
gression for ITB, FF and SBS (Figure 40). The ITB sample showed an early re-crystallization 
(0.4 p/p0, > 4% change in mass) due to its hydroscopic characteristics. It is presumed that 
amorphous material absorbs water to its inside which therefore results in a higher water up-
take [137]. This process promotes molecular mobility and facilitates the re-crystallization 
process [139]. 
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Figure 40: Absorption behavior of fully amorphous APIs 
For SBS and FF the re-crystallization events were determined in combination with a very high 
water uptake at 0.8 p/p0 (increase of > 10%). Bromide, fumarate and sulphate confirmed their 
behavior towards absorption (as shown for crystalline starting material) – a higher molecular 
mobility led to an earlier re-crystallization (ITB > FF > SBS). 
Again, the hydrophobic APIs underpin a lower affinity to water vapor (even for fully amor-
phous samples). Moisture sorption isotherms of CS and GC resulted in the lowest values (in-
crease of < 2%). BS showed a higher affinity to water vapor (increase of < 4.5%) which may 
also explain the low stability of amorphous amounts. For all hydrophobic APIs neither re-
crystallization events, nor sudden losses in mass or different curve progressions for the second 
cycle were detected for water vapor.  
Finally, the absorption values for fully amorphous samples (at level 0.4 p/p0) demonstrated a 
trend in terms of the LogP values (Table 2 and Table 3). APIs with a higher increase of mass 
are characterized by lower values of LogP. 
Also, XRPD investigations were performed to study the stability of fully amorphous ball-
milled samples. Especially the influence of temperature (Figure 41) and humidity (Figure 42) 
was evaluated by X-ray measurements. In each case the temperature or humidity was equili-
brated for 1 hour before the XRPD measurement was implemented. The same powder sample 
was measured again after 1 hour of equilibration at the next temperature or humidity step. The 
temperature steps were set at 60 °C, 70 °C, 80 °C, 90 °C and 100 °C and the humidity was 
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raised from 20% RH to 50% RH to 70% RH and again at 70% RH but for 24 hours. After-
ward, all diffractograms were compared to fully crystalline samples, respectively. 
 
Figure 41: Temperature influence on amorphous ball-milled CS and BS samples 
For the hydrophobic samples (CS and BS) significant differences were determined. The 
amorphous amounts of CS were more stable against the influence of temperature and humidi-
ty. After 24 hours at 70% RH CS demonstrated sharp peaks which can be correlated to crys-
talline parts. At all other temperature and humidity steps CS showed a fully amorphous be-
havior and a high stability. 
 
Figure 42: Humidity influence on amorphous ball-milled CS and BS samples 
On the contrary, BS showed very low temperature robustness. The re-crystallization process 
of the ball-milled sample started at a low temperature of 60 °C and the material rebuilt the 
fully crystal lattice at 100 °C. Also, a humidity of 70% RH (24 hours) led to a fully crystalline 
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material. These results verify the previous results of TMDSC (lower Tg) and DVS (higher 
water affinity). 
For SBS an influence of moisture on its molecular structure is known, however, the factor 
temperature is less identified and was also examined by XRPD (Figure 43). Again, the same 
temperature steps were chosen and the results showed that the amorphous amounts are ex-
tremely stable. Finally, the broad background signal was detected up to a temperature of 
100 °C after altogether 5 hours of temperature stress. This temperature behavior in the XRPD 
can be correlated to the TMDSC study and the determination of the glass transition. A high Tg 
value of the substance demonstrates a less sensitive re-crystallization behavior in this XRPD 
temperature-study (SBS > CS > BS). 
In summary, obvious differences between the APIs were characterized (TMDSC, DVS and 
XRPD) and indicate a fluctuating stability of the induced amorphous amounts. This post-
operational relaxation is fundamentally induced by temperature, humidity and time. 
 
Figure 43: Temperature robustness of an amorphous SBS sample 
Results and Discussion    57 
 
 
4.1.3 Semi-crystalline samples 
Different methods for the preparation of suitable samples with a low amorphous content are 
evaluated (< 20% amorphous content). The applicability of two different techniques which 
are commonly used in the pharmaceutical industry (jet-milling and blending of powders) was 
investigated. In this study the extent of amorphous amounts in the APIs (ITB, SBS, CS, BS 
and GC) was determined with individually developed DVS techniques (Chapter 4.3.4).  
4.1.3.1 Jet-milling process 
The amorphous content of the respective drugs introduced via jet-milling can be correlated to 
the grinding pressure (1 bar up to 8 bar) and the number of grinding cycles (1-3 Gc). These 
samples with unknown amorphous amounts served as test substances for DVS analytics. Dur-
ing jet-milling the particle size of the sample was reduced with each grinding cycle at 8 bar 
(JM1).  
Table 11 shows the characteristic particle size distribution for each API and each grinding 
cycle, respectively. The complete investigation was not performed for the high potent FF due 
to the hazards of the inhalation at very low concentration (a few µg). 
Table 11: Influence of the number of grinding cycles on the particle size distribution 
API x10 x50 x90 Span 
ITB starting material 0.70 ± 0.02 1.81 ± 0.01 4.21 ± 0.04 1.95 ± 0.03 
ITB JM1 Gc1 0.62 ± 0.00 1.58 ± 0.01 3.87 ± 0.04 2.05 ± 0.03 
ITB JM1 Gc2 0.59 ± 0.01 1.53 ± 0.01 3.79 ± 0.06 2.10 ± 0.05 
ITB JM1 Gc3 0.58 ± 0.00 1.45 ± 0.01 3.58 ± 0.05 2.07 ± 0.03 
SBS starting material 2.03 ± 0.01 9.11 ± 0.07 33.33 ± 1.19 3.44 ± 0.11 
SBS JM1 Gc1 0.83 ± 0.01 2.87 ± 0.01 9.87 ± 0.23 3.15 ± 0.08 
SBS JM1 Gc2 0.73 ± 0.01 2.07 ± 0.01 5.93 ± 0.01 2.51 ± 0.01 
SBS JM1 Gc3 0.71 ± 0.01 1.93 ± 0.01 5.46 ± 0.01 2.47 ± 0.00 
CS starting material 4.74 ± 0.05 57.90 ± 2.96 288.91 ± 19.18 4.91 ± 0.16 
CS JM1 Gc1 0.67 ± 0.01 2.38 ± 0.10 6.30 ± 0.53 2.36 ± 0.12 
CS JM1 Gc2 0.61 ± 0.01 1.94 ± 0.06 5.17 ± 0.29 2.35 ± 0.11 
CS JM1 Gc3 0.57 ± 0.01 1.51 ± 0.02 4.52 ± 0.10 2.62 ± 0.05 
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BS starting material 0.59 ± 0.00 1.66 ± 0.02 4.57 ± 0.10 2.40 ± 0.04 
BS JM1 Gc1 0.55 ± 0.01 1.59 ± 0.03 4.40 ± 0.03 2.42 ± 0.03 
BS JM1 Gc2 0.54 ± 0.00 1.54 ± 0.04 4.17 ± 0.14 2.36 ± 0.03 
BS JM1 Gc3 0.54 ± 0.01 1.51 ± 0.02 3.89 ± 0.06 2.22 ± 0.02 
GC starting material 7.31 ± 0.43 34.45 ± 0.39 85.38 ± 0.66 2.27 ± 0.02 
GC JM1 Gc1 0.80 ± 0.01 3.45 ± 0.12 11.47 ± 0.76 3.09 ± 0.16 
GC JM1 Gc2 0.67 ± 0.00 2.22 ± 0.06 6.25 ± 0.05 2.51 ± 0.04 
GC JM1 Gc3 0.64 ± 0.00 1.97 ± 0.06 5.46 ± 0.28 2.45 ± 0.08 
 
SEM pictures confirmed the results as the micronized powder (8 bar, 1 cycle) reveals a small-
er particle size distribution compared to the crystalline staring material of SBS (Figure 44). A 
significant difference of the needle shaped crystals is visible in the length (approximately 
from 10 µm to 1 µm). These findings can be compared to the other crystal morphologies (sig-
nificant crushing). 
 
Figure 44: Influence of one grinding cycle on particle size (SBS) 
Furthermore, a reduction in the intensity of the sharp peaks (XRPD, figure 45) was deter-
mined for the micronized powders (e.g. SBS) in correlation to the number of grinding cycles 
(1 cycle to 3 cycles). For the fully amorphous sample again no sharp peaks were detected 
(SBS SD). The same behavior was detected for micronized CS and BS (Appendix 8.3.2). 
This behavior indicates a higher amorphous content and was confirmed by a higher absorp-
tion behavior by DVS analytics (Chapter 4.3.1.3 and 4.3.4). 
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Figure 45: Influence of the number of grinding cycles on the peak intensity in XRPD 
4.1.3.2 Mixing tests with glass beads 
The quantification of amorphous amounts introduced during the preparation of physical mix-
tures (carrier and API) proved to be challenging. For this purpose, the initial carrier (e.g. lac-
tose) was replaced by different glass beads (250 µm or 400 µm, figure 46). After a mixing 
time of 45 minutes (at 42 rpm) these glass beads were removed by an air jet sieve to investi-
gate the pure stressed API. Hereby, the smaller API particles were removed by an air stream 
and collected by a cyclone.  
 
Figure 46: Blends with small and big glass beads 
The large-sized glass beads remained on the mesh and were discarded. This process enables 
to determine the amorphous amounts of the pure API. Blends containing 1.5%, 4.0% and 25% 
of API (second component: glass bead carrier) were tested to achieve a sufficient amount of 
API for quantification. High drug loss was determined because of the high press-on forces 
during mixing leading to a high drug retention on the glass beads. Furthermore the air jet siev-
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ing showed a low yield. A blank value was determined for the purely crystalline material dur-
ing the air jet sieving. Finally, the amorphous amounts generated were determined by DVS 
analytics (Chapter 4.3.4). 
4.2 Additional physico-chemical characterization of the crystalline starting ma-
terial 
The determination of major API properties of the starting material was performed in order to 
differentiate and compare specific characteristics. Beside the melting points which were de-
termined while investigation for quench cooling (Table 10) and the DVS moisture sorption 
isotherms which demonstrated initial differences in water uptake for hydrophilic APIs (Figure 
39) further characteristics are useful. Additional assessments are necessary for further calcula-
tions and experimental procedures with amorphous amounts. Table 12 presents the obtained 
values of the additional characterization.  
Table 12: Physico-chemical characterization of crystalline starting material 
API Density [g/cm³] 
Water content 
[%] 
Mass increase 
[% at 0.9 p/p0] 
Surface energy 
[mJ/m²] 
Sv 
[m²/cm³] 
ITB 1.4091 ± 0.0042 3.65 1.1 40.04 ± 0.49 4.35 ± 0.06 
FF 1.3412 ± 0.0035 2.28 0.6 51.20 ± 1.58 4.74 ± 0.04 
SBS 1.3424 ± 0.0044 0.47 0.4 41.11 ± 2.03 1.02 ± 0.01 
CS 1.1935 ± 0.0048 0.46 < 0.3 41.01 ± 1.09 0.75 ± 0.01 
BS 1.2890 ± 0.0049 0.38 < 0.3 48.40 ± 0.77 4.85 ± 0.02 
GC 1.3691 ± 0.0031 0.29 < 0.3 41.70 ± 1.04 0.37 ± 0.02 
 
The true density is required for the investigation and calculation of the common glass transi-
tion (Tg mix) of API and solvent (Gordon-Taylor-equation, chapter 4.3.1.2). In general, this 
model is used to calculate interaction parameters of the API and the plasticizer (solvent) [86].  
The initial water content (determined by infrared scale) is used for the additional estimation of 
the stability of amorphous amounts and furthermore for the optimization of the drying phases 
(DVS analytic). This residual moisture and the hygroscopic behavior can be linked to the 
mass increase of crystalline starting material at 0.9 p/p0.  
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The APIs (FF and BS) that were available as micronized starting materials, tend to electrostat-
ic charge. It is assumed that the different adhesion to the inner walls of a mixer lead to a lower 
homogeneity during the mixing process of calibration curves [140]. Furthermore, the effect of 
particle shape/size on powder flow and cohesion is well documented in the literature [141].  
This presumption can be confirmed by a higher surface energy. Micronized FF showed a sur-
face energy of 51.20 ± 1.58 mJ/m² and BS of 48.40 ± 0.77 mJ/m² compared to the crystalline 
starting materials with a surface energy of 40.04 mJ/m² to 41.70 mJ/m². Shah et al. postulated 
that powder cohesion increases in a linear correlation with an increasing surface energy of the 
API [142]. This observation of micronized powders and high surface energy is supported by 
an increasing specific surface of the particle compared to crystalline starting material. For FF 
and BS values of approximately 5 m²/cm³ were measured. The starting materials which were 
not micronized from the supplier showed values of about 1 m²/cm³. 
The values of the volumetric surface (Sv) can be linked to the measured particle size distribu-
tions of the crystalline starting materials (Table 11). 
Furthermore, XRPD pattern are determined for the crystalline starting materials and show 
characteristic sharp peaks which is resulted from a high degree of the crystal lattice, respec-
tively. These diagrams of all six active pharmaceutical diagrams are listed in the appendix 
(8.3.2). 
4.3 Development of a one-step Dynamic vapor sorption (DVS) method for the 
calculation of amorphous amounts 
Ciclesonide powder samples (fully crystalline material 0%, blends with an amorphous content 
of 5%, of 8% and of 15% and the ball-milled sample containing 100% amorphous content) 
were analyzed to determine the method sensitivity with four different techniques (DSC, 
TMDSC, Hyper-DSC, XRPD) for low amorphous content (Figure 47). 
It turned out that these four different methods were not capable of detecting very small amor-
phous amounts. Only high amorphous amounts were adequate for the exact determination and 
showed specific events such as a re-crystallization event (DSC, Hyper-DSC), glass transition 
event (TMDSC) or a broad background signal (XRPD). Some measurement techniques were 
able to detect blends with an amorphous content up to 15% (DSC, TMDSC and Hyper-DSC). 
These results were comparable to the described limit of quantification (LOQ: 5-10%) in the 
literature for the detection of very low amorphous amounts in powder samples [143]. 
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Figure 47: Comparison of different methods to determine amorphous content of CS 
Furthermore, these samples (0%, 0.25%, 2%, 5%, 8%, 15% and 100% of amorphous content) 
were investigated by Dynamic Mechanical Analysis. The powder samples were filled into 
aluminum pockets and might show a time-dependent deformation (strain) under sinusoidal 
mechanical stress. Hereby, amorphous amounts are characterized by a viscoelastic behavior 
compared to an elastic behavior which can be found in crystalline samples. 
Nevertheless, small amorphous amounts are again not detectable using this suggested tech-
nique. Until 100 °C the loss modulus G
’’
 remains at a low level for the fully amorphous ball-
milled sample (CS) in figure 48. This behavior indicates that the powder sample reacts like a 
solid and the mechanical energy is almost completely stored. Over 100 °C a significant in-
crease of the loss modulus G
’’
 is determined. The sample lost its elastic property and a con-
version into heat energy is realized. 
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Figure 48: DMA measurement of fully amorphous CS 
Another indication is the rapid simultaneous decrease of the storage modulus G
’
. The maxi-
mum is reached at the glass transition of CS (118 °C). Furthermore, a second event (melting 
temperature) was determined at 165 °C, whereby an increase of the loss modulus G
’’
 and a 
decrease of the storage modulus G
’ 
is determined.  
As expected, a glass transition temperature for the crystalline starting material cannot be 
measured. The melting temperature was detected at 194 °C (data not shown). These thermal 
events (BM and crystalline starting material) were not comparable to the data measured in the 
DSC analytics (Tg = 96.4 °C and Tm = 210.4 °C). 
For the blend with an amorphous content of 15% the DMA data showed a different curve 
progression in comparison to the fully amorphous sample (Figure 49). A decrease in the Tg 
event and a deviation of the melting point were determined. For the blends of < 5% amor-
phous content glass transitions were not visible. Finally, this approach was discarded for the 
accurately determination of very low amorphous amounts.  
Finally, the DVS-method was selected at the means of choice for the determination of amor-
phous content. This analytic tool showed a higher sensitivity for a low amorphous content 
˂ 1% and was used as technique of choice [21]. The intention of this proposed work is the 
establishment and qualification of the DVS sorption method (organic, water) to hydrophilic, 
lipophilic and hygroscopic drugs, respectively. This reliable method enables the accurate ac-
cess of the amorphous content in pharmaceutical powders down to a low level. 
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Figure 49: DMA measurement for 15% amorphous content (CS) 
4.3.1 Case study of Ciclesonide (CS) 
There is lack of qualified/validated DVS methods for the detection of minimal amorphous 
parts down to a level of 0.5%, especially for hydrophobic APIs. On the other side the quanti-
fication of amorphous parts by water moisture sorption isotherms for hydrophilic samples is 
well documented in the literature [26]. In a review Sheokand et al. divided the DVS-methods 
for the quantification of amorphous amounts into three main groups [15]. The equilibrium 
moisture uptake (based on absorption), the water uptake method (based on re-crystallization) 
and the residual weight (based on solvated solvent) method are discussed. However, for hy-
drophobic material, which is chemically more stable against water vapor and the change in 
crystallinity is self-limiting, only a few DVS approaches are available with focus on organic 
solvents. For example Mackin et al. used acetone as a solvent (for a benzyl ether derivative-
type of drug) and Samra et al. used mixtures of ethanol/water and ethanol/n-propanol in their 
investigations with hydrophobic terfenadine [25,27]. The aim of this study was primarily to 
find the solvent with the highest affinity to the API, respectively. Finally, the method is sim-
plified as much as possible to shorten measurement procedure resulting in a one-step method 
(time saving: reduction by 80% over 200 hours). Since the DVS method can easily be adapted 
to different active pharmaceutical ingredients (adjustment of temperature, vapor p/p0 and 
screening of the solvent), this method has a huge advantage compared to the methods men-
tioned in the previous chapter. At first, this DVS method development based on ‘equilibrium 
moisture uptake’ is presented extensively for CS as the hydrophobic model drug. Thereafter, 
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the applicability of the method to the other five APIs was investigated and adapted according 
to the case study of CS. A high affinity between API and solvent is targeted to receive a high 
sensitivity of the method, a higher slope of the calibration curve and to detect minimal differ-
ences between powder samples. However, the amorphous content has to be stable for an exact 
determination. The development can be divided into six main sections (water moisture sorp-
tion isotherms, organic solvent screening, optimization of the p/p0 values, temperature robust-
ness, influence of particle size/surface and validation). Finally, a schematic model for the ex-
planation of the adsorption and absorption theory is introduced [144]. 
4.3.1.1 Water moisture sorption isotherms - Influence on the absorption behavior and the 
need for organic solvents 
The measurement with water vapor showed differences in the water uptake between the fully 
amorphous spray-dried and the ball-milled CS (increase of < 1.0% at 0.4 p/p0) and SBS (in-
crease of > 5.0% at 0.4 p/p0) (Figure 50). As expected, the hydrophilic sample (SBS) shows 
higher water absorption in comparison to the hydrophobic API (CS) which was much more 
inert against water vapor. The reason is that the polar solvent only has limited access to the 
hydrophobic surfaces and pores [27]. This finding again demonstrates that the water vapor 
method is not suitable for hydrophobic powders.  
 
Figure 50: Water moisture sorption isotherms of hydrophilic and hydrophobic samples 
With this insensitive analysis low amorphous amounts are not detectable with water vapor 
because the difference in the absorption behavior between the fully amorphous hydrophobic 
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powder and the fully crystalline powder is minimal and thus no acceptable precision may be 
achieved. Further studies with small quantities of hydrophobic API (jet-milled samples) re-
vealed that the water sorption is not suitable to detect small amorphous contents. In this case 
the crystalline starting material indicates the baseline sorption behavior and the spray-dried 
and ball-milled powders represent the limit for highest detectable amorphous amounts.  
In summary, this measurement clearly shows the maximal sensitivity and the upper limit of 
detection which is obtained by a high affinity to the solvent (in this case: hydrophilic API to 
the polar solvent water). This approach will be implemented in the following for a nonpolar 
solvent and a hydrophobic model drug (CS). 
4.3.1.2 Organic solvent screening - Influence on absorption behavior 
Based on the results of the water vapor sorption study, a screening with different polar and 
nonpolar solvents was conducted to receive higher vapor absorption and therefore an increase 
in the detection limit. Table 13 shows the chemical properties of the used solvents in detail.  
Table 13: Physico-chemical characteristics of the polar and nonpolar solvents 
Solvent Water Methanol Ethanol Isopropanol Ethyl acetate 
Chemical formula H2O CH3OH C2H5OH C3H80 CH3COOC2H5 
Molecular weight  
[g/mol] 
18.02 32.04 46.07 60.10 88.11 
Boiling point  
[°C] 
99.98 64.70 78.37 82.50 77.10 
Density 
[g/cm³, 25 °C] 
1.00 0.79 0.79 0.78 0.90 
Surface tension  
[mN/m, 25 °C]  
72.75 22.55 22.27 20.77 23.75 
Viscosity  
[10
-3
 Pa s, 25 °C] 
0.89 0.59 1.19 2.06 0.45 
Solubility H2O  
[25°C] 
∞ ∞ ∞ ∞ 8.10 
Dipole moment  
[D] 
1.85 1.70 1.69 / 1.78 
Lipophilicity  
[miLogP] 
-0.29 -0.32 0.06 0.42 0.76 
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These solvents are comparable to the eluotropic series and exhibit larger differences in the 
surface tension, viscosity and of course in the lipophilicity. For each solvent the device com-
patibility (DVS) has to be checked. 
The moisture sorption isotherms of crystalline starting material and amorphous samples 
(BM/SD) were determined (Figure 51). The crystalline sample adsorbed only little vapor of 
each solvent resulting in a low increase of mass (< 0.5%). In summary, all solvents almost 
showed the same isotherms for the crystalline powder. This effect indicates the baseline sorp-
tion behavior and represents the absence of amorphous material.  
The amorphous samples showed a clear increase in the vapor sorption for methanol, ethanol, 
isopropanol and ethyl acetate compared to water (Appendix 8.3.5). Overall a mass increase of 
3.5% to 5.5% at 0.4 p/p0 was observed. For ethanol (BM material at 0.4 p/p0 and mass absorp-
tion > 3.5%), isopropanol (BM material at 0.4 p/p0 and mass absorption > 4.0%) and ethyl 
acetate ((SD material 0.15 p/p0 and mass absorption > 3.0%)/BM material 0.3 p/p0 and mass 
absorption > 5.0%) the point of recrystallization was detected.  
 
Figure 51: Increase of absorption behavior/re-crystallization to different organic solvents 
Isopropanol was found to be the solvent with the highest mass absorption (5.5% at 0.4 p/p0) 
and without a re-crystallization below 0.3 p/p0 for the spray-dried and ball-milled samples (re-
crystallization event Tc was measured by DSC, appendix 8.3.3). The BM sample showed a re-
crystallization at lower p/p0 values for each solvent. It is assumed that crystal nuclei were still 
present in the milled powder and led to a faster re-crystallization compared to the SD sample 
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(Table 14). The length of experiment is correlated to an increased absorption behavior of 
these amorphous samples. 
Table 14: Experimental observations of the organic solvent screening 
Experimental 
observations 
Water Methanol Ethanol Isopropanol Ethyl acetate 
Start of re-crystallization 
[p/p0] 
/ / BM: 0.4 BM: 0.4 
SD: 0.3 
BM: 0.15 
Length of experiment 
[days] 
3 10 10 10 9 
 
A further outcome of the initial study is that nonpolar solvents behave like plasticizers and 
lead to an earlier re-crystallization. Each solvent lowered the glass transition temperature, 
respectively. Several reasons contributed to this behavior, firstly, solvents with a lower mo-
lecular weight have a greater affinity to moisture and interact well with water (methanol, eth-
anol) and secondly solvents with a larger structure (isopropanol, ethyl acetate) interact well 
with the hydrophobic Ciclesonide [86]. The calculation of the glass transition temperature 
(CS SD), using the Gordon-Taylor equation, confirms that ethyl acetate is expected to be the 
strongest plasticizer (Figure 52). The Gordon-Taylor equation enhances the determination of 
the glass transition temperature of a mixture (Tg mix of components), requiring known parame-
ters such as the weight of the single fractions determined by DVS analytics (w1 = Ciclesonide 
and w2 = solvent), the Tg 1 of amorphous Ciclesonide (Table 9), Tg 2 of the solvents (Table 1) 
and the true density (Table 12, Table 13) of the components. Equation 4.1 and 4.2 shows the 
calculation for spray-dried CS with ethyl acetate at p/p0 value of 0.2. 
𝑲 =  
𝟏.𝟐𝟏𝟒𝟑 𝒈/𝒄𝒎³ ∙ 𝟑𝟕𝟎.𝟕 𝑲
𝟎.𝟗𝟎 𝒈/𝒄𝒎³∙ 𝟏𝟐𝟔.𝟎 𝑲
 = 3.97       4.1  
 
𝑻𝒈 𝒎𝒊𝒙 =  
(𝟗𝟓.𝟎𝟗𝟗𝟗% ∙ 𝟑𝟕𝟎.𝟕 𝑲) + (𝟑.𝟗𝟕 ∙ 𝟒.𝟗𝟎𝟎𝟏% ∙ 𝟏𝟐𝟔.𝟎 𝑲)
𝟗𝟓.𝟎𝟗𝟗𝟗% + (𝟑.𝟗𝟕 ∙ 𝟒.𝟗𝟎𝟎𝟏%)
 = 329.15 K = 56.15 °C  4.2  
In summary, ethyl acetate lowers the glass transition temperature most effectively and there-
fore, the substance can re-crystallize faster in comparison to the other used solvents. In the 
case of water, it is first sorbed as a monolayer by the material. At higher p/p0 values multi-
layers (adsorption) [80] can be found leading to a very low decrease in the Tg. On the contra-
ry, an absorption into the hydrophobic particle (e.g. fully amorphous BM and SD samples) 
can be noticed for the organic solvents. As a result of the higher content of solvent the molec-
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ular mobility increases (plasticizer) and the glass transition temperature is strongly reduced. 
This facilitates the spontaneous re-crystallization. The SD and BM samples almost showed 
the same results. 
 
Figure 52: Decrease of glass transition due to solvent type and quantity (Gordon-Taylor) 
4.3.1.3 Determination of the optimal vapor (p/p0) value 
Finally, isopropanol (high mass absorption, no early re-crystallization) was used for further 
single measurements with low amorphous amounts (jet-milled powders) to determine the in-
fluence of different vapor pressures in detail. In this test series, 0.10 p/p0, 0.15 p/p0, 0.20 p/p0 
and 0.30 p/p0 were analyzed (Figure 53) as a one-step measurement with the objective of sav-
ing time (2 days instead of 10 days). This one-step method is designed in a way that the sam-
ple is dried for 20 hours and afterward the humidity is adjusted individually for 22 hours. The 
same micronized powders were used in every measurement. The different amorphous 
amounts were received by one, two or three grinding cycles (Gc). The lowest humidity 
(0.10 p/p0, Figure 53 A) turned out to be setting of choice, it showed no re-crystallization of 
the amorphous samples (no loss of weight) and the change in mass was almost in equilibrium 
over 22 hours; therefore, this p/p0 value was chosen as the most suitable parameter. Higher 
humidity levels led to re-crystallization [145] which correlates to a strong and quick loss in 
mass. Especially for the highest humidity (0.30 p/p0, Figure 53 D) this assumption was con-
firmed. The mass loss (0.15 p/p0, 0.20 p/p0 and 0.30 p/p0) does not ensure a correct interpreta-
tion and therefore is not suitable for the calculation of the amorphous content (comparison of 
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the equilibrium dried mass and after the equilibrium of solvent absorption). However, signifi-
cant differences in the absorption behavior were determined by reason of different grinding 
cycles and small amorphous amounts. The absorption was significantly increased (0.3%) for 
JM1 Gc3 in comparison to the crystalline starting material at the optimized p/p0 value of 0.1 
(isopropanol). 
 
Figure 53: Influence of the p/p0 value (isopropanol) on the stability of amorphous amounts 
4.3.1.4 Temperature robustness - Design of Experiments (DoE) 
In this study the temperature robustness was evaluated using the software Design-Expert
®
. To 
estimate the interaction of the parameters (amorphous content and temperature) in this method 
a factorial plan was used. In general, the factors (p) and a number of levels (n) are varied to 
measure effects on the target size. The number of experiments is defined by n
p
.  
From findings of preliminary experiments (3³-factorial design, data not shown), the amor-
phous content of CS (factor 1: 8.33-15.75%) and the temperature (factor 2: 20-30 °C) were 
chosen as important factors at a fixed value of 0.10 p/p0 isopropanol. Table 15 shows the used 
3²-factorial design, whereby the center points are determined in triplication. As a response the 
change in mass [%] of the samples was determined by DVS analytics influenced by amor-
phous content and temperature.  
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Table 15: DoE to investigate the factors amorphous content (1) and temperature (2) 
Randomized number Level Factor 1 Level Factor 2 Response [%] 
2 0 11.04 0 25 0.23 
8 +1 13.68 -1 20 0.34 
3 -1 8.56 -1 20 0.20 
11 -1 8.33 +1 30 0.22 
10 +1 13.12 +1 30 0.28 
5 0 11.39 0 25 0.24 
7 +1 14.64 +1 30 0.29 
9 +1 15.75 -1 20 0.31 
1 -1 9.55 +1 30 0.21 
4 -1 9.15 -1 20 0.21 
6 0 11.35 0 25 0.24 
 
The results did not show that a higher temperature led to higher absorption or to an easier re-
crystallization of amorphous amounts in the graphical representation. Despite the knowledge 
of a higher absolute amount of isopropanol in the stream of nitrogen at an increased tempera-
ture the findings demonstrate the temperature independence (Figure 54).  
 
Figure 54: Temperature-robustness of the developed DVS method 
The evaluation of the design (Table 16) showed that the model is significant and factor 1 (A-
amo) is a fundamental model term (F value of 39.32). Factor 2 (B-Temp) is not relevant in 
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this design space. The Pred R-squared is in a reasonable agreement with the Adj R-squared 
(± 0.2). The Adeq Precision measures the signal to noise ratio where a ratio greater than 4 is 
desirable. In summary, well temperature robustness for this DVS method is reached (parallel 
surface of the model). At 0.10 p/p0 a temperature of 25 °C was chosen as suitable parameter 
for a balanced mass absorption without re-crystallization. 
Table 16: Evaluation of the DoE - Temperature robustness 
Source 
p-value 
Model 
p-value 
Lack of fit 
Pred             
R-squared 
Adj                
R-squared 
Adeq  
Precision 
A-amo < 0.0001 < 0.0001 0.7195 0.7931 13.687 
 
This model can be used to estimate very well effects in the design space. Ultimately, the mod-
el proved to be applicable to any other measured absorption of micronized powders (samples 
of amorphous amounts: 3.81-17.01%). Again, there is no significant influence of temperature 
(20-30 °C) on the absorption and stability of amorphous amounts in the DVS measurement 
(Figure 55). Particularly these new samples were integrated that were measured with the one-
step DVS method at 25 °C. 
 
Figure 55: Integration of measured absorption values in the model 
4.3.1.5 Influence of particle size/surface on the absorption behavior 
Micronized powders (CS) with different particle sizes and amorphous amounts were produced 
by a jet-mill in dependence on the grinding pressure (2-8 bar) and the number of grinding 
cycles (1-3 Gc). These powder samples were used to evaluate the influence on the absorption 
behavior during the DVS measurement. The PSD and the amorphous content were directly 
characterized after the micronization process. Afterward, all API particles were stored for 
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2 hours over pure isopropanol (10 ml). This storage guaranteed no major changes in particle 
size and nearly a complete re-crystallization. Again, the particle size and the amorphous 
amount were determined directly after the re-crystallization process. The detected ‘amorphous 
parts’ (%) were correlated to the particle size (x50) (Figure 56). 
 
Figure 56: Influence of particle size on the absorption behavior 
The DVS-measurement determined about 1% amorphous parts after the re-crystallization pro-
cess. The diagram shows that particles with a very small particle size lead to a higher vapor 
sorption directly after their production because of higher amorphous amounts resulting from 
higher grinding pressures or several grinding cycles (up to nearly 18%). After the re-
crystallization process no significant differences in the absorption of isopropanol can be found 
between smaller and larger particles (1.2 up to 2.8 µm), however, a mass increase of 1% is 
detected demonstrating that. The isopropanol has access to surface, cracks and pores and 
therefore is absorbed by particles independent on particle size range tested. 
In addition, a calibration curve (0.25-15.0% of fully amorphous ball-milled CS) was blended 
adding 2% of micronized powder (8 bar, 3 Gc). The amorphous state is localized primarily on 
the surface of the JM sample but the way of quantification with isopropanol does not differ 
from the completely amorphous content which is mainly located inside the particle of the BM 
sample. Figure 57 illustrates the almost parallel shift of the calibration curve with 2% added 
micronized powder. In conclusion this behavior demonstrates the detection of different amor-
phous amounts (surface/inside of particles) in the same manner. 
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Figure 57: Influence of amorphous state localized on the surface and inside the particle 
In general, a linear relationship between increasing amorphous content and the absorption was 
determined. Looking at the phenomena of absorption the effect of the surface should not be 
excluded (Figure 58).  
 
Figure 58: Mass specific surface and absorption behavior of different amorphous samples 
Therefore different blends with amorphous amounts were prepared (0.25-15.00%) for the de-
termination of the specific surface by a gas adsorption method. The diagram demonstrates that 
the absorption values (y-axis 2) of the blends increase due to higher amorphous amounts and 
Results and Discussion    75 
 
 
that the specific surface (y-axis 1) is constant for all blended samples. This indicates that the 
absorption is not significantly influenced by surface effects (Figure 58) in this DVS method 
and can be correlated to the investigation of the particle size (Figure 56). 
Table 17 points out major characteristics of the investigated samples. As expected, a smaller 
particle size (BM > SD) results in a higher specific surface Sm and Sv. The ratio Sm/Sv should 
be constant within a substance class (CS powder samples). 
Table 17: Powder characterization of investigated samples 
Sample 
Density 
[g/cm³] 
Sm  
[m²/g] 
Sv  
[m²/cm³] 
Sm/Sv 
[cm³/g] 
Absorption 
[%] 
CS starting material 1.19 ± 0.00 3.04 ± 0.13 3.61 ± 0.16 0.84 0.05 
CS SD 1.21 ± 0.01 4.06 ± 0.11 4.92 ± 0.13 0.83 1.73 
CS BM 1.20 ± 0.00 2.03 ± 0.08 2.44 ± 0.09 0.83 1.67 
CS 0.25% 1.20 ± 0.00 2.92 ± 0.09 3.50 ± 0.11 0.83 0.11 
CS 2.0% 1.19 ± 0.00 2.94 ± 0.15 3.49 ± 0.18 0.84 0.13 
CS 5.0% 1.19 ± 0.00 2.99 ± 0.30 3.55 ± 0.36 0.84 0.17 
CS 8.0% 1.21 ± 0.01 2.94 ± 0.21 3.55 ± 0.25 0.83 0.19 
CS 15.0% 1.20 ± 0.00 2.92 ± 0.11 3.50 ± 0.12 0.83 0.28 
 
In addition, two calibration curves, one of fully amorphous ball-milled CS and the other of 
spray-dried CS were prepared (0.25-15.0%). As shown before these two materials differ in 
particle shape, surface properties and particle size. Figure 59 shows the almost parallel shift of 
the calibration curves. This indicates that the particle shape/surface has no effect (parallel 
displacement of the lines), however, the total amounts of amorphous state in the preparation 
process (SD/BM) is slightly different.  
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Figure 59: Influence of particle shape on SD and BM samples for CS 
Nevertheless, the TMDSC measurement could not show significant differences in the amor-
phous content of both production methods (Figure 60). The analyses demonstrated approxi-
mately the same Tg and a comparable step height (delta Cp). For the crystalline starting mate-
rial no event was detectable. 
 
Figure 60: TMDSC measurement of spray-dried and ball-milled CS samples 
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4.3.1.6 Validation of the organic one-step DVS method based on the ICH Guideline Q2 (R1) 
Finally, the one-step DVS method had to be validated in order to demonstrate that the speci-
fied requirements are compliant. The linearity, precision/repeatability and the limit of quanti-
fication (LOQ) were investigated based on the ICH guideline Q2 (R1).  
Accuracy and robustness could not be determined because of a possible instability of amor-
phous amounts over a few hours. 
For all one-step DVS measurements, the mass difference between the weight of the dried 
powder (0.0 p/p0, 20 hours) and the conditioned sample (isopropanol 0.10 p/p0, 22 hours) was 
calculated. For higher amorphous amounts higher mass differences were obtained. After pre-
paring a calibration curve for CS (0.25-15.00% of amorphous content), it was possible to cal-
culate the amorphous amounts in the unknown samples. The coefficient of determination 
(R² = 0.9996) shows that there is a very good linearity between mass absorption and amor-
phous content. All five samples were determined in duplicate in one measurement.  
Furthermore, the precision/repeatability for this analytical method were investigated. There-
fore one powder sample (micronized powder at 8 bar, 1 Gc) was measured six times. The re-
sults show a good system precision in dependence to the measurements (mean = 
0.2017% ± 0.0031, CV = 1.51%)  
At the end of the method development the limit of quantification (LOQ) was determined by 
different mixtures with very low amorphous amounts (0.10%, 0.15%, 0.20%, 0.25% and 
0.50%). These blends were measured ten times by the one-step DVS method. The results of 
the LOQ (signal to noise = 10:1) showed that an amorphous content up to 0.5% could be de-
termined with a signal to noise ratio from 10.6:1. For 0.20% the signal to noise ratio was 
7.5:1. For the mixture 0.15% and 0.10% the signal to noise ratio was smaller than 5:1 because 
of a smaller change in mass due to its higher crystalline proportion.  
Figure 61 shows the increase of the absorption values of the crystalline starting material and 
blends with very low amorphous amounts at a noise value of 0.005% (mean value). In this 
case the absorption of the sample has to be twice as large for a LOQ of 10:1. That implies for 
fully crystalline material with the baseline absorption of 0.044% at least an amorphous con-
tent of 0.5%. However, if the noise value might be reduced only smaller differences in terms 
of the individual signals of crystalline starting material and sample are required. In addition, 
with increased noise value an extrapolation of the curves might be informative for the assess-
ment of the LOQ. 
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Figure 61: Estimation of LOQ based on baseline absorption of crystalline material for CS 
Figure 62 shows the new evaluated method in detail. Because of diverse mass adsorptions it is 
possible to calculate different amorphous amounts. Isopropanol (0.10 p/p0, 25 °C) which was 
found to be the most suitable solvent allows to analyze a minimal amorphous content and to 
discriminate between different hydrophobic powder samples (CS). 
 
Figure 62: One-step DVS method for CS in detail 
This figure shows the exact calculation of the LOQ (10.6:1). Hereby, the signal I (baseline 
absorption of fully crystalline material) is subtracted from the signal II (absorption of the 
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blend with 0.5% amorphous content). Finally, the absolute value is divided by the mean of the 
noise value. 
4.3.1.7 Schematic absorption behavior of hydrophilic and hydrophobic samples with polar 
and nonpolar solvents 
Water as polar solvent has a high affinity to hydrophilic powder samples. This behavior can 
be enhanced when transforming the crystalline lattice which consists of a higher order degree 
to an amorphous state (Figure 63).  
 
Figure 63: Schematic absorption behavior modified from Weiler et al., 2008 
Thereby, the adsorption on the surface is reinforced by the absorption effects into the parti-
cles. This phenomenon results in a significantly higher mass increase in comparison to simple 
adsorption (monolayer/multilayer at the surface).  
In an exchange of the amorphous powder state from a hydrophilic to a hydrophobic sample, 
the material again sorbs less water due to the good chemical stability and inertness against 
water vapor which characterizes the hydrophobic material. The absorption into the particles 
can be forced by changing the solvent from polar to nonpolar. In this case isopropanol shows 
a high affinity to the CS powder samples. This mechanism might declare the principle of the 
developed organic dynamic sorption vapor method. 
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4.3.2 Applicability to other model APIs 
In chapter 4.3.1 it was shown that low amounts of amorphous content (LOQ of 0.5%) in a 
hydrophobic model API (Ciclesonide) can be measured with a simple one-step dynamic or-
ganic vapor sorption method. This gravimetric method quantifies exactly the amorphous con-
tent once a suitable solvent, the correct p/p0 value and the exact temperature have been found. 
After the sample undergoes a drying phase, the moisture is adjusted with the particular sol-
vent (one-step). As soon as the equilibration of mass with a definite humidity is balanced, 
different amorphous amounts can be calculated on the basis of different absorption. General-
ly, the background absorption of the crystalline starting material and the blends with known 
content (between 0.25% up to 15.0%) of amorphous amounts are determined, respectively. 
Following this, the amorphous amounts of unidentified samples are measured and calculated 
using the calibration curve. 
In this part the applicability of the method is tested on various APIs which differ in lipophilic-
ity (poor water solubility) and hygroscopicity (high absorption of water). The focus is set on 
BS and GC representing hydrophobic samples and on ITB, SBS and FF representing hydro-
philic samples. In particular, the screening process of hydrophobic substances is difficult and 
time consuming. Thereby, it is necessary that the parameters are selected individually for each 
API (Figure 64).  
 
Figure 64: Overview of the DVS-method development: Production, test measurement and calculation 
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It must be kept in mind that the use of only certain solvents (toxicity in terms of personal safe-
ty, as well as device compatibility) is possible. This work is intended to show a possible ap-
proach on the procedure of adapting and refining the method for new APIs in the future. The 
primary objective is to develop a fast (less than 2 days) and accurate method with high selec-
tivity. A general guidance for the adaptation of the method to other drugs is established. Fig-
ure 64 shows a flow diagram for method development including the production of amorphous 
parts, test measurements and the calculation of the one-step DVS-method. 
4.3.2.1 Adaption for hydrophobic model drugs (BS/GC) 
Due to low water absorption in hydrophobic substances (Figure 39) a change from a polar to a 
nonpolar solvent was necessary. Isopropanol showed the best characteristics for CS powder 
samples where a high mass absorption without an early re-crystallization was found compared 
to methanol, ethanol and ethyl acetate (Figure 51). Different organic solvents were tested for 
BS and GC in order to receive a higher affinity, selectivity and higher slope of the calibration 
curve. Screening measurements were conducted with water, methanol, isopropanol and meth-
ylene chloride. As requirement a balanced mass absorption is again necessary and different 
grinding cycles of each API may lead to different mass absorption.  
Even at low humidity levels (0.05 p/p0) very nonpolar solvents (e.g. isopropanol and meth-
ylene chloride) led to a fast re-crystallization (Figure 65).  
 
Figure 65: Organic solvent screening for BS (JM1 Gc3) 
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The low absorption was comparable to the crystalline starting material and indicates an insta-
ble amorphous BS sample (micronized powder 8 bar, 3 Gc). Especially the increase in mass 
was very low and demonstrated a minor affinity for methylene chloride. Methanol was deter-
mined as the most appropriate solvent with an increased, stable mass absorption and the high-
est affinity to this hydrophobic powder (methanol > isopropanol > methylene chloride). Op-
timized vapor for methanol was a p/p0 with the value of 0.05; higher p/p0 values of 0.2 to 0.3 
can initialize a re-crystallization for all tested solvents. These results were confirmed by fur-
ther test measurements with blends that contained defined amorphous amounts of 0.25% up to 
15.0% (Figure 66). 
 
Figure 66: BS calibration curves measured with different solvent types and intensity levels 
Hereby, the nonpolar isopropanol led to re-crystallization at low humidity levels (0.05 p/p0 
and 0.3 p/p0). Also higher amorphous blends (8.0% and 15.0%) were re-crystallized by higher 
methanol vapors. The calibration curves of BS showed a decreasing mass especially for 0.1 
and 0.2 p/p0. For 0.05 p/p0 a good linearity was shown between the increasing amorphous 
content and absorption (R² = 0.9914). This behavior indicates a stable amorphous state and 
enables the entire determination.  
For GC all solvents led to a balanced mass increase at 0.05 p/p0, however, significant differ-
ence in mass absorption (maximal 0.03%) was not detectable due to the low affinity to all 
solvents (Figure 67). The absorption behavior was hardly increased in relation to the more 
nonpolar solvents (water < methanol < isopropanol < methylene chloride). However, a re-
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crystallization of the amorphous amounts is initiated by a prolonged moisture-level time of 
methylene chloride (quick mass loss). At higher p/p0 values of 0.1 to 0.2 a balanced mass ad-
sorption was not measured for methanol and isopropanol. At these humidity levels amorphous 
amounts were not stable. Finally, isopropanol and methylene chloride showed a lower mass 
adsorption (0.05 p/p0) compared to water (0.5 p/p0) due to the poor solubility of GC. The sol-
vents demonstrated significant differences in the absorption behavior when changing the hu-
midity level (10 times higher). 
 
Figure 67: Organic solvent screening for GC (JM1 Gc3) 
For water a good linearity was shown between an increasing amorphous content and the ab-
sorption at 0.5 p/p0 (R² = 0.9949) (Figure 68). As mentioned in the literature benzyl alcohol 
and dimethyl sulfoxide should increase the solubility, but cannot be used because of their tox-
icity in terms of personal safety, as well as device compatibility. 
It is recommended to measure at higher levels of water vapor (0.5 p/p0) since none of the sol-
vents show a high affinity/solubility to the hydrophobic GC. As a consequence the raising of 
the humidity level led to an extreme increase in mass and allowed a more precise determina-
tion of the amorphous content. 
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Figure 68: GC calibration curves measured with different solvent types 
Figure 69 shows the one-step measurement and corresponding sorption behavior of the hy-
drophobic samples (CS, BS and GC). The amorphous amounts of the GC and CS samples 
were more stable in comparison to the BS samples during the screening process. 
 
Figure 69: Optimized one-step DVS method for the calculation of amorphous parts (CS, BS and GC) 
A total gas flow of 200 sccm and a temperature of 25 °C were used for all organic solvents. 
Table 18 summarizes the final parameters which were used for the determination of the amor-
phous contents in these powder samples. 
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Table 18: Final parameters for all hydrophobic APIs for the determination of amorphous content by DVS 
API Solvent 
Drying time 
[min] 
p/p0 value 
Temperature 
[°C] 
Total gas flow 
[sccm] 
CS Isopropanol 1200 0.1 25 200 
BS Methanol 1200 0.05 25 200 
GC ddH2O 1200 0.5 25 400 
 
In conclusion, optical investigations were conducted to find significant differences in particle 
morphologies of these hydrophobic powders. These pictures may clarify important interac-
tions with the organic solvents and explain mechanisms of the one-step DVS method. The 
storage was carried out in a desiccator (2.4 l, room temperature) for 2 hours with the organic 
solvent, respectively. Hereby, no significant changes in PSDs were determined. In this study 
the respective solvents from the organic solvent screening of the DVS measurements were 
used again. SEM photographs of crystalline and micronized APIs (CS, BS and GC) are inves-
tigated and compared to the conditioned samples (organic solvents: methanol, isopropanol 
and methylene chloride). Figure 70 demonstrates the influence of isopropanol on the starting 
materials of the hydrophobic samples.  
 
Figure 70: Hydrophobic starting material and the conditioned samples with isopropanol 
It can be seen that isopropanol seems to have a high affinity to the CS sample because the 
surface structures look slightly melted and very smooth (CS > BS > GC). This phenomenon 
was reinforced with amorphous content in micronized powders (Figure 71).  
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Figure 71: Micronized powders compared to conditioned samples with isopropanol 
Again, a very smooth surface was determined which is an indication of the high affinity. Par-
ticle corners are rounded and touching particles are melted together (coalesce). This behavior 
might prove to be advantageous for higher absorption and enable a precise detection of amor-
phous content. For the other hydrophobic samples (BS and GC) no optical changes were 
observed when storing over isopropanol for 2 hours. 
This changing of appearance was also determined when storing BS over appropriate solvent. 
In this case the starting material and the micronized powder were stored over methanol for 
2 hours. 
 
Figure 72: Further organic solvent storages for BS and GC 
The SEM pictures (Figure 72) showed a very smooth surface as well which is in correspond-
ence to a high solvent affinity. GC visualized a low affinity to methylene chloride which re-
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flects a comparable situation looking at the isopropanol storage. These results can explain the 
findings from the screening enabling a suitable solvent for GC. The problem of low affinity 
leading to low absorption was solved by a significant higher water vapor (10 times) in the 
DVS method. 
4.3.2.2 Adaption for hydrophilic model drugs (ITB/FF/SBS) 
The results of moisture sorption isotherms (Figure 39and Figure 40) can provide an indication 
which can be used for further measurement parameters. The investigated humidity levels pro-
vide a first overview of the stability of amorphous amounts in these hydrophilic samples and 
furthermore help to receive p/p0 values in order to gain a balanced equilibration of mass. Es-
pecially the re-crystallization events for ITB, FF and SBS are helpful in the development of 
the one-step DVS-HT method. After the drying phase of the sample the amorphous amounts 
have to stay stable without a re-crystallization during the measurement.  
For the hydrophilic APIs, all further screening measurements (DVS-HT) were conducted with 
water as the solvent. Humidity levels were chosen below the determined re-crystallization 
events. For SBS and FF p/p0 values between 0.3 p/p0 and 0.4 p/p0 were tested (re-
crystallization 0.8 p/p0) and for ITB p/p0 values between 0.1 p/p0 and 0.2 p/p0 were tested (re-
crystallization 0.4 p/p0). Test series were performed with micronized powders (JM1, Gc 1 to 
Gc 3) of each API, a number of higher grinding cycles led to higher amorphous amounts and 
therefore to higher absorption values. 
Especially the drying time had to be adapted and was increased for these hydroscopic APIs 
(FF: 30 hours and ITB: 36 hours). The increase of 10 hours/16 hours enables a balanced dry-
ing phase. Because of the risk of an easy re-crystallization an optimized p/p0 value of 0.1 was 
chosen for ITB despite the equilibrium for both vapor values. For SBS and FF a higher p/p0 
value of 0.4 was chosen on the basis of the re-crystallization point at a higher humidity. A 
total gas flow of 400 sccm and a temperature of 25 °C were chosen for all measurements.  
Figure 73 gives an overview of the optimized parameters for all investigated hydrophilic APIs 
and the corresponding sorption behavior. At the time of moisture increase, a sudden increase 
in mass (Y-axis 1) is visible and over the entire period an equilibrium mass was maintained. 
This indicates a stable and calculable amorphous content for all three samples. Y-axis 2 
shows the used p/p0 value (water) of the method for all three hydrophilic drugs. 
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Figure 73: Optimized one-step DVS method for the calculation of amorphous parts (ITB, FF and SBS) 
Table 19 shows the final parameters which were used for the determination of the amorphous 
content in these powder samples. In the screening process amorphous samples of ITB showed 
the lowest stability compared to FF and SBS. 
Table 19: Final parameters for all hydrophilic APIs for the determination of amorphous content 
API Solvent 
Drying time 
[min] 
p/p0 value 
Temperature 
[°C] 
Total gas flow 
[sccm] 
ITB ddH2O 1800 0.1 25 400 
FF ddH2O 2160 0.4 25 400 
SBS ddH2O 1200 0.4 25 400 
4.3.3 Conclusion I 
This DVS study demonstrates with a high accuracy how amorphous regions are specifically 
detectable as “reactive spots” [15] to vapor. The amorphous content is the critical outstanding 
factor and becomes the deciding part of nearly the total signal [23] distinguished to various 
analytical techniques (e.g. DSC and XRPD measurements). It was shown that different APIs 
behave individually; in this case hygroscopicity and lipophilic behavior play an important 
role. Since hydrophilic APIs show a high initial water content (> 2.0 % for crystalline materi-
al, table 12), these APIs (ITB and FF) interact well with vapor. This phenomenon resulted in a 
longer drying phase for the measurement (over 30 hours). ITB samples were quantified at low 
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water vapor (0.1 p/p0) because of a facilitated re-crystallization at higher humidities. Amor-
phous samples of SBS were more stable and consequently measured with an increased humid-
ity-level (0.4 p/p0). CS as a hydrophobic model drug was measured with isopropanol 
(0.1 p/p0) after an implemented organic solvent screening. Also, BS had to be measured with 
an organic solvent (in this case: methanol) and at a low humidity (0.05 p/p0). GC showed a 
low solubility for all usable solvents therefore the measurement was performed with water 
(0.5 p/p0) and an enormously raised humidity level (10 times higher, without re-
crystallization).  
4.3.4 Usability of the one-step method on selected powder samples 
After the measurement of the respective mixtures (0.25-15.0% of amorphous content) it was 
possible to calculate the amorphous amounts in the unknown samples (e.g. jet-milled pow-
ders). Figure 74 shows an overview of the calibration curves for all APIs. The coefficient of 
determination shows that there is a very good linearity between mass absorption and mixed 
amorphous content for almost all APIs (R² > 0.99). These results confirm that amorphous 
amounts are detectable with these methods and amorphous amounts remain stable during the 
measurement, respectively. 
 
Figure 74: Calibration curves of all investigated APIs for the calculation of amorphous amounts 
Only the hygroscopic ITB showed a low stability of its amorphous parts (data not shown), 
which was not induced by the measuring method. The mixture of the amorphous freeze-dried 
component absorbed moisture coming from the crystalline sample (> 3.7% water content). 
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This led to the re-crystallization process and resulted in a decreasing mass absorption. In this 
case a calibration is not possible and practicable. For FF the highest baseline sorption behav-
ior was determined compared to the other APIs. 
Furthermore, the process standard deviation (Sx0) and the process coefficient of variation (Vx0) 
of these calibration curves were calculated (Table 21). The performance of the measurement 
method is reflected in the process standard deviation (Sx0) (Equation 4.3). Hereby, the calcula-
tion of the spread of the measured values of the calibration curve (RSD) and the slope of 
curve (b), which represents the precision and the sensitivity, were used for this further calcu-
lation. 
The determined value is corresponding to a process coefficient of variation (Vx0) 
(Equation 4.4). This parameter describes the relative measure of the precision including the 
process standard deviation (Sx0) and the mean of the amorphous amounts (x-axis) [146]. The 
content of unknown samples was determined by using the created linear equation, respective-
ly. 
𝑺𝒙𝟎 =  
𝑹𝑺𝑫
𝒃
  4.3 
 
𝑽𝒙𝒐 =  
𝑺𝒙𝟎
?̅?
 ∙ 𝟏𝟎𝟎%  4.4 
 
Table 20: Process standard deviation and process coefficient of variation of the calibration curves of the 
developed DVS methods 
Sample RSD [%] Sx0 [%] Vx0 [%] 
FF 0.0216 0.5297 8.7557 
SBS 0.0099 0.1799 2.9741 
CS 0.0036 0.3145 5.1981 
BS 0.0039 0.6459 10.6762 
GC 0.0042 0.4766 7.8774 
 
For these DVS methods a respectable precision was reached. Nearly all APIs showed a low 
coefficient of variation for this new introduced method. Nevertheless, FF and BS demonstrat-
ed an increased value. 
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Table 21 shows the significant mass increase of the single CS blends with varying amorphous 
content in detail. These mixtures were compared to fully crystalline material at 0.1 p/p0 and 
0.3 p/p0.  
Table 21: Absorption values of different amorphous blends at 0.1 p/p0 and 0.3 p/p0 
Amorphous content [%] Mass increase [%], 0.1 p/p0 Mass increase [%], 0.3 p/p0 
0.0 0.0440 0.1022 
0.25 0.0556 0.1516 
2.0 0.0811 0.2145 
5.0 0.1317 0.3193 
8.0 0.1792 0.4334 
15.0 0.2945 0.7249 
 
The following chart shows an obvious enhancement of the curves from m15% > m8% > m5% > 
m2% > m0.25% > mcryst. (Figure 75). On the x-axis the ratio of the increase in mass and the ratio 
of the change in humidity of fully crystalline material are given whereas the change in mass 
and the ratio of humidity of the respective samples are fixed at the y-axis. 
 
Figure 75: Increase of mass absorption of the single blends of CS in dependence to the vapor value 
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In this case Y = X applies for the fully crystalline material. For all other amorphous blends 
Y > X is given resulting from higher absorption values. 
Furthermore, an alternative method for the blending process was tested avoiding the long 
mixing time and sample preparation of 5 hours (nearly 1 hour preparation time for 1 blend). 
For this investigation the Turbula mixer was replaced by a Vortex mixer (SBS). Thereby, the 
mixing time was reduced to 2 minutes for each blend. Figure 76 shows the two calibration 
curves and a consensus of the gradient. The coefficient of determination was only slightly 
decreased (R² = 0.9993 to R² = 0.9967). However, these findings could not be confirmed with 
a repeated experiment with FF. A ball-like formation of particles was determined because of 
higher residual moisture in the starting material. 
 
Figure 76: Alternative method for the preparation of homogenous mixtures of amorphous amounts 
The absorption behavior of  jet-milled powders (8 bar, 1 grinding cycle up to 3 grinding cy-
cles) were measured using the individual methods and finally the amorphous content was cal-
culated (Table 22).  
The hydrophilic APIs almost showed no amorphous amounts (< 0.25%) for FF, however, 
amorphous amounts were measured from 1.5%, 4.2% and 5.1% for SBS. The amorphous 
amounts for hydrophobic APIs resulted in 5.5%, 14.0% and 17.0% for CS, almost no amor-
phous content (< 0.25%) for BS and finally 5.7%, 7.7% and 8.5% of amorphous content for 
GC. In summary, FF and BS tend to re-crystallize very fast. GC and CS demonstrate a high 
stability of amorphous amounts because these hydrophobic materials are much more inert 
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against water vapor. For SBS a lower affinity to water was measured which results in more 
stable powders. 
Table 22: Determination of the amorphous content of micronized powders 
API Suitable method? Possible calibration? Amorphous content? 
ITB yes No, blends are not stable No calculation possible 
FF yes yes < 0.25% 
SBS yes yes 1.5% up to 5.1% 
CS yes yes 5.5% up to 17.0% 
BS yes yes < 0.25% 
GC yes yes 5.7% up to 8.5% 
 
Furthermore, powder samples from the mixing tests with glass beads (stress of crystal lattice) 
were investigated and compared to micronized powders (for SBS and CS). These DVS meas-
urements are intended to give a short overview of how the amorphous content alters depend-
ing on production and processing. All measurements were accomplished with the introduced 
one-step DVS method for both APIs.  
The water vapor method for SBS (0.4 p/p0) shows the difference in water uptake between 
fully amorphous spray-dried and ball-milled SBS (> 5.0% at 0.4 p/p0) and semi-crystalline 
SBS (micronization and blending; < 0.4% at 0.4 p/p0) in figure 77. The fully crystalline start-
ing material results in a baseline sorption of 0.09% at 0.4 p/p0. Small differences were deter-
mined for the blending and micronization process compared to this crystalline starting materi-
al. The micronized powder showed the highest mass adsorption (0.39% at 0.4 p/p0) at 8 bar 
grinding pressure and 3 grinding cycles which is due to the highest amorphous amounts ex-
cept for SD- and BM-samples. It is assumed that the number of grinding cycles increases the 
amorphous amount as mentioned. The mixing tests with small (0.15% at 0.4 p/p0) and big 
(0.12% at 0.4 p/p0) glass beads showed a lower absorption than the micronization process at 
8 bar grinding pressure and 1 grinding cycle (0.20% at 0.4 p/p0). The value ‘cyclone’ is the 
fully crystalline material which was sieved with the air jet sieve for the simulation of the sepa-
ration process of the glass beads. In summary, there is a significant higher absorption for all 
performed micronization tests, ball-milled and spray-dried samples. 
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Figure 77: Overview of the absorption behavior of SBS samples 
Similarly, high vapor sorption for the fully amorphous SD and BM samples (> 1.6% at 
0.1 p/p0) and low vapor sorption (< 0.35% at 0.1 p/p0) for the semi-crystalline starting materi-
al were detected using the isopropanol-based measurement (0.10 p/p0) for CS (Figure 78). 
The fully crystalline starting material results in a baseline sorption of 0.05% at 0.1 p/p0. After 
blending with the big glass beads (0.17% at 0.1 p/p0) a slightly higher vapor sorption was ob-
served than after the micronization of Ciclesonide at 8 bar grinding pressure and 1 grinding 
cycle (0.14% at 0.1 p/p0). Again, with a higher number of grinding cycles (Gc2 and Gc3) sig-
nificant differences were detectable. Beside the fully amorphous samples, Gc3 showed the 
highest absorption (0.33% at 0.1 p/p0) due to the highest amorphous amounts.  
Comparing the results from both APIs, a different behavior is observed when looking at the 
mixing tests with big glass beads and micronization using one grinding cycle. It is assumed 
that the particle shape (SBS: needle crystals and CS: angular crystals) may also have an influ-
ence on amorphous parts which are localized on the surface. The calculation of the amorphous 
parts showed that the high values are maintained when stored over P2O5 in a desiccator espe-
cially for micronized powders with a higher number of grinding cycles (JM1 Gc3). The CS 
powder showed a significant higher amount of amorphous parts compared to the hydrophilic 
SBS. Some SBS samples (e.g. big glass beads, cyclone) show highly crystalline properties 
and they cannot be distinguished from the baseline sorption of the fully crystalline starting 
material. 
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Figure 78: Overview of the absorption behavior of CS samples 
4.3.5 Conclusion II 
In summary, FF showed unstable amorphous amounts due to its hygroscopic behavior 
(< 0.25%). Furthermore no stability (fast re-crystallization) of the amorphous amounts (cali-
bration curve) was determined for ITB blends. In comparison SBS showed significant stable 
amorphous amounts (up to 5.1%). CS as a hydrophobic drug showed the most stable amor-
phous content (up to 17.0%). The investigated amorphous parts for GC (up to 8.5%) are also 
stable against water vapor and thereby not likely to switch to their crystalline counterparts. 
Also, BS showed minimal and less stable amorphous amounts (< 0.25%). In general, all mi-
cronized starting materials (FF and BS) have to be treated with an electrostatic discharge stick 
to achieve blend homogeneity for the calibration of this DVS-method. These micronized start-
ing materials showed a high surface energy (increased by > 6.5 mJ/m²).  
However, it is assumed that these stable amorphous amounts can influence drug delivery and 
product stability. The amorphous content might have a huge influence on the FPFs of inhala-
ble mixtures (Chapter 4.4.1 and 4.4.2) as well as on the dissolution behavior (Chapter 4.5). 
The hydrophilic APIs might show a high trend for re-crystallization over the storage time. 
Thereby, a change in the surface morphology is assumed. These modifications could be rein-
forced by a hydrophilic carrier (e.g. lactose). Hydrophobic APIs might interact less with vapor 
and therefore show an increased stability of the amorphous amounts.  
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A general estimation for the stability of further inhalation grade APIs seems to be possible 
based on the conducted measurements for the different types of APIs. In general, hydrophilic 
APIs (e.g. Tiotropium bromide) might interact well with water vapor and could show a low 
stability of amorphous amounts (hours, days or weeks) compared to other hydrophobic APIs 
(e.g. Salmeterol xinafoate) (up to several months). In summary, it is necessary that amorphous 
parts are determined and re-crystallized after the production process under controlled condi-
tions. This approach of the one-step DVS method may facilitate the specifications for in-
process controls in the pharmaceutical industry. 
4.4 Aerodynamic investigations: Influence of different amorphous amounts on 
the de-agglomeration and deposition behavior 
Methods such as spray-drying, grinding, jet milling and liquid-liquid antisolvents [147] are 
used for the micronization of the drug (particle size < 5 µm). These operations used in the 
pharmaceutical industry lead to structural changes (for example amorphous regions, chap-
ter 4.3.4) and thus could alter the surface properties. This involuntarily produced metastable 
state may change during handling, over storage time or by changes in humidity and/or tem-
perature (Chapter 4.1.2). It is well documented that it could induce re-crystallization of amor-
phous regions and particle size changes post-production [95].  
In order to investigate the impact of these amorphous amounts, inhalable homogenous powder 
mixtures with very high/low amorphous content and a defined particle size were prepared 
with a Turbula blender for each API (SBS/CS), respectively. These amorphous amounts are 
calculated on the basis of the approved one-step dynamic vapor sorption method (DVS). A 
hydrophilic lactose carrier was chosen which could absorb moisture during storage time in the 
study 1. In addition, blends with an inert carrier (glass beads) instead of the hydrophilic lac-
tose were prepared for the study 2. Thereby, a lower affinity to water vapor and a higher sta-
bility of the amorphous amounts are expected. All blends were stored (6 months, 45% RH, 
room temperature) to evaluate the influence of storage on amorphous amounts. The fine parti-
cle fraction (FPF: % of delivered dose < 5µm) was determined at defined time points (1 day, 
1 week, 2 weeks, 1 month, 3 months and 6 months) using the Next Generation Impactor. 
In general, the de-agglomeration behavior and the aerodynamic deposition are characterized 
by a complex interplay of many different mechanisms. Primarily the reduction as well as the 
increase of cohesion or adhesion forces (drug-to-drug or drug-to-carrier) depend on macro-
scopic properties of the particles [84]. Important parameters that have an influence on the aer-
osolization behavior, which may change during re-crystallization, are mainly the particle size 
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of API and the carrier [56], but also the particle shape [70] and surface rugosity [148]. During 
milling and blending electrostatic charging [65] may occur causing new contact areas on par-
ticles. In the course of use, whenever a higher relative humidity is reached and more water 
molecules are present a thin film layer is formed which induces higher capillary forces [149]. 
Furthermore, regarding the flow properties a change in physico-chemical properties may in-
fluence important parameters such as binding energy and binding forces (e.g., van der Waals 
forces) between the detaching drug and the lactose carrier during dispersion [150].  
4.4.1 Study 1: Lactose, SBS, CS and the Easyhaler® 
In this investigation the same α-lactose-monohydrate was used as a carrier for all four blends 
(Table 4). Only the type of API (hydrophilic or hydrophobic) and the extent of amorphous 
content (high or low) were varied (Figure 79).  
 
Figure 79: Design of Study 1: Investigation of the influence of different amorphous amounts in hydro-
philic and hydrophobic APIs on the de-agglomeration and aerodynamic deposition behavior 
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In both designs of storage stability processing parameters such as the micronization or the 
blending (grinding pressure, grinding cycles, type of mixer [151], mixing speed [152], mixing 
time [153] and batch size), the drug content [154] (drug-to-carrier ratio of 1:100), the carri-
er/drug properties (particle size, roughness [155]) and the storage conditions (6 months, 
45% RH, room temperature) are identical. All these parameters can lead to changes in the 
FPF and are well-documented in the literature.  
To re-crystallize parts of the amorphous amounts of both APIs (type SBS 2 und CS 2), a con-
ditioning time was chosen which did not lead to changes in particle size (type SBS 3 und 
CS 3). Although both APIs still had a small detectable residue of amorphous parts the same 
desired particle size distribution was maintained. Furthermore, the blend homogeneity was 
determined by validated HPLC analytics.  
In initial experiments an in-house constructed model inhalation device was used to apply 
these powder blends to the NGI. But a low FPF and thus no possibility of discrimination be-
tween different powders (data not shown) resulted in the decision to change the device to the 
Easyhaler
®
. Due to a better de-agglomeration, higher values in the FPF and an improved dis-
crimination were obtained. This change in the device might demonstrate trends for the FPF to 
higher and also lower values. 
4.4.1.1 Bulk powder and blend characterization 
The PSD shows that the micronized powder particles of both APIs are significantly reduced in 
size (x50) compared to the crystalline starting material (Table 23). 
Table 23: PSD and amorphous content of the conditioned SBS and CS samples - Study 1 
Sample x50 Span Amorphous content [%] 
Respitose SV003 57.92 ± 0.15 0.99 ± 0.02 / 
SBS starting material 9.11 ± 0.07 3.44 ± 0.11 / 
SBS 2 1.94 ± 0.01 2.43 ± 0.01 5.09 ± 0.56 
SBS 3 1.96 ± 0.01 2.40 ± 0.02 0.76 ± 0.34 
CS starting material 57.90 ± 2.96 4.91 ± 0.16 / 
CS 2 1.51 ± 0.02 2.62 ± 0.05 17.01 ± 0.47 
CS 3 1.52 ± 0.03 2.63 ± 0.06 1.35 ± 0.09 
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In addition, SBS and CS both show no significant change in particle size (x50) after the tempo-
rary conditioning (SBS: 16 hours at 85% RH, CS: 2 hours over 10 ml isopropanol). These 
significant changes in the particle size when jet-milling the SBS samples can be seen looking 
at the overview of the cumulative distribution (Q3) (Figure 80). Again, three grinding cycles 
(SBS 2) led to smaller particle sizes than one grinding cycle (SBS 1). No significant change 
was determined in the conditioning process. The re-crystallized sample SBS 3 is in line with 
the unconditioned sample SBS 2 (white squares are on top of the black circles). 
Because of the similar particle size distribution these micronized powders can be used in the 
storage stability test over half a year. Furthermore, the evaluation of the influence of the 
amorphous content on the de-agglomeration behavior is achieved for this study 1. 
 
Figure 80: Relation of the cumulative distribution of SBS particles - Study 1 
These findings were equal for the CS samples (Figure 81). Nevertheless, the particle size of 
the starting material was of a larger size compared to the SBS starting material.  
The detection of the amorphous parts (Table 23) showed that the high values are maintained 
when storing over P2O5 in a desiccator especially for micronized powders with a higher num-
ber of grinding cycles (JM1 Gc3, SBS 2/CS 2). In general, the CS powder samples showed 
significantly higher amorphous amounts compared to the hydrophilic SBS samples. The re-
crystallized samples (SBS 0.8% of amorphous parts at 85% RH and CS 1.4% of amorphous 
parts at isopropanol for 2 hours) showed profound crystalline properties. Both APIs and their 
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induced amorphous amounts provide ideal conditions for the storage stability tests and analy-
sis with the Next Generation Impactor.  
 
Figure 81: Relation of the cumulative distribution of CS particles - Study 1 
The coefficient of variation for the homogenous mixtures was below 5% for all formulations 
which indicates a suitable mixing time (3 × 15 minutes) and mixing speed (42 rpm). Table 24 
shows the characteristic parameters of the 1.0% API blends.  
Table 24: Content uniformity of the blended inhalable mixtures - Study 1 
Blend Content [%] sd CV [%] Recovery [%] 
SBS 2 0.9749 0.0091 0.9377 97.5767 
SBS 3 0.9750 0.0485 4.9698 97.4581 
CS 2 1.0045 0.0113 1.1266 100.0597 
CS 3 1.0165 0.0235 2.3169 101.4477 
 
A striking aspect is that the re-crystallized APIs (SBS 3/CS 3) led to less homogenous mix-
tures (higher values of the coefficient of variation). It is assumed that small agglomerates 
(API-to-API) are easily formed due to the higher moisture content in the bulk powder prior to 
the mixing process [156]. These capillary forces might impede the uniform distribution of 
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lactose and the API. A significant drug loss for both types of blends was not determined 
(< 2.6%). 
The scanning electron microscopy (Figure 82) showed the typical needle shaped SBS crystals. 
The micronized powder (SBS 2) exhibits very small and rough particles (2 µm) compared to 
the crystalline starting material (10 µm). These particle sizes can be linked to the PSD deter-
mined by laser diffraction analysis. Furthermore, the re-crystallized powder (SBS 3) showed 
no significant change in surface morphology and particle size (2 µm). An increased particle 
agglomeration as mentioned above was not visible on various magnifications for SBS 3. 
 
Figure 82: SEM pictures of the conditioned SBS samples - Study 1 
Looking at the CS samples a more angular particle shape can be seen (Figure 83). Again, the 
micronized powder (CS 2) showed a smaller particle size (2 µm).  
 
Figure 83: SEM pictures of the conditioned CS samples - Study 1 
A change in the surface morphology was not visible for this sample. However, a smoother 
surface was visible for the re-crystallized sample (CS 3) (2 h, over isopropanol). This result 
can be compared to other re-crystallized CS samples with isopropanol (Chapter 4.3.2.1). In 
general, an increase of smoothness was achieved by a higher grinding pressure or a higher 
number of grinding cycles. 
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4.4.1.2 Impaction analysis 
Over the storage of 6 months both APIs showed opposing aerodynamic particle size distribu-
tions in the deposition behavior determined by impaction analysis. Larger particles impact on 
initial stages whereas smaller particles are able to further follow the airflow and impact on the 
final stages (Stage 4 - Stage 8). Primarily, the particle size, density and induced inertial forces 
are responsible for the deposition behavior [38].  
The SBS blends led to a significantly higher deposition on the final stages (stage 3, 4, 5, 6 and 
7) compared to the CS blends after 1 day (Figure 84). However, the amorphous amounts of 
both blends resulted in an increased aerodynamic deposition behavior compared to the re-
crystallized blends. The major part of the API was quantified in the induction port and the 
preseparator. It is assumed that these API particles did not de-agglomerate from the large-
sized carrier particles or remained stable as larger aggregates. 
 
Figure 84: Deposition behavior of SBS and CS blends with different amorphous amounts after 1 day of 
storage at 45% RH - Study 1 
A change in the deposition behavior was determined after 180 days of storage (Figure 85). 
The amorphous SBS 2 showed an increased impact on initial stages matching SBS 3. For re-
crystallized SBS 3 no significant changes were visible. On the contrary, both CS blends led to 
higher depositions on the final stages. 
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Figure 85: Deposition behavior of SBS and CS blends with different amorphous amounts after 180 days of 
storage at 45% RH - Study 1 
For an accurate assessment the calculated fine particle fraction (% of delivered dose < 5 µm) 
from measurements at different time points (1 day, 1 week, 2 weeks, 1 month, 3 months and 
6 months) was compared. Furthermore, possible interactions between the hydrophilic carrier, 
the respective API and the humidity (H2O) were discussed. 
The hydrophilic SBS blends showed a significantly higher FPF (> 29%) after 1 day (Figure 
86). Samples that initially contained 5.1% amorphous content showed a FPF of 36% at the 
beginning which decreased constantly over the storage time (Storage: 45% RH, room temper-
ature) to about 27%. The initially re-crystallized sample achieved a comparable constant level 
of about 25%. In addition, significant changes in surface morphology cannot be observed in 
SEM analysis after the conditioning process (Figure 82). Young and Price have made similar 
observations with amorphous SBS blends which showed decreasing FPFs over storage time 
[157]. 
It can be assumed that the amorphous blend (SBS 2) re-crystallizes over storage time 
(6 months) to an extent that can be compared to the initially conditioned sample (SBS 3). The 
reduction of the FPF could be explained by an increase in particle size due to a) stronger in-
ter-particular forces (capillary forces) at the higher humidity [158] and b) solid material 
bridges that were formed during re-crystallization between the particles [159].  
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It is expected that the water molecules interact with the hydrophilic API and hydrophilic ex-
cipient leading to a re-crystallization of the remaining amorphous amounts of both mixtures 
over the period of storage.  
 
Figure 86: Change of fine particle fraction for amorphous SBS blends (storage over 6 months at 45% RH 
and RT) - Study 1 
Table 25 summarizes the SBS study 1. Thereby, FPF, MMAD, GSD and FPD are listed cor-
responding to each time point. Mechanisms such as inter-particular forces, material bridges, 
changes of particle shape/size or degradation of hydrogen bonds have a strong influence on 
these FPF/FPD values.  
The MMAD values demonstrate a minor increase over the storage time. It is assumed that the 
particle size changed due to higher moisture content in the powder [160]. The GSD seems to 
be less affected and remained constant at one level over six months. The DVS measurements 
showed a decrease of the amorphous amounts for pure SBS powder samples over several 
weeks. 
The delivered doses of SBS depending on the storage time (1 day, 1 week, 2 weeks, 1 month, 
3 months and 6 months) are listed in the appendix (8.3.6). 
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Table 25: NGI results of both SBS blends with lactose - Study 1 
Sample 
SBS_5.1%  
1 day 
SBS_0.8% 
1 day 
SBS_5.1% 
1 week 
SBS_0.8% 
1 week 
SBS_5.1% 
2 weeks 
SBS_0.8% 
2 weeks 
FPF (% < 5 µm) 35.56±0.56 29.62±0.98 33.26±1.04 25.18±1.33 30.16±0.37 25.00±2.45 
MMAD [µm] 2.64±0.02 2.76±0.04 2.70±0.02 2.85±0.02 2.80±0.02 2.84±0.04 
GSD 1.78±0.02 1.76±0.03 1.73±0.05 1.73±0.04 1.77±0.02 1.79±0.02 
FPD (µg < 5 µm) 35.10±3.42 25.79±1.34 30.82±6.98 19.60±1.05 24.60±0.21 21.56±1.23 
 
SBS_5.1% 
1 month 
SBS_0.8% 
1 month 
SBS_5.1% 
3 months 
SBS_0.8% 
3 months 
SBS_5.1% 
6 months 
SBS_0.8% 
6 months 
FPF (% < 5 µm) 29.74±0.87 25.98±0.23 26.95±0.22 24.43±0.72 26.66±0.73 22.65±0.08 
MMAD [µm] 2.86±0.06 2.96±0.03 2.96±0.04 2.94±0.04 3.03±0.02 3.11±0.04 
GSD 1.74±0.02 1.74±0.02 1.73±0.03 1.76±0.03 1.73±0.00 1.77±0.01 
FPD (µg < 5 µm) 27.66±2.88 22.14±1.30 22.41±0.46 21.84±0.60 22.62±1.63 18.77±0.80 
 
The hydrophobic CS showed a relatively low FPF (< 10%) directly after production (1 day) 
which is presented in figure 87. The constantly increasing FPF (> 15%) during the 3 months 
of storage (Storage: 45% RH, room temperature) in both types of blends (with and without 
conditioning) can be explained by a) a reduction in surface electrostatics in presence of hu-
midity [158] and b) a reduction of inter-particular forces (weak hydrogen bridge bonds) by 
water up-take from the surface of lactose particles [161]. Similar results were determined for 
hydrophobic Budesonide by Harjunen et al [158]. At all points of time, except for day 1, the 
powder with the actively re-crystallized amorphous amounts (1.4%, CS 3) tends to a higher 
FPF. It even shows a FPF 3% higher than the samples which initially contained more amor-
phous parts (17.0%, CS 2).  
From SEM analysis (Figure 83) a significant change in morphology can be observed for the 
samples conditioned over isopropanol for 2 hours. The shape of these particles turned from an 
angular shape to a more spherical shape. This induced smooth surface may reduce inter-
particular contacts and therefore could lead to the higher FPF values. It is assumed that the 
nonpolar API does not interact with 45% RH and that the amorphous parts have barely 
changed over storage time (6 months). 
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Figure 87: Change of fine particle fraction for amorphous CS blends (storage over 6 months at 45% RH 
and RT) - Study 1 
Table 26 summarizes all relevant data of the CS study 1. Surface electrostatics and the de-
crease of inter-particular forces (weak hydrogen bridge bonds) might be involved in the in-
crease of the FPFs. Differences in FPFs of both blends are caused by the surface modification 
of the API particles during the initially executed conditioning process (smoothness).  
Table 26: NGI results of both CS blends with lactose - Study 1 
Sample 
CS_17.0% 
1 day 
CS_1.4% 
1 day 
CS_17.0% 
1 week 
CS_1.4% 
1 week 
CS_17.0% 
2 weeks 
CS_1.4% 
2 weeks 
FPF (% < 5 µm) 8.01±1.24 6.43±0.35 9.30±0.12 10.47±0.79 8.91±0.39 10.60±0.57 
MMAD [µm] 4.23±0.36 4.61±0.08 4.11±0.05 3.92±0.13 4.07±0.15 3.88±0.11 
GSD 2.14±0.21 2.01±0.03 2.07±0.01 2.11±0.03 2.16±0.06 2.13±0.03 
FPD (µg < 5 µm) 7.20±1.84 6.11±0.33 8.13±0.31 9.84±1.57 9.54±0.87 11.11±0.57 
 
CS_17.0% 
1 month 
CS_1.4% 
1 month 
CS_17.0% 
3 months 
CS_1.4% 
3 months 
CS_17.0% 
6 months 
CS_1.4% 
6 months 
FPF (% < 5 µm) 11.04±0.20 15.07±0.68 15.36±0.54 18.72±0.51 15.80±0.15 18.52±0.40 
MMAD [µm] 3.84±0.05 3.62±0.06 3.38±0.13 3.45±0.04 3.67±0.07 3.72±0.07 
GSD 2.13±0.03 2.07±0.02 2.16±0.02 2.01±0.03 2.00±0.01 1.92±0.00 
FPD (µg < 5 µm) 11.77±0.46 16.19±1.68 19.75±2.08 20.65±3.25 13.59±0.26 16.45±1.34 
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A decreasing trend was determined for the MMAD and GSD values. These findings can be 
explained by an easier de-agglomeration caused by high moisture content over storage time. 
The delivered doses of CS depending on the storage time (1 day, 1 week, 2 weeks, 1 month, 
3 months and 6 months) are listed in the appendix (8.3.6). 
The optical SEM analysis was again performed at the end of the 6 months storage at 45% RH. 
The pictures showed API needles which might be of the same particle size for both SBS 
blends (Figure 88 A and B). These needles are marked with white circles. Also, for the CS 
blends no differences were optically visible (data not shown). In conclusion a precise state-
ment about the particle size (particle growth) is difficult because the distinction between small 
carrier particles and API particles with this SEM technique is problematic.  
 
Figure 88: Blends of SBS 2 and SBS 3 after storage at 45% RH for 6 months (A) overview and (B) magni-
fication - Study 1 
4.4.1.3 Schematic model based on NGI results - Influence on FPF (Study 1) 
The FPFs constantly decreased (9%) in relation to the amorphous parts in the case of SBS 
during storage time. Figure 89 A shows a possible mechanism of the de-agglomeration at the 
beginning of the stability study (dry powder state). Hereby, the small API particles are easily 
de-agglomerated from the lactose carrier which results in high FPFs during the inhalation 
process.  
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This situation may change during storage at 45% RH over a few weeks (Figure 89, B). Higher 
humidity and a higher water content in the powder blend led to a particle growth of the mi-
cronized and amorphous SBS. For this study, it is assumed that the particle size, particle 
shape and surface rugosity of the API changes over storage time. In addition, an increasing of 
the inter-particular forces (e.g. capillary forces) might occur. Also, the building of solid mate-
rial bridges between particles is induced. The described phenomena take place during the re-
crystallization process of the blend which contains a higher amorphous amount. In conclusion 
these modifications lead to decreasing FPFs. In the case of the initially re-crystallized API 
blend a comparable constant level was achieved. 
 
Figure 89: De-agglomeration model of SBS (A) at the beginning of storage (B) during storage at 45% RH 
Strong hydrogen bridge bonds are built between the hydrophilic lactose and the SBS molecule 
(Figure 90). The degradation process of these bonds plays a minor role in comparison to the 
high binding forces which are present during complete storage time. In general, three double-
hydrogen bridge bonds can be established assuming the three polarized hydroxyl-groups of 
the molecule (show strong electronegative properties). An increase of the water content might 
be necessary to solve these bonds between both types of molecules (lactose and SBS). The 
water molecules have to be present in overage and are indicated by many H2O molecules. In 
this study the degradation of hydrogen bonds might not be the primary factor for this hydro-
philic API; the de-agglomeration rather is influenced by the other described phenomena. 
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Figure 90: Degradation of strong hydrogen bridge bonds (SBS) during storage at 45% 
The results for CS showed that the re-crystallized API achieves higher FPFs (3%) due to its 
smoother surface. A lower interaction took place on the relatively rough surface of lactose 
particles at every storage time point, after day 1 (Figure 91, A). This phenomenon led to high-
er FPFs. The smooth surface that was induced by isopropanol did probably not convert be-
cause of the constant 3% difference in FPF over the 6 months of storage time.  
In case of the un-conditioned amorphous CS particles that show a rougher surface (Figure 
83), more mechanical interlocking can be expected [162]. The formation of agglomerates and 
a poor detachment led to lower FPFs (Figure 91, B). It is assumed that the particle size of CS, 
the particle shape and the surface rugosity were not significantly altered by water vapor at 
45% RH (from SEM analysis no significant changes are optically visible) during the storage 
stability test over a six month period. For the hydrophobic CS it may only be possible with 
organic solvents. The increase of the FPFs for both mixtures (with and without conditioning) 
can be explained by a reduction in surface electrostatics in the presence of humidity and the 
degradation of weak hydrogen bridge bonds during storage time. 
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Figure 91: De-agglomeration model during inhalation for CS (A) smooth and (B) rough API particle 
surface 
Hydrogen bridge bonds between the disaccharide lactose (condensation of D-galactose and D-
glucose) can only be formed with one hydroxyl-group (more electronegative) and two car-
bonyl-groups (also hydrogen-bond acceptor) in the CS molecule (Figure 92).  
 
Figure 92: Degradation of weak hydrogen bridge bonds (CS) during storage at 45% RH 
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These bonds can be affected by the presence of water resulting in the reduction of hydrogen 
bonds between CS and lactose molecules. This phenomenon may also explain the increase in 
the FPFs. 
4.4.2 Study 2: Glass beads, SBS, CS and HandiHaler® 
In a second investigation the α-lactose-monohydrate carrier was replaced by glass beads 
(250 µm). This type of carrier might be inert against water vapor (45% RH) which leads to the 
expectation of a change in the de-agglomeration behavior of the API. The aim of the aerody-
namic characterization is to determine a higher influence of amorphous amounts over the 
storage for 6 months compared to study 1. A strong re-crystallization process is excluded for 
both types of API on the basis of lower moisture content in the blends (Figure 93).  
 
Figure 93: Design of Study 2: Investigation of the influence of different amorphous amounts in hydro-
philic and hydrophobic APIs on the de-agglomeration and aerodynamic deposition behavior 
Again, four blends were prepared, whereby the type of API (hydrophilic or hydrophobic) and 
the extent of amorphous content (high or low) were changed, respectively. In both designs of 
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storage stability processing parameters such as the micronization or the blending (grinding 
pressure, grinding cycles, type of mixer, mixing speed, mixing time and batch size), the drug 
content (drug-to-carrier ratio of 1:166.7), the drug properties (particle size) and the storage 
conditions (6 months, 45% RH, room temperature) were identical. 
A change in the inhalation device from the Easyhaler
® 
to the HandiHaler
®
 was necessary due 
to serious dosing issues using glass beads. The single dose was therefore filled into capsules 
and subsequently aerodynamically assessed to the NGI (Figure 94). 
 
Figure 94: Formulated glass beads with a concentration of 0.6% API 
To re-crystallize parts of the amorphous content in both APIs (type SBS2 und CS2), a condi-
tioning time was chosen which did not lead to changes in particle size (type SBS3 und CS3). 
This conditioning process was similar to study 1 with the lactose carrier. Therefore, both APIs 
still had a measurable residue of amorphous parts but the same desired particle size distribu-
tion. Finally the blend homogeneity was determined by validated HPLC analytics. 
4.4.2.1 Bulk powder and blend characterization 
Again, SBS and CS showed no significant change in particle size (x50) after temporary condi-
tioning (SBS: 16 h at 85% RH, CS: 2 h over 10 ml isopropanol). Because of the same particle 
size distribution (Table 27) these micronized powders can be used for the storage stability test 
over half a year. Thereby, a precise evaluation of the influence of the amorphous content can 
be done. The glass beads exhibit a larger PSD compared to the lactose carrier. Nevertheless, 
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the spherical and smooth surface led to a lower drug-to-carrier ratio. Thus, the API concentra-
tion was reduced from 1.0% to 0.6% for both, SBS and CS. 
Table 27: PSD and amorphous content of the conditioned SBS and CS samples - Study 2 
Sample x50 Span Amorphous content [%] 
Glass beads 343.70 ± 6.13 0.40 ± 0.01 / 
SBS starting material 9.11 ± 0.07 3.44 ± 0.11  / 
SBS 2 1.60 ± 0.02 2.24 ± 0.05 1.69 ± 0.31 
SBS 3 1.68 ± 0.01 2.26 ± 0.06 0.18 ± 0.14 
CS starting material 57.90 ± 2.96 4.91 ± 0.16  / 
CS 2 1.67 ± 0.02 2.43 ± 0.05 15.75 ± 0.82 
CS 3 1.71 ± 0.06 2.23 ± 0.06 0.45 ± 0.28 
 
The detection of the amorphous parts (Table 27) showed that the high values are maintained 
over the storage time in a desiccator over P2O5 especially for micronized powders with a 
higher number of grinding cycles (JM1 Gc3, SBS 2/CS 2). The CS powder samples showed 
significantly higher amorphous amounts compared to the hydrophilic SBS samples. The re-
crystallized samples (SBS 0.2% of amorphous parts at 85% RH and CS 0.5% of amorphous 
parts at isopropanol for 2 hours) showed highly crystalline properties. Ideal conditions are 
provided by both APIs and their induced amorphous amounts to perform the storage stability 
tests with the Next Generation Impactor.  
Table 28 shows characteristic parameters for the content uniformity of the 0.6% API-glass 
beads-blends. The coefficient of variation is significantly increased for all formulations con-
taining glass beads. This result is an indication for a poor homogenous mixture.  
Table 28: Content uniformity of the blended inhalable mixtures - Study 2 
Blend Content [%] sd CV [%] Recovery [%] 
SBS 2 0.5139 0.0461 5.3684 89.9743 
SBS 3 0.4877 0.0286 2.2643 84.0538 
CS 2 0.5668 0.0104 1.8393 94.2814 
CS 3 0.5351 0.0606 5.2860 94.8720 
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The spherical and smooth surface of the glass bead led to a lower loading ratio for the API 
(Figure 95 A). It is assumed that API-API agglomerates are present in the mixtures despite the 
reduction of the API concentration (1.0% to 0.6%). This phenomenon might also explain a 
lower recovery for both types of blends.  
Figure 95 B demonstrates an API-glass beads-blend with an excess of API which is localized 
between two glass beads (white circle). An easily performed detachment of these API-API 
agglomerates can be an indicator for a higher drug loss. In the second study the re-crystallized 
APIs (SBS 3/CS 3) did not lead to less homogenous mixtures compared to study 1 with the 
lactose. The SEM pictures that show the pure unconditioned and conditioned APIs are not 
presented because of the similarity in the results for SBS and CS compared to study 1 (Chap-
ter 4.4.1.1). 
 
Figure 95: SEM pictures of glass beads without (A) and with API (B) 
4.4.2.2 Impaction analysis 
Both APIs showed nearly the same aerodynamic particle size distribution which was deter-
mined by an impaction analysis. Larger particles impact on the initial stages (on the basis of 
size, density and induced inertial forces) whereas smaller particles can follow the airflow fur-
ther and impact on the final stages (Stage 4 - Stage 8). In this investigation the SBS blends did 
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not lead to a significantly higher deposition on the final stages (stage 3, 4, 5 and 6) at day 1 
compared to the CS blends (Figure 96).  
In addition, the amorphous amounts of both blends did not result in an increased aerodynamic 
deposition behavior compared to the re-crystallized blends after 1 day. The major part of the 
API was again quantified in the induction port and the preseparator.  
 
Figure 96: Deposition behavior of SBS and CS blends with different amorphous amounts after 1 day of 
storage at 45% RH - Study 2 
The value at the induction port was even higher for the CS blends. It is assumed that these 
API particles were not de-agglomerated from the glass beads because of high press-on forces 
during the blending process resulting in earlier deposition [163]. 
After 180 days of storage no significant change in the deposition behavior was determined 
(Figure 97). The amorphous and re-crystallized blends showed a nearly similar and low im-
pact on the final stages.  
Finally the fine particle fractions (% of delivered dose < 5 µm) were compared at single time 
points (1 day, 1 week, 2 weeks, 1 month, 3 months and 6 months). Furthermore, possible in-
teractions between the inert glass bead carrier, the respective API and the humidity (H2O) 
were discussed. 
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Figure 97: Deposition behavior of SBS and CS blends with different amorphous amounts after 180 days of 
storage at 45% RH - Study 2 
The hydrophilic SBS blends showed significantly lower FPFs compared to the blends contain-
ing the lactose carrier. The value was reduced by 30%. Study 1 is indicated by the arrows in 
the diagram of study 2 (Figure 98).  
 
Figure 98: Change of fine particle fraction for amorphous SBS blends (storage over 6 months at 45% RH 
and RT) - Study 2 in comparison to study 1 
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Samples that initially contained 1.7% amorphous content showed an FPF of about 6% at the 
beginning which did not decrease constantly (approximately 5% FPF) over storage time 
(Storage: 45% RH, room temperature) as it was determined in study 1. 
On the contrary, the initially re-crystallized sample (0.2% amorphous content) achieved a 
comparable constant level of about 5% FPF. Significant changes in surface morphology for 
SBS cannot be observed after the conditioning process by SEM analysis (data not shown). It 
can be assumed that the carrier material plays a major role on the de-agglomeration behavior. 
Especially the extent of the surface area and its roughness might influence the loading ratio 
[164], the type of interaction and the intensity of binding forces. In this study the inert glass 
beads demonstrated a low affinity to water vapor (45% RH). Nevertheless, a high stability of 
amorphous amounts for hydrophilic SBS is not realistic during six months. It is presumed that 
API-API interactions are more present in these blends because of the high press on forces 
during the mixing process [57]. An API coating (film) and an incomplete de-agglomeration of 
these stabile agglomerates are assumed (Figure 95) and could lead to low FPFs and high dep-
osition on the preseparator.  
Table 29 summarizes the SBS study 2. Thereby, FPF, MMAD, GSD and FPD are listed cor-
responding to each time point for each of the SBS blends.  
Table 29: NGI results of both SBS blends with glass beads - Study 2 
Sample 
SBS_1.7%  
1 day 
SBS_0.2% 
1 day 
SBS_1.7% 
1 week 
SBS_0.2% 
1 week 
SBS_1.7% 
2 weeks 
SBS_0.2% 
2 weeks 
FPF (% < 5 µm) 5.95±0.32 5.47±0.28 4.62±0.08 4.68±0.37 5.58±0.16 5.28±0.30 
MMAD [µm] 1.68±0.03 1.55±0.03 1.75±0.02 1.62±0.02 1.68±0.02 1.54±0.06 
GSD 2.19±0.06 1.87±0.04 2.21±0.04 1.95±0.03 2.09±0.07 1.82±0.06 
FPD (µg < 5 µm) 7.46±0.40 6.02±0.44 5.21±0.16 5.07±0.59 6.40±0.47 5.40±0.32 
 
SBS_1.7% 
1 month 
SBS_0.2% 
1 month 
SBS_1.7% 
3 months 
SBS_0.2% 
3 months 
SBS_1.7% 
6 months 
SBS_0.2% 
6 months 
FPF (% < 5 µm) 4.56±0.22 4.87±0.19 5.19±0.24 4.31±0.25 5.36±0.02 5.15±0.07 
MMAD [µm] 1.72±0.04 1.56±0.06 1.67±0.03 1.61±0.04 1.58±0.07 1.32±0.36 
GSD 2.24±0.16 1.82±0.10 2.08±0.09 1.88±0.06 2.21±0.03 2.08±0.22 
FPD (µg < 5 µm) 5.10±0.28 4.95±0.50 5.82±0.22 4.56±0.21 5.59±0.14 5.24±0.45 
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A strong influence on FPF/FPD values was not recognized. Also, the MMAD/GSD values 
demonstrated no significant changes in six months. 
Directly after production (1 day) relatively low FPFs (< 5%) were obtained for the hydropho-
bic CS in figure 99. The values for both blends were only lowered by 2-3% in their FPF com-
pared to the lactose carrier blends (study 1). A constantly increasing FPF was not determined 
for both types of blends over storage time (45% RH, room temperature). Again, study 1 is 
indicated by the arrows in the diagram. After 6 months a change in the FPF was not recog-
nized similar to SBS.  
Once more it was shown that the carrier material plays a major role on the de-agglomeration 
behavior. The surface area and its roughness influences the loading ratio [164], the type of 
interaction and the binding forces. In conclusion the inert glass beads demonstrated a low af-
finity to water vapor (45% RH). It is presumed that the amorphous amounts are stable in the 
case of hydrophobic CS over six months. 
 
Figure 99: Change of fine particle fraction for amorphous CS blends (storage over 6 months at 45% RH 
and RT) - Study 2 in comparison to study 1 
Table 30 shows a summary of the CS study 2. The values of FPF, MMAD, GSD and FPD are 
listed corresponding to each time point for both CS blends. In addition, a strong influence on 
FPF/FPD values was not recognized. The MMAD/GSD values again demonstrated no signifi-
cant changes over 6 months. 
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Table 30: NGI results of both CS blends with glass beads - Study 2 
Sample 
CS_15.8% 
1 day 
CS_0.5% 
1 day 
CS_15.8% 
1 week 
CS_0.5% 
1 week 
CS_15.8% 
2 weeks 
CS_0.5% 
2 weeks 
FPF (% < 5 µm) 3.38±0.39 4.81±0.09 3.22±0.12 2.80±0.22 3.60±0.07 3.03±0.08 
MMAD [µm] 2.40±0.08 2.52±0.05 2.36±0.04 2.13±0.05 2.29±0.05 2.08±0.01 
GSD 1.81±0.06 1.82±0.06 1.82±0.06 1.75±0.06 1.82±0.05 1.77±0.01 
FPD (µg < 5 µm) 5.57±0.15 6.38±0.16 4.85±0.28 3.39±0.18 5.23±0.20 4.30±0.16 
 
CS_15.8% 
1 month 
CS_0.5% 
1 month 
CS_15.8% 
3 months 
CS_0.5% 
3 months 
CS_15.8% 
6 months 
CS_0.5% 
6 months 
FPF (% < 5 µm) 3.30±0.07 2.60±0.10 3.09±0.15 3.06±0.16 3.24±0.05 3.07±0.24 
MMAD [µm] 2.35±0.01 2.11±0.02 2.29±0.03 2.05±0.01 2.09±0.13 1.83±0.03 
GSD 1.69±0.02 1.57±0.01 1.66±0.02 1.63±0.02 1.84±0.09 1.69±0.03 
FPD (µg < 5 µm) 4.35±0.28 3.78±0.21 4.36±0.16 4.70±0.26 4.90±0.02 5.04±0.51 
 
A significant change in morphology (for pure CS) can be again observed by SEM analysis for 
the samples conditioned with isopropanol for 2 hours. The shape of these particles turned 
once more from an angular shape to a more spherical shape and a smooth surface which may 
reduce inter-particular contacts.  
However, a change in surface morphology of the APIs was determined after the blending pro-
cess with the glass beads by SEM. The pictures demonstrate that the spherical shape/surface 
of the glass beads are coated by the API particles (Figure 100).  
Almost a thin and continuous film appeared on the surface. These API crystals are solidified 
during the mixing time (film formation). A change in particle shape is the logical conse-
quence (particle fusion). Significant differences in particle size and shape were not deter-
mined for SBS (A) and CS (B) in figure 100. These finding might explain a similar low FPF 
for both types of API. 
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Figure 100: SEM pictures of the thin API-film on the surface of glass beads formulation with (A) SBS and 
(B) CS 
4.4.2.3 Schematic model based on NGI results (Study 2) 
The type of carrier has a fundamental influence on the API particles. Especially, the particle 
size and shape is modified during the mixing procedure. Similar results were received when 
mixing for 15 to 45 minutes. Higher centrifugal forces were achieved which originated from 
the increased weight of the glass beads compared to the lactose carrier. This behavior led to a 
crushing of the crystal shape and solidified a thin film on the surface (Figure 101).  
 
Figure 101: Change of crystal shape during the mixing process 
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Finally for both APIs a low and comparable FPFs were determined that did not change during 
the storage at 45% RH over 6 months. 
4.4.3 Conclusion III 
The aerodynamic investigations demonstrated that the amorphous content has a huge influ-
ence on the FPFs. The hydrophilic SBS showed a high trend for re-crystallization over the 
storage time. Thereby, a change in the surface morphology is assumed. These modifications 
are reinforced by a hydrophilic carrier (e.g. lactose). Finally, capillary forces and solid materi-
al bridges complicate the detaching of API particles. After 6 months both types of blends 
showed almost similar FPFs.  
The hydrophobic API seems to be less affected by water vapor (45%). Electrostatic charges 
and a reduction of hydrogen bonds lead to higher FPFs over storage time. A significant differ-
ence was detected for both blends in the smooth surface of the initially re-crystallized API 
(isopropanol). This re-crystallized blend showed an increase in FPFs over the whole storage 
time.  
Low FPFs were determined for both blends with glass beads. An increase in the press-on 
forces led to a thin API film on the surface of the beads. Figure 102 shows a possible mecha-
nism; hereby the structure of the glass beads surface enables a higher compaction of the API 
crystals during the collision over the mixing time. The resulted binding forces cause a low de-
agglomeration behavior.  
 
Figure 102: Press-on forces on different types of carrier (lactose/glass bead) modified from de Boer et al., 
2006 
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On the contrary, API particles which were agglomerated on a rough and heterogenic lactose 
surface were less compacted. An increased binding capacity and a higher degree of saturation 
of the active lactose carrier sites (g/m²) were determined [165]. 
In summary, it is necessary that amorphous amounts are determined and further re-
crystallized under controlled conditions. Otherwise the product stability is not guaranteed 
because of the possibility of a re-crystallization and a change in the particle size (crystal 
growth) [166]. Ultimately, an impact on the dissolution characteristics or drug delivery cannot 
be ruled out. 
4.5 Dissolution testing 
The dissolution testing is an extremely well established and standardized method in all Phar-
macopoeias for evaluating solid and semi-solid dosage forms [167].  It is defined as the pro-
cess by which a solid substance enters into a solvent to yield a solution. This solubility is con-
trolled by the affinity between the solid substance and the solvent [168]. Furthermore, it al-
lows the investigation of the dissolution behavior in-vitro to provide some predictions of the 
dissolution behavior in-vivo [169]. These release methods are routinely used in the quality 
control/R&D sector and enable the specification of batch-to-batch consistency and the estima-
tions of stability issues. However, several factors can influence the dissolution process, such 
as the particle size and surface, the wettability of the materials, the temperature, pH value, the 
stirring speed and the surrounding concentration of already dissolved substance in the medi-
um [170]. 
Up to this date there is no compendial dissolution method for testing aerosols compared to 
standardized dissolution test methods for solid dosage forms such as tablets and capsules. 
Unfortunately, it is not an easy task to truthfully model the lung and simulate small amounts 
of aqueous fluids and the lung surfactant [171]. Furthermore, the dose collection of the API is 
challenging because of very fine and electrostatic powder characteristics [172]. For example, 
the deposition can be determined using initially impactor systems (e.g. Andersen Cascade 
Impactor). Afterward, the solubility of these particles (less than 5 µm) can be characterized by 
different dissolution techniques. May et al. compared the flow through cell, Franz diffusion 
cell and paddle apparatus 2 and studied their ability to differentiate between various formula-
tions [173]. Basically the dissolution process is characterized by the dissolution rate, the dose-
to-solubility ratio and the permeation rate [174] and is poorly indicated for hydrophobic sub-
stances. The biopharmaceutical classification system (BCS) was introduced and hydrophilic 
and hydrophobic drugs were categorized based on their aqueous solubility and intestinal per-
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meability into four different classes. Hereby, low dose-to-solubility ratio/high permeability 
(as class I), high dose-to-solubility ratio/high permeability (as class II), low dose-to-solubility 
ratio/low permeability (as class III) and high dose-to-solubility ratio/low permeability (as 
class IV) are defined [175]. 
In this part of the study the applicability of the introduced dissolution testing system (ACI and 
USP paddle apparatus 2) is investigated for SBS and CS (Figure 103). 
 
Figure 103: Overview of the dissolution testing 
The objective is to evaluate the influence of different amorphous amounts in inhalation pow-
ders on the dissolution rate. Three different blends with low, middle and high amorphous 
amounts were prepared. These amounts were achieved by different jet-milling parameters and 
varied storage conditions. In addition, hydrophilic and hydrophobic characteristics were stud-
ied with the attention on SBS and CS. The blends with lactose as a carrier were prepared and 
tested for a homogenous distribution. Finally, the ACI (Device: Easyhaler
®
) with modified 
filter stage (better sedimentation) was utilized to collect a defined amount of fine powder on a 
membrane (dose collection) [126,127]. In the last step the API that was impacted on the 
membrane was released in triplicate determination by a USP paddle apparatus 2. 
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4.5.1 Bulk powder and blend characterization 
It should be mentioned that the same bulk powders (type 2 and 3 for both APIs) were pre-
pared in the same week for the production of the blends for study 1 (aerodynamic deposition) 
and for the dissolution testing (Table 23). Only the PSD of the micronized powder with one 
grinding cycle (SBS 1 and CS 1) is presented at this point and is as well strongly reduced in 
size compared to the crystalline starting material (Table 31).  
Table 31: PSD and amorphous content of the conditioned SBS and CS samples for the dissolution testing 
Sample x50 Span Amorphous content [%] 
Respitose SV003 57.92 ± 0.15 0.99 ± 0.02 / 
SBS starting material 9.11 ± 0.07 3.44 ± 0.11 / 
SBS 1 2.87 ± 0.01 3.15 ± 0.08 1.51 ± 0.34 
CS starting material 57.90 ± 2.96 4.91 ± 0.16 / 
CS 1 2.38 ± 0.10 2.36 ± 0.12 5.48 ± 0.22 
 
The API bulk powder SBS 1 and CS 1 showed a larger particle size because of the one grind-
ing cycle that was conducted compared to the SBS 2 and CS 2 (3 Gc). Furthermore, an in-
crease of the amorphous amount was induced by a higher number of grinding cycles for these 
powders. The particle size distribution and the amorphous content are API properties that 
might significantly influence the dissolution profile.  
Table 32 shows the characteristic parameters of the homogenous 1.0% API blends.  
Table 32: Content uniformity of the blended inhalable mixtures for the dissolution testing 
Blend Content [%] sd CV [%] Recovery [%] 
SBS 1 1.0255 0.0436 4.2559 101.2405 
SBS 2 0.9884 0.0192 1.9435 98.8812 
SBS 3 1.0105 0.0363 3.5880 101.1005 
CS 1 1.0047 0.0287 2.8581 100.4317 
CS 2 1.0490 0.1018 3.9217 101.8788 
CS 3 0.9966 0.0672 1.7043 97.5235 
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The coefficient of variation for these homogenous mixtures was below 5% for all formula-
tions. This result indicates a suitable mixing time (3 × 15 minutes) and mixing speed 
(42 rpm). A trend in the re-crystallized APIs (SBS 3/CS 3) to result in a less homogenous 
mixture was not detectable. Also, a significant drug loss for both types of blends was not de-
termined (± 2.0%). 
The scanning electron microscopy again demonstrated typical needle shaped crystals for the 
SBS samples. Very small particles (2 µm) with a rougher surface were visible for all mi-
cronized powders. Larger particles were determined for SBS 1 (1 Gc) compared to SBS 2 and 
SBS 3 (Figure 104). These results can be correlated to the PSDs determined by laser diffrac-
tion analysis. Furthermore, the re-crystallized powder (SBS 3) did not show a significant 
change in surface morphology and particle size (2 µm). An intensified particle agglomeration 
because of a higher humidity (85% RH) was not visible on various magnifications for SBS 3 
compared to SBS 2. 
 
Figure 104: SEM pictures of the bulk powders for SBS 
In contrary, the CS samples showed a more angular particle shape (Figure 105). For all mi-
cronized powders a small particle size distribution was determined (approximately 2 µm). In 
addition, larger particles were visualized for CS 1 (1 Gc).  
 
Figure 105: SEM pictures of the bulk powders for CS 
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A change in the surface morphology was visible for CS 3. The smooth surface is a character-
istic for the re-crystallized sample (2 h, over isopropanol). The result was comparable to other 
re-crystallized CS samples with isopropanol (Chapter 4.3.2.1). 
4.5.2 Optimization of the phosphate buffer as dissolution media for CS 
In general, solubility is defined as the degree to which a hydrophilic or hydrophobic substance 
dissolves in any solvent to reach a homogenous solution. As mentioned the solubility of sub-
stances differs and is strongly dependent on the chemical properties of the API and the sol-
vent. Particle properties (such as particle size, morphology and amorphous content) are prede-
fined by the production method (jet-milling) and the conditioning process, respectively. These 
API properties should eventually enable a determination of different dissolution profiles of 
the prepared inhalable blends possible. During the release investigation a constant tempera-
ture and pH value of the dissolution media should allow comparable and reproducible process 
parameters. 
In consequence to the poor solubility behavior of CS only the dissolution media can be opti-
mized by adding different and various amounts of surfactants. Sodium dodecyl sulfate (SDS), 
Tween
®
 20 and Plasdone
®
 were screened in a preliminary test (Figure 106).  
 
Figure 106: Solubility test of CS by adding different and various amounts of surfactants 
First, a mixture of methanol and water (9:1) was prepared to determine the maximal solubility 
of the hydrophobic CS (100% of recovery). Pure phosphate buffered saline (PBS, pH 7.4) was 
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used to access the poor solubility of CS (minimal concentration). The API recovery rate was 
determined at 41.6% without surfactant (Table 33). Afterward, defined amounts of SDS 
(0.1% and 0.5%), Tween
®
 20 (0.5%) and Plasdone
® 
(0.5%) were added to 100 ml of PBS 
buffer and used for the solubility test with high (CS 2) and low (CS 3) amorphous amounts in 
a beaker. For almost all surfactants the recovery was significantly increased. Especially SDS 
and Tween
®
 20 led to a recovery rate of almost 100%. Unfortunately, this data cannot give an 
indication of the influence of the amorphous amounts on the dissolution rate for further con-
ducted dissolution tests. 
It is assumed that the blends may show higher dissolution rates/permeation rates when con-
taining an increased amorphous amount which is the case for CS 2 (17.0%). An increase of 
the solubility (4.2%) compared to pure PBS buffer and an increase of the solubility rate with 
regard to the amorphous amounts (13.0%) was realized only with the surfactant Plasdone
®
. 
Table 33: Screening for an optimized solubility of CS powder samples 
Solution Sample Concentration [µg] Recovery [%] 
9:1 MeOH/H2O CS 3 526.42 101.63 
PBS-Puffer CS 3 203.68 41.57 
0.1% SDS CS 3 524.12 102.17 
0.5% SDS CS 3 480.00 98.77 
0.1% SDS CS 2 495.36 96.19 
0.5% SDS CS 2 516.25 98.33 
0.5% Tween
®
 20 CS 3 479.28 97.81 
0.5% Tween
®
 20 CS 2 508.10 96.41 
0.5% Plasdone
®
 CS 3 221.82 45.74 
0.5% Plasdone
®
 CS 2 306.69 58.75 
 
Further solubility tests showed that a significantly higher amount of the hydrophobic CS is 
soluble (Figure 107). Nearly 25% of this poor soluble API can be solved when enhanced by 
the surfactant Plasdone
®
. Normally it is used to manufacture wet granulates, dry granulates or 
to facilitate the direct compression whereas in this approach it is used to increase the viscosi-
ty/solubility of the dissolution media. A significant improvement in the solubility was recog-
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nized for CS 2 compared to CS 1. The higher amorphous amount can cause this effect. Never-
theless, this trend was not visible for CS 3 (re-crystallized with isopropanol). It is assumed 
that residual solvent molecules can facilitate the drug wetting and thereby result in a higher 
soluble API amount. 
 
Figure 107: Adding of 0.5% Plasdone
®
 for higher solubility of CS samples 
Furthermore, adding very low concentrations of SDS (0.05%) to improve the solubility of 
hydrophobic CS were investigated (Figure 108). In the first screening tests concentrations of 
0.1% and 0.5% led to completely solved API amount. Blends containing higher amorphous 
amounts may improve the solubility of CS and can be compared to the results achieved with 
Plasdone
®
. The soluble amount of the re-crystallized sample (CS 3) was greater than CS 1 
(amorphous content of 5.5%). Nevertheless, all samples showed an increase in the solubility 
when adding 0.05% SDS although the total amount was significantly lower than with the sur-
factant Plasdone
®
. As a result to these findings 0.5% of Plasdone
®
 was added to the dissolu-
tion media for the quantification of the poorly soluble CS powder samples in the dissolution 
tests. This type of surfactant might allow the discrimination between the dissolution rates/total 
amounts of blends containing varying amorphous amounts. 
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Figure 108: Adding of 0.05% SDS for higher solubility of CS samples 
4.5.3 Optimization of the dose collection for SBS and CS with the Andersen Cascade 
Impactor (ACI) 
Upon the optimization of the dissolution media the dose collection had to be adapted for SBS 
and CS. The aim was to define equal doses of both APIs on the membrane. Therefore, the 
Andersen Cascade Impactor and two types of filter stages were used. The first filter stage 
consists of a high number of little cavities and the second one persists of three large openings 
(highlighted with Ο in each figure). On top of these stages a regenerated cellulose membrane 
filter was placed to collect the amount of the fine particle doses (FPDs). Afterward, the con-
centration of the API was determined by the validated HPLC analytic. The deposition exper-
iments were conducted with the HandiHaler
®
 where the produced API blends were filled into 
capsules, respectively. After each inhalation (capsule) the sedimentation time was set to 
5 minutes to ensure the complete impaction of the powder on the membrane. Figure 109 
shows the deposition of each SBS blend. A significant trend was visible with regard to the 
number of capsules. As expected the API concentration was increased with the usage of more 
and more capsules for all three blends. No differences in the deposition behavior for SBS 1, 
SBS 2 and SBS 3 were detectable. The second type of filter stage (Ο) led to very low concen-
trations despite a high number of used capsules. 
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Figure 109: Impaction of SBS blends in dependence to multi dosing (HandiHaler
®
) 
On the contrary, lower concentrations were reached for CS (Figure 110). It is assumed that 
the particle shape has an enormous influence on the deposition behavior. The crystal needles 
of SBS might reach the final stages of the Andersen Cascade Impactor easier.  
 
Figure 110: Impaction of CS blends in dependence to multi dosing (HandiHaler
®
) 
Nevertheless, an increase of the API deposition was determined with regard to a higher num-
ber of capsules used. An exception is blend CS 2. Again, lower depositions were detected for 
the second type of filter stage (Ο). In summary, the amount of CS is not sufficient for a suita-
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ble dissolution testing therefore another type of device (Easyhaler
®
) was investigated where 
an increase in FPD should be found. 
Figure 111 shows the deposition behavior of each SBS blend that was applied to the Andersen 
Cascade Impactor with the Easyhaler
®
. Fortunately, a higher amount of API was determined 
compared to the HandiHaler
®
 (nearly double quantity). Again, a significant trend was visible 
with regard to the number of actuations which resulted in an increase of the API concentration 
on the membrane.  
 
Figure 111: Impaction of SBS blends in dependence to multi dosing (Easyhaler
®
) 
In general, the blend SBS 1 showed the highest amounts despite the largest measured x50 val-
ue. These findings were not manifested in the first impaction analysis with the HandiHaler
®
. 
As sedimentation is one of the assumed mechanisms it appears reasonable. The second type 
of filter stage (Ο) again led to very low concentration despite 5 actuations. 
An increase in the concentration was also well determined for the hydrophobic CS (at least a 
third of the amount impacted with the HandiHaler
®
). In addition, an increase of the API depo-
sition was determined due to a higher number of actuations (Figure 112). But in comparison 
to the SBS blends only a half of the quantity was impacted on the membrane.  
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Figure 112: Impaction of CS blends in dependence to multi dosing (Easyhaler
®
) 
As a final conclusion the Easyhaler
®
 was selected to apply the powder blends to the impactor 
in the following dissolution testing. Finally, the number of actuations was determined which 
facilitates the impaction of similar amounts of APIs on the membrane. Therefore it is neces-
sary that higher actuations are conducted in case of the hydrophobic CS blends compared to 
the hydrophilic SBS blends.  
 
Figure 113: Equal doses of both blends because of different actuations applied with the Easyhaler 
®  
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The final investigation led to the conclusion that 20 actuations are needed for CS using the 
Easyhaler
® 
compared to only 15 actuations for SBS to impact equal FPDs (160 µg) on the 
membrane, respectively (Figure 113). 
4.5.4 Burst release and poor solubility 
Using the Easyhaler
®
 (15 actuations) and ACI a final dose collection was conducted for SBS 
on the membrane. Afterward, a watch glass and a plastic mesh were used to fix the membrane 
(standard membrane holder). Finally, the dissolution testing was performed with a stirring 
speed of 100 rpm at 37 °C in PBS buffer pH 7.4 in the paddle apparatus 2. The dissolution 
media was optimized with 0.5% of Plasdone
®
 for the hydrophobic samples. 
Figure 114 shows the concentrations of each SBS blend in the paddle apparatus with the 
membrane holder over the time of 248 minutes. Despite the 15 equal actuations it can be seen 
that different API amounts were solved. Especially, the concentration of SBS 1 was signifi-
cantly increased (middle amorphous content and largest particle size). This result can be cor-
related to figure 111 where it was noticed that SBS 1 led to the highest deposition amounts on 
the membrane. SBS 2 and SBS 3 demonstrated a similar release and thus the discrimination 
between the dissolution profiles/rates could not be achieved.  
 
Figure 114: Absolute amount of each SBS blend dissolved over 4 hours 
It can be assumed that the blend containing the highest amorphous amount (SBS 2) led to a 
re-crystallization during the handling and afterward was comparable to the initially re-
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crystallized (SBS 3). The amorphous SBS 2 demonstrates an increased affinity to water va-
por. In contrast the SBS 1 blend which contains a lower amorphous content might be more 
stable over handling. 
After the dissolution testing the residual amounts of API on the membrane and on the watch 
glass were determined by washing both parts (Figure 115). For all SBS samples very low re-
sidual concentrations were detected on the membrane and on the watch glass. A significant 
difference between SBS 1, SBS 2 and SBS 3 was not detected.  
 
Figure 115: Residual amounts of each SBS blend on the watch glass and on the membrane 
In addition, the concentration on the watch glass was increased compared to the cellulose 
membrane. In conclusion, it is supposed that nearly the entire amount of hydrophilic API was 
solved in the dissolution testing over 4 hours.  
The total amount of drug that was initially loaded on the membrane was determined using the 
maximum of the cumulatively released amounts and adding the remaining quantity on the 
membrane determined at the end of each experiment. The fraction of released drug was calcu-
lated by dividing the amount of drug released with the initial drug mass loaded on the mem-
brane. 
Figure 116 demonstrates the calculated dissolved amount of each SBS blend. The sampling 
was automated according to a defined time schedule. For all hydrophilic blends a high solu-
bility was detected (nearly 100%). Unfortunately, the whole amount of API impacted on the 
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membrane was released after 4 minutes and the concentration barley changed over 
248 minutes. Only at the first sampling the released amount of drug can be correlated to the 
amorphous content (SBS 3 < SBS 1 < SBS 2). However, this burst release did not enable the 
discrimination between the single dissolution profiles. An influence of the amorphous content 
was not demonstrated because of the hydrophilic characteristics and the thereby resulted fast 
release (high dissolution rate and high permeation rate). This release behavior can also be 
linked to the processing conditions, surface characteristics and particle morphology of the 
hydrophilic fine particles [176]. 
 
Figure 116: Release profiles of the SBS blends with different amorphous amounts 
In summary, these profiles might explain the quick stimulation of the β2-adrenergic receptors 
and the induced bronchodilating effect in reversible, obstructive airway diseases such as 
bronchial asthma. Following the oral administration this effect might occur within 2 to 
3 hours [177]. In addition, due to its high solubility and permeability, SBS is considered a 
class I drug by the Biopharmaceutics Classification System (BCS). As an amphoteric com-
pound with an acidic phenolic group and a basic secondary amine group it has two ionization 
constants (pKa1 = 9.07 and pKa2 = 10.37). At the used physiological pH its solubility is not 
expected to be affected by its ionization [178]. 
On the contrary, the dissolution experiment of each CS blend did not show a measureable 
concentration in the paddle apparatus with membrane holder (Figure 117). It was not possible 
to solve even minimal concentrations despite the optimized 20 actuations (increase of FPD) 
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and the optimization of the dissolution media which contains an additional of surfactant (0.5% 
Plasdone
®
). Even for the blends containing higher amorphous amounts (CS 1 and CS 2) a 
release from API of the standard membrane holder was not possible. 
 
Figure 117: Absolute amount of the CS blends dissolved after 4 hours 
It is assumed that the very hydrophobic API is more inert against the hydrophilic dissolution 
media and therefore poorly soluble. Maybe the type of dissolution apparatus is not suitable or 
the release of the standard membrane holder is not adequate. In the solubility experiments 
conducted in a beaker it was shown that this poor soluble API might solve when enhanced by 
the surfactant Plasdone
®
 (Chapter 4.5.2). These findings were not confirmed when transfer-
ring them to the USP apparatus 2. Furthermore, a higher affinity to the membrane could be 
one reason for a poor solubility. Probably high hydrophobic binding forces led to strong inter-
actions [179]. The adhesion forces might be reinforced by cohesive properties between indi-
vidual CS particles. In summary, it is surprising that no release was detectable despite a small 
particle size (< 5 µm) and the resulting increase of the surface area for all CS blends. 
The residual amounts of CS were determined by washing the cellulose membrane and the 
watch glass (Figure 118). As expected, high concentrations were detected on these mem-
branes for all CS blends. The concentration on the watch glass was rather little. A significant 
trend was determined for the blends of CS 3, CS 1 and CS 2. The decrease of the concentra-
tion on the membrane was visible with regard to higher amorphous amounts. In conclusion, it 
is supposed that nearly the entire amount of hydrophobic API was not solved in the dissolu-
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tion testing over 4 hours. A reason could be a low wettability because of the highly hydro-
phobic properties. 
 
Figure 118: Residual amounts of each CS blend on the watch glass and membrane 
4.5.5 Conclusion IV 
The dissolution testing demonstrated a diverse behavior for both types of APIs. Dissolution 
profiles were obtained after the optimization of the dose collection (ACI + Easyhaler
®
) for 
hydrophilic SBS samples. The improvement of the solubility of the dissolution media 
(Plasdone
®
) for the hydrophobic substance (CS) did not lead to dissolution profiles. 
The hydrophilic blends demonstrated a fast release through the membrane. A difference in the 
release speed corresponding to the amorphous amounts (low to high) was not recognized. All 
blends nearly showed a complete dissolving after a few minutes (burst release). Figure 119 
might explain a feasible mechanism of these findings. The hydrophilic SBS offers a high wet-
tability and therefore a good solubility in this dissolution media. The diffusion layer (liquid 
layer) adheres easily to the solid surface of this hydrophilic drug. 
Furthermore, the thickness of liquid layer is influenced by the particle size distribution (µm) 
[180] and the paddle speed (rpm) [181] but should be almost similar for both investigated 
APIs. In addition, a time independent diffusion layer with a constant diameter is described 
during particle shrinking [182]. It is assumed that this phenomenon occurs when testing the 
dissolution behavior of the hydrophilic SBS blends. 
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Figure 119: Time-depending diffusions layer of SBS and CS 
In contrast the hydrophobic CS showed a poor solubility and dissolution profiles could not be 
determined. An increased concentration of API was detected on the cellulose membranes after 
the dissolution testing (4 hours). Also a change in the dissolution rate/permeation rate was not 
visible for amorphous amounts (up to 17.0%). It is assumed that the wettability is very low 
and a diffusion layer is formed to a lesser extent on the hydrophobic surface. This behavior 
might explain a low to almost no release of API through the membrane. 
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5 OVERALL CONCLUSION AND FUTURE PERSPECTIVES 
The presented work highlights that standard pharmaceutical unit operations can lead to batch 
variations due to induced structural changes (amorphous parts). These variations could affect 
performance and stability characteristics of dry powder inhaler (DPI) products. It is shown 
that dynamic vapor sorption techniques can be used for an accurate assessment of the amor-
phous content in pharmaceutical powders down to a level of < 0.5%. The developed one-step 
DVS method helps to gain an understanding of induced amorphous amounts in hydrophilic 
and hydrophobic powders. 
The first part clearly demonstrates that structural and thermal properties as well as characteris-
tics may differ slightly once different preparation techniques are used. The imitation of pro-
cess-induced disorders (semi-crystalline) can be accomplished by the introduced jet-milling 
process and the mixing tests with glass beads. Ball-milling, spray-drying, freeze-drying and 
quench-cooling may be used for the production of the fully amorphous state depending on the 
type of API. 
Secondly, after evaluating different methods (DSC, TMDSC, XRPD and DMA) the practical 
applicability of the dynamic vapor sorption techniques is demonstrated. The developed one-
step DVS method which is based on ‘equilibrium moisture uptake’ is adaptable for hydro-
philic and also hydrophobic APIs. This highly accurate DVS study demonstrates how amor-
phous regions are specifically detectable as “reactive spots” to vapor. A high affinity of the 
API to the solvent was targeted to receive a high sensitivity of the method, a higher slope of 
the calibration curve and to detect minimal differences between powder samples. However, 
the amorphous content had to be stable for an exact determination. The development consid-
ered different factors influencing the sensitivity of the assay (water moisture sorption iso-
therms, organic solvent screening, optimization of the p/p0 values, temperature robustness, 
influence of particle size/surface and validation) and based on the results, a schematic model 
for the explanation of the adsorption and absorption theory was illustrated. This approach may 
facilitate the specifications for in-process controls in the pharmaceutical industry. 
In the third part aerodynamic investigations demonstrated that the amorphous content has a 
great influence on the fine particle fractions. The hydrophilic SBS showed a high trend for re-
crystallization over the storage time (six months). Thereby, a change in the surface morpholo-
gy is assumed. These modifications are reinforced by a hydrophilic carrier (e.g. lactose) com-
pared to the inert glass beads. Finally, capillary forces and solid material bridges complicate 
the detaching of API particles. After 6 months storage-time both types of blends showed al-
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most similar FPFs. The hydrophobic API seemed to be less affected by water vapor (45%). 
Electrostatic charges and a reduction of hydrogen bonds can lead to higher FPFs over storage 
time. A significant difference in the smooth surface of the initially re-crystallized API (iso-
propanol) was detected for both blends. Low FPFs were determined for both blends with glass 
beads. An increase in the press-on forces led to a thin API film on the surface of the beads. 
Hereby, the structure of the glass beads’ surface enables a higher compaction of the API crys-
tals during the collision over the mixing time. The resulted binding forces induced a low de-
agglomeration behavior. In summary, it is necessary that amorphous amounts are determined 
(e.g. one-step DVS method) and further re-crystallized under controlled conditions. Otherwise 
the product stability is not guaranteed because of a possible re-crystallization and a change in 
the particle size (crystal growth). 
In the attempt to investigate the effect of amorphous contents in powders on the dissolution of 
APIs, the used dissolution testing system (Andersen Cascade Impactor and USP paddle appa-
ratus 2) was found to be unsuitable despite the continuous optimization for SBS and CS. The 
influence of different amorphous amounts in inhalation powders on the dissolution rate could 
not be determined. The hydrophilic API showed a burst release and the hydrophobic one 
showed only low solubility. Up to this date there is no applicable method available for testing 
aerosols whereas standardized dissolution test methods for solid dosage forms such as tablets 
and capsules are specifically defined. 
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6 SUMMARY 
The efficient delivery of active pharmaceutical ingredients (APIs) to the lung by inhalation 
products depends on several parameters which include the formulation, the inhaler device, 
and the patient’s inhalation technique. APIs which exhibit larger sized particles (> 5 µm) 
might impact in upper airways and thus boost side effects. 
In general, the common active pharmaceutical ingredients (APIs) are synthesized as crystal-
line solids and subsequently processed by standard pharmaceutical operations such as milling, 
blending and even sieving. These processing steps can lead to structural changes, crystal de-
fects and amorphous regions which may have an enormous potential to change during han-
dling and storage and should be limited to a minimum. The conditions and kinetics of such 
process-induced disorders and changes during storage may affect product stability. In terms of 
the determination and control of the amorphous content, there is still lack in reliable methods 
that accurately assess the amorphous content in pharmaceutical powders down to a minimal 
level (< 1%). 
Therefore, this thesis focuses on the impact of amorphous parts of inhalation APIs, the im-
provement of their production techniques and detection methods for quantifying minimal 
amorphous amounts as well as the understanding of their influence on inhalation powder for-
mulations. In a first step the preparation techniques of semi-crystalline/fully amorphous sam-
ples were investigated by using different technologies and process conditions. The focus was 
set on ball-milling, spray-drying, freeze-drying and quench cooling for the establishment of 
purely amorphous material. On the contrary, jet-milling and intensive blending (simulation 
with glass beads) led to the generation of partially amorphous APIs (up to 17%) mainly local-
ized on the surface of the particles. Furthermore, the influence of these process-induced disor-
ders on the stability and shelf-life was investigated (humidity/temperature/time). 
The accurate assessment of the amorphous content down to a level < 0.5% in pharmaceutical 
powders was demonstrated by a developed one-step DVS method which is based on ‘equilib-
rium moisture uptake’. The applicability was tested for various hydrophilic and hydrophobic 
powders and their induced amorphous amounts. This highly accurate DVS study demonstrates 
how amorphous regions are specifically detectable as “reactive spots” to polar or nonpolar 
vapors. A high affinity of the API to the solvent was targeted to receive a high sensitivity of 
the method, a higher slope of the calibration curve and to detect minimal differences between 
powder samples. The development was divided into six main sections (water moisture sorp-
tion isotherms, organic solvent screening, optimization of the p/p0 values, temperature robust-
Summary    142 
 
 
ness, influence of particle size/surface and validation). Finally, a schematic model for the ex-
planation of the adsorption and absorption theory was illustrated. This approach may facilitate 
the specifications for in-process controls in the pharmaceutical industry. 
Additionally performed aerodynamic investigations demonstrated that the amorphous content 
has a huge influence on the fine particle fraction (% of delivered dose < 5 µm). Especially the 
hydrophilic sample showed a high trend for a re-crystallization over the storage time of six 
months and showed decreasing values for the FPFs (9%). This behavior is a proof for insuffi-
cient product stability. In summary, it is necessary to determine amorphous amounts 
(e.g. one-step DVS method) and further to ensure complete re-crystallization under controlled 
conditions. Otherwise the product stability is not guaranteed because of a possible re-
crystallization with consequences such as solid bridging and changes in the particle size (crys-
tal growth). 
 
 
 
Summary (German)    143 
 
 
7 SUMMARY (GERMAN) 
Die effiziente Applikation von Arzneistoffen in der Lunge hängt von vielen Parametern ab, 
wie zum Beispiel der Arzneiformulierung, dem Inhalationssystems und der Inhalationstechnik 
des Patienten. In der Regel scheiden sich Arzneistoffpartikel, die größer als 5 µm sind, in den 
oberen Atemwegen ab und können deshalb zu Nebenwirkungen führen.  
Im Allgemeinen werden heutzutage die Arzneistoffe als kristalline Feststoffe synthetisiert und 
danach durch verschiedene pharmazeutische Techniken wie die Mikronisation, Mischvorgän-
ge und Siebungen prozessiert. Bei diesen Verarbeitungsschritten kann es jedoch zu strukturel-
len Veränderungen, Kristalldefekten oder amorphen Regionen kommen, welche dann wieder-
um eine hohe Tendenz zur Umwandlung während der weiteren Verarbeitung und Lagerung 
zeigen. Deshalb sollten besonders amorphe Anteile auf ein Minimum reduziert werden, da 
dieser metastabiler Zustand die Produktstabilität des Endprodukts stark beeinflussen kann. Im 
Hinblick auf die Detektion und Kontrolle dieser amorphen Regionen mangelt es an vernünfti-
gen Methoden zur Charakterisierung minimaler Anteile in pharmazeutischen genutzten Pul-
vern (< 1 %). 
Aufgrund dessen beschäftigt sich diese Arbeit explizit mit dem Thema der amorphen Anteile, 
um ein besseres Verständnis über Herstelltechniken, der Bestimmung und Quantifizierung 
von minimalen Anteilen und den Einfluss auf inhalative, speziell in hydrophoben Arz-
neistoffpulvern zu erhalten. Im ersten Teil wurden dabei Herstellmethoden für geringe und 
vollständig amorphe Pulver mittels verschiedener Technologien und Prozessbedingungen 
untersucht. Der Schwerpunkt für die Etablierung von stark amorphen Substanzen lag dabei 
auf der Mahlung mittels Kugelmühle, der Sprühtrocknung, Gefriertrocknung und dem 
Quench cooling. Im Folgenden wurde gezeigt, wie mittels Luftstrahlmahlung und Intensiv-
Mischung (Simulierung mit Glass beads) geringe amorphe Bereiche speziell auf der Partikel-
oberfläche erzeugt wurden (bis zu 17 %). Des Weiteren wurde der Einfluss dieser prozessin-
duzierten Kristallstrukturveränderungen in Hinblick auf die Stabilität und Haltbarkeit unter-
sucht (Feuchtigkeit/Temperatur/Zeit). 
Die exakte Bestimmung des amorphen Anteils bis zu einem Level von 0.5 % wurde durch 
eine selbst entwickelte 1-Schritt DVS-Methode, die auf der Grundlage der Gleichgewichtsab-
sorption basiert, gewährleistet. Die Anwendbarkeit wurde dabei für hydrophile und besonders 
auch für hydrophobe Pulver mit organischen Lösungsmitteln, im Hinblick auf die Detektion 
minimal amorphe Mengen, getestet. Diese DVS-Methode konnte zeigen, dass amorphe Re-
gionen als ‚reaktive Spots‘ mit Hilfe von polaren oder organischen Lösungsmitteln mit einer 
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hohen Genauigkeit sehr gut zu quantifizieren waren. In der Regel musste eine hohe Affinität 
zwischen dem Arzneistoff und dem Messlösungsmittel erreicht werden, um letztendlich eine 
hohe Sensitivität der Methode und eine entsprechende Steigung der Kalibriergerade zur Be-
stimmung geringster Mengen zu garantieren. Im Allgemeinen ließ sich dieser Entwicklungs-
prozess in 6 Hauptschritte (Wasserdampfabsorptions Isotherme, Organisches Lösungsmittel-
screening, Optimierung der Feuchtigkeit, Belegung der Temperaturstabilität, Möglicher Ein-
fluss auf Partikelgröße/Partikeloberfläche und Validierung) unterteilen. Im Anschluss daran 
konnten schematische Modelle für Adsorptions- und Absorptionstheorien erstellt werden. 
Zusammenfassend kann dieser Ansatz mittels der entwickelten 1-Schritt DVS-Methode die 
Bestimmung und Einhaltung von bestimmten Spezifikationen für amorphe Anteile in der 
Pharmazeutischen Industrie erleichtern. 
Im weiteren Verlauf der Arbeit zeigten aerodynamische Bestimmungen, dass auch bei diesen 
der amorphe Anteil in inhalativen Pulvermischungen einen großen Einfluss auf die lungen-
gängige Feinpartikelfraktion hat (% der Dosis, die < 5 µm ist). Besonders hydrophile Arz-
neistoffe zeigten dabei einen großen Trend zur Rekristallisation und damit verbundenen Ab-
nahme der FPF (9 %) über eine Lagerzeit von 6 Monaten. Dieses Verhalten deutet auf eine 
nicht ausreichende Produktstabilität hin und kann mit den induzierten amorphen Regionen in 
Zusammenhang gebracht werden. Zusammenfassend lässt sich festhalten, dass es absolut 
notwendig ist, amorphe Regionen zu quantifizieren (z.B. mit der vorgestellten 1-Schritt DVS-
Methode) und diese danach unter kontrollierten Bedingungen zur Rekristallisation zu bringen. 
Andernfalls kann eine Produktstabilität nicht garantiert werden, da es speziell bei Inhalativa 
zu gravierenden Partikelgrößenveränderungen (Kristallwachstum des Arzneistoffs) kommen 
kann. 
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8 APPENDIX 
8.1 Methods 
8.1.1 Quantification of API content - HPLC 
A Waters HPLC system (Waters Corp. Milford, USA) was used for the quantification of the 
sample contents of SBS and CS. The obtained data was evaluated with Empower
®
 Pro2 soft-
ware (Waters Corp. Milford, USA). 
8.1.1.1 Salbutamol sulphate 
Mobile phase: 78% buffering system (containing 2.87 g/l sodium heptanesulfonate and 
2.5 g/l KH2PO4 (0.2 mmol); pH adjusted to 3.65 with ortho-phosphoric 
acid 85%) 
   22% acetonitrile 
Flow rate:  0.8 ml/min 
Stationary phase: LiChroCART
®
 125-4,  
LiChrospher
®
 100 RP-18 (5 µm) with precolumn 
Wavelength:  220 nm  
Retention time: 4 min 
Calibration:  1-80 µg/ml 
Injection volume:  100 µl 
Oven temperature: 25 °C 
Samples were dissolved in 100% ddH2O. 
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8.1.1.2 Ciclesonide 
Mobile phase: 85% methanol 
   15% ddH₂O 
Flow rate:  1.2 ml/min 
Stationary phase: LiChroCART
®
 125-4,  
LiChrospher
®
 100 RP-18 (5 µm) with precolumn 
Wavelength:  243 nm  
Retention time: 8 min 
Calibration:  1-80 µg/ml 
Injection volume:  100 µl 
Oven temperature: 25 °C 
Samples were dissolved in 9:1 methanol/ddH2O. 
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8.2 Materials 
Acetone    SIGMA-ALDRICH, Inc., St. Louis, USA 
Acetonitrile    SIGMA-ALDRICH, Inc., St. Louis, USA 
Brij
®
 35    ICI Specialty, Essen, Germany 
Cellulose membrane   Whatmann, Dassel, Germany 
ddH2O freshly produced with Finn Aqua 75, San-Asalo Sohl-
berg Corp., Helsinki, Finland 
Decane    SIGMA-ALDRICH, Inc., St. Louis, USA 
Ethanol  Merck KGaA, Darmstadt, Germany 
Ethyl acetate  Merck KGaA, Darmstadt, Germany 
Glass beads Ø 0.25 mm  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Glass beads Ø 4.0 mm  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Glycerol  Merck KGaA, Darmstadt, Germany 
Helium 5.0  Air Liquide, Paris, France 
Heptane  Merck KGaA, Darmstadt, Germany 
HPMC capsules  Qualicaps Europe S.A., Madrid, Spain 
Hydrogen 5.0  Air Liquide, Paris, France 
Isopropanol  AppliChem GmbH, Darmstadt, Germany 
Methanol  J.T. Baker, Deventer, The Netherlands 
Methylene chloride   LGC Standards GmbH, Wesel, Germany 
Nitrogen 5.0  Air Liquide, Paris, France 
Nonane    SIGMA-ALDRICH, Inc., St. Louis, USA 
Octane     SIGMA-ALDRICH, Inc., St. Louis, USA 
o-phosphoric acid 85%  Merck KGaA, Darmstadt, Germany 
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Phosphate buffered saline  SIGMA-ALDRICH, Inc., St. Louis, USA 
Plasdone
® 
   Ashland Industries GmbH, Schaffhausen, Switzerland 
Potassium dihydrogen phosphate FAGRON, Barsbüttel, Germany 
Respitose SV003  DFE pharma, Goch, Germany 
Sodium dodecyl sulfate  Merck KGaA, Darmstadt, Germany 
Sodium heptanesulfonate  SIGMA-ALDRICH, Inc., St. Louis USA 
Syringe top filter, Minisart RC 15 Sartorius AG, Göttingen, Germany 
Tween
® 
20  Croda Europe Ltd., Yorkshire, UK  
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8.3 Raw data 
8.3.1 Validation of High Performance Liquid Chromatography (HPLC) methods for 
SBS and CS 
A coefficient of determination of R² > 0.999 was determined for both calibration curves of 
SBS and CS in the linearity test series. Seven different concentrations showed a linear relation 
to the area under the curve (AUC) of the detected signal, respectively. Table 34 demonstrates 
this directly proportional behavior. Each concentration was measured six times for both APIs. 
The performance of the measurement method is reflected in the process standard deviation 
(Sx0) which was of 0.113 µg for SBS and 0.313 µg for CS. The determined value is corre-
sponding to a process coefficient of variation (Vx0) of 0.442% for SBS and 1.242% for CS. 
Table 34: HPLC linearity of different SBS and CS amounts 
Amount [µg/ml] AUC (mean) sd CV [%] 
SBS CS SBS CS SBS CS SBS CS 
82.56 81.64 15058165 10810575 21214 7445 0.14 0.07 
51.60 51.03 9467013 6844578 30956 13458 0.33 0.20 
20.64 20.41 3774338 2657125 5063 5209 0.13 0.20 
10.32 10.21 1891951 1339451 5991 1821 0.32 0.14 
8.26 8.16 1518202 1073440 17088 712 1.13 0.07 
4.13 4.08 751936 547551 2760 1278 0.37 0.23 
1.03 1.02 191843 136592 1808 648 0.94 0.47 
 
The limit of quantification (LOQ) was determined using dilutions of 1.0 µg/ml, 0.5 µg/ml, 
0.2 µg/ml, 0.1 µg/ml, 0.08 µg/ml and 0.05 µg/ml for each API. An aimed ratio of a signal-to-
noise value of 10:1 was reached with the amount of 0.1 µg/ml for SBS and 0.05 µg/ml for CS. 
Figure 120 visualizes the described ratio 10:1 of signal/noise for SBS (4.05 minutes) and for 
CS (8.30 minutes), respectively. 
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Figure 120: HPLC signal/noise ratio of both APIs 
Furthermore, the same concentrations were produced six times for both APIs. The accuracy 
was determined by the closeness of the agreement between the value which is accepted either 
as a conventional true value and the value found. Hereby, respectable recovery rates between 
98-102% were found for both APIs. Table 35 shows the recovery rates [%] of the six samples 
with the same concentration for SBS and CS. 
Table 35: HPLC recovery rates of both APIs in the accuracy test series 
AUC (mean) True value [µg/ml] Value found [µg/ml] Recovery [%] 
SBS CS SBS CS SBS CS SBS CS 
13818473 8817162 75.12 65.43 75.05 65.16 99.91 99.60 
13897434 8969742 75.12 65.43 75.48 66.29 100.48 101.32 
13913146 8932953 75.12 65.43 75.56 66.02 100.59 100.91 
13915229 8734967 75.12 65.43 75.57 64.55 100.61 98.67 
13834715 8745134 75.12 65.43 75.14 64.63 100.02 98.78 
13887777 8691927 75.12 65.43 75.43 64.24 100.41 98.18 
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The closeness of the agreement between a series of measurements (6 times) obtained from 
multiple sampling of the same homogenous sample was determined for evaluation of the pre-
cision. A coefficient of variation of < 2.0% is target and was defined for both APIs. Table 36 
shows the precision values for SBS and CS, respectively. 
Table 36: Closeness of agreement between a series of measurements for the precision 
Injection 
AUC 
SBS CS 
1 202652 130192 
2 203394 130634 
3 203392 130730 
4 202516 131696 
5 201565 130763 
6 202091 129688 
mean 202602 130617 
sd 721 670 
CV [%] 0.36 0.51 
 
Concerning the stability testing (robustness) of one concentration over 1 day, 3 days and 5 
days, SBS and CS showed constant and precise results when stored at room temperature and 
daylight. The robustness of this analytical procedure showed its high capacity to detect signif-
icant results unaffected by small variations (Table 37). It is an indication of the reliability dur-
ing normal usage. 
In summary, the objective of validating this HPLC analytical procedure was to demonstrate 
the suitability for the individual measurement of SBS and CS. Typical validation characteris-
tics such as linearity, limit of quantification (LOQ), accuracy, precision and robustness were 
determined and are within its specified range, respectively. These findings enable a specific 
quantification of the API for the investigations with the impactors and dissolution experi-
ments. 
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Table 37: Robustness of SBS and CS HPLC analytics up to 5 days 
Injection 
Amount [µg/ml] 1 day Amount [µg/ml] 3 days Amount [µg/ml] 5 days 
SBS CS SBS CS SBS CS 
1 1.05 1.39 1.06 1.40 1.07 1.40 
2 1.04 1.38 1.04 1.41 1.06 1.41 
3 1.05 1.39 1.06 1.40 1.07 1.39 
4 1.04 1.39 1.04 1.40 1.06 1.42 
5 1.04 1.40 1.06 1.54 1.05 1.43 
6 1.04 1.40 1.06 1.55 1.06 1.40 
mean 1.04 1.39 1.05 1.45 1.06 1.41 
sd 0.00 0.01 0.01 0.07 0.01 0.01 
CV [%] 0.47 0.50 0.81 5.03 0.70 0.90 
 
8.3.2 Selected XRPD diagrams 
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8.3.3 Selected DSC diagrams 
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8.3.4 Selected TMDSC diagrams 
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8.3.5 Selected organic moisture sorption isotherms by DVS 
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8.3.6 Delivered dose (Easyhaler®) of the NGI Study 1 
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